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Abstract 
 
Abstract 
During the course of development, specification of the three embryonic germ layers, ectoderm, 
mesoderm and definitive endoderm (DE), is a critical process by which pluripotent cells acquire 
the temporal and spatial information needed to form specialised tissues. Of these initial germ 
layers, the DE arises during gastrulation, which latterly gives rise to the liver, pancreas, lung and 
epithelial lining of the digestive tract. Elucidation of the molecular mechanisms that govern DE 
specification not only facilitates our understanding of developmental biology but also aids in the 
differentiation of human pluripotent stem cells to specific cell types for disease modelling and 
regenerative therapies. DE formation is largely driven by the cooperation of Activin/Nodal and 
Wnt/β-catenin signalling, however recent evidence has additionally implicated PI3K/Akt 
signalling in modulating this process. Although it has been previously reported that PI3K 
activation acts to antagonise the in vitro differentiation of DE, the molecular mechanisms 
responsible for this effect remains unclear. To address this issue, this study utilises pluripotent 
human embryonic stem cells (hESCs) as an in vitro model to interrogate the molecular 
underpinnings of DE formation through a fully defined differentiation protocol. Modulation of 
PI3K activity was found to reciprocally downregulate the activation of Smad2/3, which was 
mitigated in the presence of the PI3K inhibitor LY294002 (LY). Suppression of PI3K/Akt 
signalling prolongs the activation of Smad2/3 in response to Activin, promoting their nuclear 
accumulation and the enhancement of transcriptional activity, resulting in the upregulation of 
mesendoderm and DE gene expression. Activation of PI3K negatively impacts the activity of 
Smad2/3 via phosphorylation of the Smad2/3 linker T220/T179 residue, which is fully 
independent of Erk and CDK activity. Phosphorylation of this residue induces the recruitment of 
the E3 ubiquitin ligase Nedd4L to activated Smad2/3, which in turn promotes their ubiquitin-
mediated degradation and attrition of activity. Inhibition of mTORC2 activity by both inhibitor 
supplementation and genetic manipulation, rather than modulation of Akt or mTORC1 activity, 
recapitulates the LY-mediated reduction of T220/T179 phosphorylation and increases the 
duration of Smad2/3 transcriptional activity, promoting a more robust mesendoderm and 
endoderm differentiation. These findings reveal a new and novel connection between the 
PI3K/mTOR and TGFβ/Activin pathways, which will greatly impact our understanding of both 
cell fate determination and the preservation of normal cellular functions. Notably, identification 
of mTORC2 as a key player in the regulation of this differentiation provides new avenues through 
which hESCs differentiation protocols can be improved for both regenerative and biomedical 
applications.
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Chapter One Introduction 
1.1 Preface 
The initial emergence of multicellularity one billion years ago allowed for the evolution of complex 
organisms, resulting in the diversity of life we see around us today. However, the concept of being 
multicellular over unicellular presented a unique series of challenges for our ancestral eukaryotes. 
Principally, was the need to communicate and exchange information between cells in order to 
facilitate the specialisation of functions, as well as conveying the state of an ever-changing 
extracellular environment in order to coordinate adaptive responses. These challenges drove the 
evolution and diversification of early signal transduction pathways; multi-protein phosphorylation 
cascades which conveyed information from the cell surface to the nucleus from which different 
gene expression programs could be initiated depending on extrinsic cues. 
Perhaps more importantly, an even greater obstacle for the evolution and persistence of 
multicellular life came upon reproduction, as multicellularity and cellular specialisation must once 
again arise anew from the zygote; the first cell of the new organism. It is this transitional process 
from a single cell to an entirely new organism, the development of new life from old that truly 
underscores the importance of signal transduction to the propagation of multicellular life. As the 
zygote proceeds through development, it undergoes cleavage and division, giving rise to new 
daughter cells that also proliferate and acquire the correct temporal and spatial information to 
form specialised tissues. During this transition, certain cells transitorily acquire the property of 
pluripotency; the unique ability to give rise to any cell type of the adult organism. The rapid 
conversion of a pluripotent to a specialised cell state is driven not only by signals received from 
the environment, but is also reinforced by mutual intercellular signalling cues which act to 
stringently consolidate the genetic programs needed to form functional tissues. 
Whilst developmental studies using a variety of model multicellular organism from fruitfly to 
mouse have revealed the remarkable preservation of these signalling pathways across all species 
studied, there is nonetheless significant debate as to whether these pathways perform the same 
functions given that the reproductive systems across all organisms demonstrate significant 
variation. As such, although past studies have uncovered the inherent sophisticated molecular 
mechanisms controlling developmental progression, the regulative mechanisms coordinating their 
activities on a spatial and temporal level are likely to differ from species to species. For example, 
although the formation of morphogen gradients is a key mechanism that is conserved in fruitfly 
and mouse development, how different signalling gradients interact to drive formation of the body 
axes and the robust differentiation of certain tissues is very much different between both species.  
___________________________________________________________________________ 
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Nevertheless, further studies of vertebrate development have helped shaped our understanding of 
the potential role signal crosstalk plays in human development, and has consequently allowed for 
the isolation and propagation of human embryonic stem cells (hESCs) from the pre-implantation 
blastocyst. These are cells resembling the zygotic daughter cells, which are able to be cultured 
indefinitely, and can differentiate to any cell type of the adult human in vitro. Thus, they are said to 
possess the dual properties of self-renewal and pluripotency. Isolation of hESCs has for the first 
time provided a platform from which to investigate the signalling processes that occur during 
human development, in that by simply changing the signalling molecules in the culture dish, one 
can directly manipulate the differentiation of the cells to a range of different lineages. Additionally, 
the advent of hESCs as well as induced pluripotent stem cells (iPSCs) has finally allowed the 
promise of regenerative therapies to be realised and has brought the allied fields of bioscience and 
medicine to the cusp of revolution.  
The work described in this thesis utilises the hESC model to investigate the signalling crosstalk 
mechanisms driving the formation of the definitive endoderm; the precursory germ layer that gives 
rise to the gut, liver and pancreas. This chapter will firstly address the in vivo evidence garnered 
from developmental biology, which has contributed greatly to our understanding of how this germ 
layer is formed in mammalian systems and allowed the identification of the key signalling pathways 
involved. Next, this section will explore how this knowledge has been applied in the culture and 
directed differentiation of hESC to definitive endoderm followed by a detailed review of the 
signalling requirements facilitating the formation of definitive endoderm in vitro. Lastly, the current 
disparities of proposed crosstalk mechanisms between Activin/Smad and PI3K/Akt/mTOR in 
regulating the formation of this germ layer will be discussed, leading to the hypothesis of a direct 
role for mTORC2 in regulating this process. 
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1.2 The Definitive Endoderm  
1.2.1 Emergence of the definitive endoderm in vertebrates 
Amongst all vertebrates studied, germ layer differentiation and the specification of progenitor 
populations is one of the earliest events to occur upon fertilisation. In mammals, prior even to 
implantation, the zygote has already undergone several rounds of cleavage to form the first 
differentiated multicellular entity known as the blastocyst, consisting of two distinct populations 
of cells; the trophectoderm (TE) and inner cell mass (ICM), which further differentiate into the 
epiblast and hypoblast (also known as the primitive endoderm or PrE). After implantation, TE 
and PrE differentiate into the visceral (VE) and parietal (PE) endoderm, which contribute to the 
formation of yolk sac structures. Contrastingly, the epiblast cells undergo gastrulation to form the 
three initial germ layers of ectoderm, mesoderm and definitive endoderm (DE), which then give 
rise to all the tissues of the embryo (Figure 1.1). A clear distinction in terminology is required as 
PrE, VE and PE gives rise to mainly extraembryonic structures, with only the DE arising from the 
ICM giving rise to the embryo proper. 
Figure 1.1: Emergence of definitive endoderm in the mouse 
Diagram depicting early developmental progression in the mouse. Prior to implantation, cells of the 
ICM differentiate to form the epiblast and primitive endoderm (PrE) by E4.5. Gastrulation occurs post-
implantation after E5.5. Cells of the TE form the extra-embryonic ectoderm, whilst cells of the PrE form 
visceral endoderm. Cells of the epiblast give rise to the primitive streak, which in turn will give rise to 
the mesoderm and definitive endoderm, with the residual cells making up the ectoderm. Image taken 
and adapted from Developmental Biology Interactive, 2013. 
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The process of gastrulation is a prime example where signalling plays a critical role in driving 
developmental progression. Specification of the DE begins with the ingression of mesendoderm 
progenitors into the anterior primitive streak, accompanied by epithelial to mesenchymal transition 
(EMT), which is necessary for the cells to gain mobility. During the latter stages of gastrulation, 
both mesoderm and endoderm progenitors are exposed to the node as it transits posteriorly, which 
confers positional and patterning instructions to the cells (Brennan et al., 2002). Whilst studies in 
C. elegans, sea urchin and zebrafish have suggested that both the mesoderm and endoderm derive 
from a common mesendoderm progenitor (Rodaway and Patient, 2001), this population of cells 
has never been formally demonstrated to exist in higher vertebrates. Nevertheless, it is clear that 
the initial separation of ectoderm progenitors from mesendoderm progenitors via internalisation 
through the primitive streak acts to spatially lay the foundations for further specification. 
1.2.2 Induction of DE by signalling pathways 
The molecular underpinnings governing the induction of both endoderm and mesoderm post-
internalisation were elucidated mainly from studies made in Xenopus and mouse, which found that 
members of TGFβ signalling pathway are essential inducers of both germ layers. The introduction 
of a dominant negative Activin receptor which blocks the signalling activities of secreted TGFβ 
ligands such as Activin and Vg1 into Xenopus embryos induces the expression of ectoderm and 
mesoderm genes at the expense of endoderm markers (Henry et al., 1996), whilst ectopic 
expression of Xnr4; a Xenopus TGFβ ortholog, induced the formation of mesoderm (Joseph and 
Melton, 1997). In tandem with this finding, retroviral mutagenesis in the mouse allowed for the 
identification of the Nodal gene encoding for a mammalian TGFβ ligand, which had similar roles 
to Activin, Vg1 and Xnr4 in regulating mesendoderm formation (Zhou et al. 1993; Conlon et al., 
1994;). Correspondingly, hypomorphic mutation of Nodal results in the selective loss of endoderm 
and mesoderm (Lowe et al., 2001), whilst inactivation of the natural Nodal antagonist Lefty2 leads 
to excessive endoderm formation (Meno et al., 1999). Further studies in zebrafish confirmed the 
importance of Nodal and its orthologs in specifying mesendoderm across multiple species, as in 
the absence of this signal, zebrafish embryos lacked all major mesendoderm derived structures 
such as the heart, kidney, liver and gut (Feldman et al., 1998; Gritsman et al., 1999). The mechanism 
by which Nodal and its orthologs acted to specify certain populations of cells as mesoderm whilst 
others are fated to become endoderm was deduced based on seminal work carried out on Activin 
and its Xenopus homologues, which alluded to the existence of morphogens; secreted proteins 
which act over a long-range to specify cell fates in a concentration-dependent manner (Green and 
Smith, 1990; Gurdon et al., 1994). The ability of Nodal to behave as a morphogen was first tested 
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and proved in zebrafish, in that high levels of Nodal signalling were required to induce the 
expression of goosecoid whilst lower levels maintained the expression of brachyury, markers of 
anterior and posterior mesoderm respectively (Chen and Schier, 2001). Concurrently, the 
specification of DE and mesoderm in mice was also found to be dependent on high and low levels 
of Nodal signalling respectively (Lowe et al., 2001; Vincent et al., 2003), which again emphasises 
the importance of TGFβ signalling to the development of both germ layers. However, it is 
important to note that although TGFβ signalling is required, it is not the sole regulator of DE 
formation. Studies in Xenopus have revealed that transcriptional integration of Wnt and Nodal 
pathways are required for the expression of goosecoid, hence cooperating to specify and consolidate 
the mesendoderm fate (Watabe et al., 1995). Furthermore, mice embryos lacking Nodal or β-
catenin, a component of the canonical Wnt signalling pathway, fail to even form primitive streak 
(Conlon et al., 1994; Haegel et al., 1995) whilst Wnt3-null mutants demonstrate the need for Wnt3 
in driving anterior-posterior definition as well as mesendoderm and primitive streak formation 
(Liu et al., 1999). Lessons learned from these developmental studies would later prove to be 
invaluable in the initial isolation and in vitro differentiation of hESCs to DE. 
1.2.3 Intrinsic consolidation of the endoderm fate 
The stimulation of both Nodal and Wnt pathways ultimately results in the upregulation of 
transcription factors that serve to reinforce the endoderm identity. In particular, Nodal signalling 
directly induces the expression of many of these factors which can act to both consolidate the 
definitive endoderm as well as endoderm-derived tissues: 
i. Gata factors 
The Gata factors constitute an ancient family of zinc finger transcription regulators whose role in 
consolidating mesendoderm-derived tissues can be traced right back to invertebrates. Loss of the 
drosophila Gata factor Serpent prevents endoderm and fat body formation, an organ analogous 
to the liver (Rehorn et al., 1996), whilst loss of Gata5 in zebrafish precludes the formation of heart 
and gut tissue (Reiter et al., 1999). In Xenopus, ectopic expression of Gata4, 5 or 6 converts 
ectomesoderm into endoderm, and are implicated in the proper formation of heart and intestinal 
tissues (Jiang and Evans, 1996; Gao et al., 1998; Afouda et al., 2005), whilst Gata4 and Gata6 
knockout mice demonstrate defects in both visceral and endoderm development as well as 
improper differentiation of the gastric epithelium (Morrisey et al., 1998; Jacobsen et al., 2002). The 
observation of defects occurring in the liver and gut of organisms where Gata function is impaired 
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or absent therefore additionally suggests that these factors activate genes that are required to 
maintain endoderm-derived tissues in the adult organism. 
ii. Forkhead factors 
The Forkhead (Fox) family are another well-conserved group of transcription factors that are 
particularly important to the maintenance of endoderm-derived tissues. As a large and diverse 
family of proteins, many members have diversified in function and have gone on to regulate 
processes outside of development, yet certain members have been shown to play major roles in 
the development and maintenance of adult endodermal tissues. Loss of FoxA2 (HNF-3β) in 
mouse embryos results in severe developmental abnormalities, including the absence of node, 
notochord and foregut accompanied by the failure to progress beyond E8.5 (Ang and Rossant, 
1994; Weinstein et al., 1994). Equally, loss of FoxH1 (FAST), a cofactor of the Nodal-activated 
transcription factor Smad2, produced a similar lethal phenotype in terms of complete node and 
mesendoderm loss (Chen et al., 1996; Hoodless et al., 2001; Yamamoto et al., 2001). More 
importantly, conditional and tissue specific inactivation have revealed further roles for Fox factors 
in both the organogenesis and homeostasis of the liver. FoxA1 deficient mutants fail to form the 
liver bud (Lee et al., 2005) whilst loss of FoxA3 results in decreased expression of hepatic-specific 
genes, such as the hepatic glucose transporter 2 protein (GLUT2), which results in fasting 
hypoglycaemia (Kaestner et al., 1998; Shen et al., 2001). Furthermore, conditional inactivation of 
FoxA2 in the pancreas also induces hypoglycaemia but due to excess insulin production (Sund et 
al., 2000). These findings therefore highlight the critical role Fox factors play in the consolidation 
of endoderm-derived tissues.  
iii. Mixer factors and Sox17 
The Mixer (Mix/Bix) family are a group of homeobox transcription factors that have been 
implicated in the specification of mesoderm and endoderm solely in vertebrates. Unlike the Gata 
and Fox factors, studies in Xenopus have shown that Mix factors possess the unique ability of being 
able to induce specifically endoderm fates in the absence of mesoderm and ectoderm (Henry and 
Melton, 1998), whilst being only able to induce mesoderm at lower expression levels (Tada et al., 
1998; Latinkic and Smith, 1999). Mice embryos lacking MixL1 are characterised by a thickening of 
the primitive streak, accompanied by a reduction in DE recruitment and loss of hindgut (Hart et 
al., 2002; Tam et al., 2007), thus implicating its involvement in the consolidation of specifically 
endoderm fates.  
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The phenotype of MixL1 knockout mice closely resembles that of the high-mobility group (HMG) 
transcription factor Sox17-null mice, which is therefore yet another factor that has been implicated 
in the maintenance of specifically endoderm fates. Both mice and Xenopus embryos lacking Sox17 
show a depletion in DE and despite still being able to form anterior endoderm, cannot form mid 
and hindgut structures (Kanai-Azuma et al., 2002; Clements et al., 2003). Further to its role in DE 
specification, Sox17 has also been implicated in the proper vascularisation of organs post-natal 
and hence may play a role in maintaining the proper function of highly vascularised tissues such 
as the liver and pancreas (Matsui et al., 2006). The similarity of the null phenotype of both MixL1 
and Sox17 in the mouse and the ability of Mixer to induce Sox17 expression in Xenopus immediately 
suggest some form of coordination on the transcriptional level between these two factors.  
iv. Eomesdermin 
Although the T-box transcription factor Eomesdermin (Eomes) was originally identified as a 
mesoderm inducer in Xenopus (Ryan et al., 1996), more recent findings in zebrafish have 
highlighted the additional role it plays in consolidating the definitive endoderm. Specifically, 
ectopic expression of Eomes induces the increased expression of goosecoid and chordin accompanied 
by the formation of a secondary body axis (Bruce et al., 2003), whilst maternal Eomes coordinates 
with Gata5 in driving the expression of Casanova, the first endoderm specific factor expressed in 
zebrafish (Bjornson et al., 2005). Studies in mice have supported this argument, in that selective 
deletion of Eomes in epiblast derivatives blocks EMT and results in failed migration of the 
mesoderm away from the primitive streak concomitant with the loss of definitive endoderm 
(Arnold et al., 2008). However, given that the absence of Eomes does not affect mesoderm 
formation, it is likely that rather than being an endoderm-specifying factor, the mesoderm- 
specifying actions of Eomes also indirectly promote the consolidation of the endoderm identity in 
conjunction with Gata and Mix/Bix factors.  
1.2.4 Epistatic regulation of endoderm identity 
Cross-regulation and interaction amongst the endoderm-specifying factors serves as an important 
mechanism that acts to consolidate the specification of the germ layer. As summarised in Figure 
1.2, auto-regulatory loops centred around Sox17 act to strengthen the endoderm identity in Xenopus 
(Sinner et al., 2006). The interlinking of these factors explains why ectopic expression of any one 
factor results in rapid endoderm induction, as feed-forward mechanisms ensures that all other 
required factors are expressed in conjunction with the first. As such, this consolidation is both 
self-sustaining long after the disappearance of Nodal ligand, whilst also being self-reinforcing, in 
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that Mixer and Sox17 can act to repress Eomes and β-catenin expression respectively to prevent 
mesoderm induction. However, although the endoderm specifying functions of the individual 
factors are generally well conserved across all species studied, whether or not these epistatic 
relationships also hold in higher vertebrates remains to be explored.  
 
Figure 1.2: Epistatic consolidation of the definitive endoderm identity 
Summary of the epistatic relationships uncovered in Xenopus and the proposed transcriptional network 
that exists to consolidate the definitive endoderm identity. Grey lines indicate induction, black lines 
indicate direct regulation and red lines indicate experimental evidence for direct interaction between 
factors. Integration of Nodal and Wnt signalling activities function to augment the transcriptional 
consolidation. Images taken and adapted from Sinner et al., 2006 (A) and Grapin-Botton, 2008 (B). 
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___________________________________________________________________________ 
 
25 
 
Chapter One Introduction 
1.3 Signalling pathways that regulate DE differentiation  
Although it has been formally demonstrated that Activin/Nodal and Wnt/β-catenin cooperatively 
act to specify the DE in vivo, recent evidence has shown that many other signal pathways act to 
regulate this process to ensure stringent specification. In particular, the PI3K/Akt pathway has 
been shown to regulate specification of foregut precursors by regionalising the surrounding 
extracellular matrix (Villegas et al., 2013), whilst in vitro differentiation of hESCs is impeded by the 
presence of serum containing stimulators of the PI3K/Akt pathway (D’Amour et al., 2005; 
McLean et al., 2007). As such, both in vivo and in vitro studies have increasingly shown the 
PI3K/Akt pathway to be a critical modulator of Activin/Nodal signalling activities that mediate 
DE formation.  
1.3.1 Activin/Nodal  
Activin/Nodal signalling plays a major role in both the maintenance of hESC pluripotency and in 
vivo specification of the DE (Vincent et al., 2003; Vallier et al., 2005), which is highly dependent 
on the level and duration of the signalling response. Taking a more molecular based overview, 
whether stimulation of this pathway induces differentiation or maintains pluripotency is dependent 
on the presence of determinants at both the signalling and gene level. Although the core 
components of the signalling cascade remain shared with other TGFβ family members, the 
presence or absence of these determinants drive the regulatory mechanisms that govern their 
functional competence. 
1.3.1.1 Induction - Ligands and Receptors 
TGFβ, Activin and Nodal are defining members of a TGFβ subfamily of ‘Activin-like’ ligands, 
which differ from the BMP subfamily in terms of their protein sequence and the mode by which 
they stimulate the receptor complex. These ligands operate as diffusible proteins, which are first 
synthesised as precursory proteins carrying a long N-terminal pro-peptide and short C-terminal 
polypeptide, which are separated upon cleavage by furin-like proteases prior to secretion from the 
cell (ten Djike and Arthur, 2007). The longer pro-peptide, termed latency associated peptide (LAP) 
remains associated with the shorter mature protein, and acts as a molecular chaperone, stabilising 
the mature protein whilst keeping it in a latent state. Emergence from this state is marked by the 
dimerization of ligand monomers stabilised by a network of intrachain disulphide bonds, 
hydrophobic interactions and a single disulphide bridge between them (Sun and Davis, 1995). Only 
dimerised ligands are conducive in binding receptor complexes consisting of type I and type II 
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receptor Ser/Thr protein kinases that cooperate to initiate the intracellular signal cascade. TGFβ 
receptors are the only Ser/Thr protein kinases receptors identified to date from which two distinct 
modes of induction are apparent, which serves to distinguish the Activin-like from the BMP 
subfamily (Figure 1.3).  
 
Figure 1.3: The TGFβ Signalling Pathway 
Diagram illustrating the core components of the TGFβ signalling cascade. The TGFβ superfamily can 
be subdivided into two main subfamilies consisting of the ‘Activin-like’ ligands that stimulate the 
activation of Smad2 and 3 (in orange) and the BMP ligands that activate Smad1, 5 and 8 (in green). 
Smad4 (in purple) acts the Co-Smad common to both signalling branches. Trimeric Smad/Co-Smad 
complexes translocate into the nucleus to regulate gene expression. SBE indicates regions of DNA 
constituting Smad Binding Elements. 
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The Activin-like subfamily of ligands possess a high affinity for type II receptors, which upon 
binding, induces the phosphorylation of the type I receptor at multiple sites within the 
juxtamembrane Gly-Ser (GS) rich region, a highly conserved regulatory sequence which when 
phosphorylated permits the dissociation of the inhibitory 12 kDa FK506 binding protein 
(FKBP12) and recruitment of Smad substrate (Massagué, 1998; Huse et al., 2001). In the case of 
the BMP subfamily, given that BMP ligands have a greater affinity for type I receptors over type 
II and that formation of the BMP-type I receptor complex leads to improved affinity for type II 
receptors, ligand binding first occurs on the type I receptors before type II receptors are recruited 
to activate the GS region. However, the simplicity of the induction mechanism masks a range of 
regulatory mechanisms acting on both the ligand and receptor level that will ultimately affect the 
functional outcome of the signalling induction. For example, ligand-trapping proteins and 
antagonists such as Noggin and inhibin prevent the recruitment of BMPs and Activin to their 
receptors respectively (Lewis et al., 2000; Groppe et al., 2002), whilst other ligands such as Nodal 
requires cofactors such as Cripto to mediate receptor binding (Yeo and Whitman, 2001). 
Furthermore, given that there are over thirty TGFβ ligands, seven type I and five type II receptors 
that have been found to exist in humans, there is significant scope for mechanistically complex 
interplay that gives rise to the milieu of TGFβ-attributed functions observed in development, 
tissue homeostasis and tumourigenesis.  
1.3.1.2 Transduction – Smad function and regulation 
The translation of extrinsic cues into a meaningful gene response requires the transduction of the 
signal from the receptor down into the nucleus. In the TGFβ signalling cascade, Smad proteins 
(Figure 1.4) serve as the conduits through which the extrinsic signal is transmitted intracellularly. 
Eight Smad proteins have been identified and categorised into three groups: the receptor-regulated 
Smads termed R-Smads including Smad1, Smad2, Smad3, Smad5 and Smad8; the common 
mediator Smad, or Co-Smad, Smad4; and the inhibitory Smads or I-Smads which includes Smad6 
and Smad7. Structurally, Smads consists of two globular MAD homology 1 (MH1) and 2 (MH2) 
domains linked by an unstructured, Pro-rich linker region. The N-terminal MH1 domain is 
responsible for the binding of Smad to the DNA and carries a nuclear localisation signal (NLS) 
motif, whilst the C-terminal MH2 domain facilitates Smad-receptor and Smad-Smad interactions, 
as well as the recruitment of transcriptional cofactors within the nucleus. The linker region carries 
multiple Ser/Thr residues, which are targeted by proline-directed Ser/Thr kinases that act to 
regulate Smad function and allow further recruitment of other modifying proteins such as ubiquitin 
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ligases. Phosphorylation of the type I receptor GS region allows for the recruitment and 
subsequent activation of R-Smads at the C-terminal Ser-X-Ser (SxS) motif facilitated by the Smad 
anchor for receptor activation or SARA protein (Tsukazaki et al., 1998; Xu et al., 2000). This results 
in conformational changes in the R-Smads, which permits the homo and heterologous 
dimerisation of R-Smads (Abdollah et al., 1997). Activated R-Smad dimers subsequently recruit 
the Co-Smad (Smad4), forming trimeric units that translocate into the nucleus and together with 
other factors, initiates the transcription of target genes (Chacko et al., 2001). Another key 
distinguishing feature between the Activin-like and BMP branches of TGFβ signalling is that 
Activin/Nodal stimulates the activation of Smad2 and Smad3, whilst BMP type I receptors 
phosphorylate Smad1, Smad5 and Smad8. 
Figure 1.4: R-Smads – Structure and Function Relationships 
X-ray crystallography has revealed the structural basis for Smad function. Phosphorylation of the GS 
region (in green) of the type I TGFβ receptor induces conformational changes that permit association 
with the R-Smad MH2 domain (in cyan) at the L3 loop (in purple) and phosphorylation of the SxS motif. 
DNA binding is mediated through the MH1 domain (in yellow) whilst cofactor recruitment is mainly 
facilitated by the αH-2 of the MH2 domain. No crystal structure is available for the linker region (dotted 
black line) due to the presence of crystal distorting proline residues. Adapted and presented with 
permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology, Massagué, 
copyright 2000. 
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As with the induction of the signalling cascade, R-Smads are also regulated by a variety of 
mechanisms that affect their functional activities. In the absence of stimulation, Smads remain 
monomeric and constantly shuttle between the nucleus and cytoplasm to establish a basal state 
equilibrium (Shi and Massagué, 2003). The balance between the import and export activities results 
in the homogeneous distribution of Smad4 between both compartments, however R-Smads 
appear to be restricted to the cytoplasm (Pierreux et al., 2000; Watanabe et al., 2000). This is due 
to the occlusion of the NLS motif within the MH1 domain and binding by SARA, which is only 
diminished upon the receptor-mediated phosphorylation of the SxS motif (Xiao et al., 2000a; 
Kurisaki et al., 2001). However, the MH2 domain of R-Smads have also been shown to bind 
directly to nucleoporins themselves, indicating that shuttling of monomeric R-Smads may very 
well occur in a constant fashion (Xu et al., 2002). As such, the preferential nuclear exclusion of 
monomeric R-Smads in establishing the basal state may well be due to their inability to bind to 
stabilising factors within the nucleus that preferentially bind to trimeric complexes, resulting in a 
bias for export back out into the cytoplasm over nuclear import. The dynamic shuttling of R-
Smads and preferential retention of transcriptionally active trimeric complexes allows for constant 
sensing of the receptor activation state, allowing for rapid signal termination once the exogenous 
ligand pool is exhausted and direct stoichiometric translation of receptor activation to levels of 
activated Smad (Inman et al., 2002). 
1.3.1.3 Termination of Smad signalling 
Since TGFβ signalling has been shown to be of great importance to development and tissue 
homeostasis, stringent mechanisms exist to regulate not only the stimulation, but also the 
termination of the signal to prevent aberrant functions. Given that receptor-mediated activation 
of Smads is essential for their nuclear retention and function, and that inhibition of the type I 
receptor results in the rapid dephosphorylation of Smads (Vogt et al., 2011), much attention has 
been focused on the identification of the phosphatase responsible. Protein phosphatases function 
to remove phosphate groups from phospho-Ser/Thr or Tyr residues and are subdivided based on 
their substrate preference. Since all reported phosphorylation sites on Smads are either Ser or Thr 
residues, the Ser/Thr subfamily of protein phosphatases have been the subject of intense scrutiny 
in this regard. The members within the subfamily can be further characterised into three groups 
based on the structure of their catalytic domains: the phospho-protein phosphatases (PPP), protein 
phosphatase Mg2+/Mn2+-dependent (PPM) and the transcription factor IIF-interacting CTD 
phosphatase 1 (FCP) families (Cohen, 2004). The utilisation of a functional genomic approach 
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resulted in the identification of PPM1A as the long sought nuclear R-Smad phosphatase, which 
was convincingly shown to impact TGFβ mediated responses through a series of gain and loss of 
function experiments in zebrafish (Lin et al., 2006). However, recent findings have cast doubt as 
to whether PPM1A is truly a bona fide nuclear phosphatase in that it has been reported to be 
exclusively cytoplasmic in greater than 10 different cell lines tested (Bruce et al., 2012), as well as 
functioning promiscuously to dephosphorylate targets such as phosphatidylinositide-3-kinases 
(PI3K) and axin which also reside in the cytoplasm (Strovel et al., 2000; Yoshizaki et al., 2004). 
Given that these targets are also key components in the PI3K/Akt and Wnt/β-catenin signalling 
pathways respectively, and that the same pathways have been shown to augment or antagonise 
TGFβ signalling activities, it is debatable whether the in vivo evidence truly reflects the direct 
function of PPM1A solely on TGFβ signalling. As such, although the major role phosphatases 
play in the termination of BMP-induced Smad activity has clearly been demonstrated (Duan et al., 
2006; Knockaert et al., 2006), this has yet to be the case for the R-Smads and awaits further 
interrogation. 
In addition to phosphatase-mediated dephosphorylation, activated R-Smads are also subject to 
degradation and turnover via the ubiquitin-proteasomal system (Lo and Massagué, 1999). Several 
E3 ubiquitin ligases have been reported to act upon activated R-Smads, including Smurf2, Arkadia 
and Nedd4L. Smurf2 has been shown to bind Smad1, Smad2 and Smad3, but not Smad4, whilst 
also having a preferential bias in binding activated Smads, particularly Smad2 (Lin et al., 2000). The 
notion of ubiquitin-mediated degradation as a valid mechanism by which TGFβ signalling can be 
terminated was further supported by the discovery of the RING-domain E3 ligase Arkadia, which 
was found to act upon activated Smad2 and Smad3 only upon entry into the nucleus (Mavrakis et 
al., 2007). More recently, characterisation of the Smad linker region has allowed for the 
identification of another homologous to the E6-AP carboxyl terminus (HECT) E3 ubiquitin ligase, 
neural precursor cell expressed developmentally downregulated gene 4-like (Nedd4L), which is 
recruited to Smad2/3 upon linker phosphorylation by cyclin-dependent kinases or CDKs (Alarcón 
et al., 2009; Gao et al., 2009). Thus ubiquitin-mediated turnover of R-Smads appears to be a 
stringently controlled mechanism that is regulated not only by the activation state of R-Smads, but 
also dependent on the phosphorylation status of the linker region. Furthermore, the fact that both 
Smurf2 and Arkadia have been demonstrated to act on active Smads alone strongly suggests that 
ubiquitin-mediated proteasomal degradation works in tandem with nuclear phosphatases to 
terminate Smad signalling, however whether this bias also applies to Nedd4L recruitment remains 
unknown.  
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1.3.1.4 Regulation of Activin/Nodal signalling 
i. Role of the Smad linker region 
The Smad linker region is an important site at which Smad activity is regulated on both branches 
of the TGFβ family, consisting of several Ser/Thr residues that are targeted by a plethora of 
kinases originating from many different signalling cascades (Figure 1.5).  
Figure 1.5: Smad linker region 
Diagram depicting the linker region of human BMP-Smads and R-Smads. Linker regions are 
characterised by an abundance of Ser, Thr and Pro residues. Ser/Thr residues are targeted by kinases 
such as CDK, GSK3β and Erk2, which facilitate the recruitment of modifying factors including E3 
ubiquitin ligases such as Smurf1 and Nedd4L. Image taken and adapted from Chen and Wang, 2009. 
 
The identification of so many kinases acting upon the R-Smad underscores the importance of the 
linker region in modulating inter-pathway crosstalk. However, phosphorylation of the linker 
residues can act to both augment and antagonise R-Smad function in a context dependent manner. 
For example, although oncogenic induction of rat sarcoma (Ras) protein or stimulation of 
MEK/Erk signalling prevents the nuclear accumulation of R-Smads and preserves mesoderm 
competence in Xenopus during development (Kretzschmar et al., 1999; Grimm and Gurdon, 2002), 
phosphorylation of the same residues by p38 mitogen activated protein kinase (MAPK), Rho-
associated protein kinase (ROCK) or c-Jun N-terminal kinase (JNK) enhances R-Smad 
transcriptional activity (Engel et al., 1999, Mori et al., 2004, Kamaraju et al., 2005). Furthermore, 
the phosphorylation of specific linker residues by one group of linker kinases can serve to augment 
the activities of another. The modulation of linker phosphorylation in BMP-Smads is an exemplary 
case, in that MAPK-mediated phosphorylation primes the site for further phosphorylation by 
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glycogen synthase 3 (GSK3), acting in a concerted fashion to inhibit Smad function by targeting 
nuclear localised active Smad for ubiquitin-proteasomal-mediated degradation (Kretzschmar et al., 
1997; Fuentealba et al., 2007; Sapkota et al., 2007). This mechanism by which linker 
phosphorylation acts to direct the binding of E3 ubiquitin ligases which in turn earmarks Smad 
proteins for degradation, appears to be a key mechanism conserved between both BMP and 
Activin/Nodal pathways. Furthermore, an additional regulatory layer exists in that these linker 
residues are also targeted by linker phosphatases that act to promote Smad signalling activities 
(Sapkota et al., 2006; Wrighton et al., 2006). The pleiotropic activation of Activin/Nodal signalling 
by kinases belonging to other signalling streams such as the MAPKs, Akt and ROCK also function 
to regulate Smad and hence Activin/Nodal activity via the linker site, adding further layers of 
regulation on top of the canonical mechanisms. 
ii. Function of I-Smads 
Whilst the core regulatory process controlling the efficacy of Activin/Nodal signalling primarily 
occurs on the R-Smads, it is important to note that several other regulatory processes are in place 
to increase the stringency of regulation. Notably, Smad6 and Smad7 constitute members of the 
inhibitory Smad subgroup, and act to antagonise Smad signalling by blocking access to the active 
type I receptors (Hayashi et al., 1997). Smad7 binds and works cooperatively with Smurf1 and 
Smurf2 to block and terminate Activin/Nodal signalling via the degradation of the receptor 
complex (Ebisawa et al., 2001; Suzuki et al., 2002; Tajima et al., 2003). On the other hand, Smad6 
mainly operates on the BMP branch in competing with Smad4 for Smad1 binding, sequestering 
and preventing access to active type I receptors (Hata et al., 1998). The existence of many different 
regulative mechanisms that control Smad activity acts to redundantly ensure stringent control over 
TGFβ signalling on a spatial and temporal level. 
1.3.1.5 Regulation of gene expression by Smad – effects on development 
Once inside the nucleus, Smad complexes are able to bind to specific regions of DNA to stimulate 
gene transcription, however it is notable that these complexes bind with relatively low affinity to 
Smad binding elements (SBE) which were initially minimally identified as 5’-GTCT-3’ or its reverse 
complementary equivalent (Dennler et al., 1998; Shi et al., 1998). In fact, Smad2 itself has no 
inherent DNA binding ability due to an insertion within the MH1 domain that is missing in the 
Smad2-Δexon3 alternative splice variant (Yagi et al., 1999). Thus, all Smad complexes require the 
recruitment and binding to cofactors that possess higher affinity for DNA to cement the DNA to 
protein interaction (Feng and Derynck, 2005). Upon binding, Smad complexes and their 
___________________________________________________________________________ 
 
33 
 
Chapter One Introduction 
transcriptional partners recruit histone acetyl transferases (HATs) such as p300 and C/EBP-
binding protein (CBP), acting to open the chromatin and stimulate targeted gene transcription 
(Massagué et al., 2005). Additionally, Smad complexes are able to recruit ubiquitin ligases such as 
Arkadia or Smurf2 to degrade SnoN, Ski and their associated co-repressors, thus facilitating the 
de-repression of Smad target genes (Bonni et al., 2001; Mavrakis et al., 2007; Le Scolan et al., 2008) 
(Table 1.1.). Conversely, Smad complexes can also act to repress gene expression, with the 
recruitment of transcriptional co-repressors such as 5’-TG-3’-interacting factors (TGIF) and 
chromatin modifiers such as histone deacetylases (HDACs) to silence Activin/Nodal gene targets. 
The repressive functions of Smad complexes are of equal importance to the stimulatory effects on 
gene transcription, as Tgif mutations in humans are associated with craniofacial defects, whilst 
complete loss of Tgif in the mouse results in persistent activation of Nodal responses that lead to 
holoprosencephaly and cyclopia (Taniguchi et al., 2012). Overall, these are but a few examples of 
the critical role Smad2/3 cofactors play in the regulation of both gene expression and cellular 
functions, acting to diversify the range of Smad2/3-dependent activities within the cell (Table 1.1). 
Many Smad complex-cofactor interactions have been shown to have developmental relevance and 
are in most cases absolutely required for normal developmental progression. FoxH1 was the first 
cofactor reported to interact with Smads and mediates several developmental processes including 
formation of the endoderm and dorsal mesoderm (Zhou et al., 1998; Hoodless et al., 2001; 
Yamamoto et al., 2001). Interaction of Gata factors with Smad1 drives the expression of Smad7 
and Nkk2.5, a key cardiac differentiation factor (Benchbane and Wrana, 2003; Brown et al., 2004), 
whilst Mixer factors interact with Smad2 and Smad4 to activate the expression of the mesoderm 
factor goosecoid (Germain et al., 2000). In addition, Smad complex-cofactor interactions have also 
been implicated in the maintenance of adult tissues, such as the skin and liver. For example, Smad3 
has been shown to cooperate with FoxO in skin keratinocytes to inhibit Myc and hence 
proliferative gene responses (Chen et al., 2002), whilst Smad3 and Smad4 interact with hepatocyte 
nuclear factor-4a (HNF4a) to drive hepatic gene expression (Chou et al., 2003). Coordination of 
gene expression by Smad complex-cofactor interactions also extends to ES cells, in that bone 
morphogenetic protein (BMP)-induced Smad1, myeloid leukaemia inhibitory factor (LIF) and 
signal transducer and activator of transcription 3 (STAT3) were found to co-occupy sites of active 
gene transcription, including Oct4, Sox2, and Nanog in mouse embryonic stem cells or mESCs 
(Chen et al., 2008). As such, Smad complexes may initially function as pioneering factors, which 
act to recruit chromatin modifiers, and either pluripotency or lineage specific factors that cooperate 
to ultimately regulate lineage specific gene expression.  
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Table 1.1: List of experimentally verified Smad2/3 cofactors curated by BioGRID 
Cofactor Uniprot ID Function 
ACVR1B P36896 Activin receptor 
AKT1 P31749 Protein kinase 
ANK3 Q12955 Membrane-cytoskeleton linker protein 
ARKADIA Q6ZNA4 E3 ubiquitin-protein ligase 
CDK2 P24941 Cyclin dependent kinase 
CDK4 P11802 Cyclin dependent kinase 
CPSF7 Q8N684 mRNA processing factor 
CREBP/CBP Q92793 Histone acetylase 
DAB2 P98082 Adaptor protein 
DOCK9 Q9BZ29 Guanine nucleotide-exchange factor  
EP300 Q09472 Histone acetyltransferase 
EPAS1 Q99814 Transcriptional regulator of hypoxia response 
FOXH1 P70056 Transcriptional activator 
HDAC1 Q13547 Histone deacetylase 
ITCH Q96J02 E3 ubiquitin-protein ligase 
JUN P05412 Transcription factor 
MAP2K3 P46734 Mitogen activated protein kinase 
MTMR4 Q9NYA4 Ser/Thr/Tyr phosphatase 
NEDD4 P46934 E3 ubiquitin-protein ligase 
NEDD4L Q96PU5 E3 ubiquitin-protein ligase 
OLIG1 Q8TAK6 Oligodendrocyte maturation factor 
OTUB1 Q96DC9 Deubiquitinase 
PCK2 Q16822 Metabolic enzyme 
PHC2 Q8IXK0 Polycomb group protein/transcriptional repressor 
PPM1A P35813 Broad specificity protein phosphatase 
PPP2R1A P30153 Protein phosphatase 
RANBP3 Q9H6Z4 Nuclear export cofactor 
RHOA P61586 Plasma membrane signal transducer 
ROCK1 Q13464 Rho associated protein kinase 
SETD2 Q9BYW2 Histone methyltransferase 
SKI P12755 TGF-beta signalling repressor 
SKIL/SnoN P12757 TGF-beta signalling repressor 
SMAD2 Q15796 TGF-beta signal transducer/transcription modulator 
SMAD3 P84022 TGF-beta signal transducer/transcription modulator 
SMAD4 Q13485 TGF-beta signal transducer/transcription modulator 
SMAD7 O15105 TGF-beta signalling repressor 
SMURF1 Q9HCE7 E3 ubiquitin-protein ligase 
SMURF2 Q9HAU4 E3 ubiquitin-protein ligase 
SP1 P08047 Transcription factor 
SQSTM1 Q13501 Autophagy receptor 
TGFBR1 P36897 TGF-beta receptor 
TGIF1 Q15583 Homeobox protein 
TP53 P04637 Tumour suppressor/cell cycle regulator 
TRIM33 Q9UPN9 E3 ubiquitin-protein ligase 
TSC2 P49815 GTPase-activating protein 
USP7 Q93009 Deubiquitinase 
WWP1 Q9H0M0 E3 ubiquitin-protein ligase 
WWP2 O00308 E3 ubiquitin-protein ligase 
ZFYVE9/SARA O95405 Early endosome protein/transcriptional regulator 
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1.3.2 Wnt/β-catenin  
Evident from developmental studies, the canonical Wnt/β-catenin signalling pathway plays a 
critical role in the regulation of embryonic development, cell proliferation and tissue homeostasis. 
The involvement of Wnt ligands in the regulation of developmental processes was first 
demonstrated in the fruitfly, whereby the Wnt1 homolog Wingless (Wg) was shown to control the 
segment polarity and hence the anterior-posterior patterning of the developing larvae (Nüsslein-
Volhard and Wieschaus, 1980). Further studies performed in fruitfly, Xenopus, and mammalian 
models allowed for the elucidation of the intracellular components responsible for Wnt signal 
transduction, including GSK3 (Siegfried et al., 1992), adenomatous polyposis coli gene product or 
APC (Su et al., 1993), dishevelled (Noordermeer et al., 1994), lymphoid enhancer factor 1 or LEF-
1 (Behrens et al., 1996), β-catenin (Molenaar et al., 1996), Frizzled (Bhanot et al., 1996) and casein 
kinase 1 or CK1 (Zeng et al., 2005). Each component forms a critical part of the transduction 
cascade that contribute directly to human diseases when mutated (Clevers and Nusse, 2012). 
Key to the Wnt signal transduction cascade, the accumulation and translocation of β-catenin 
regulates the Wnt-activated genes, however the exact mechanisms by which Wnt induces this 
translocation remains unclear. Classically, in the absence of Wnt ligand (Figure 1.6), the axin 
degradation complex consisting of the scaffolding protein axin, APC, CK1 and GSK3 acts to 
downregulate cytoplasmic β-catenin via sequential phosphorylation first by CK1 and then by 
GSK3 at the N-terminal region. This phosphorylation recruits β-Trcp, an E3 ubiquitin ligase that 
acts to target β-catenin for proteasomal-mediated degradation (He et al., 2004). Loss of 
cytoplasmic β-catenin results in the binding of the transcriptional repressor Groucho (Cavallo et 
al., 1998) to LEF or T cell factor (TCF), resulting in the suppression of Wnt responsive gene 
activation. Conversely Wnt signalling is induced upon the binding of Wnt ligands to receptor 
complexes consisting of a 7-pass G-coupled transmembrane receptor Frizzled and its co-receptor 
LRP5/6 (Angers and Moon, 2009). This leads to the recruitment of the scaffolding protein 
dishevelled, which in conjunction with the lipoprotein receptor related protein 5/6 (LRP5/6) co-
receptor and downstream G-proteins act to recruit axin to the plasma membrane. This 
sequestration of axin mitigates the formation of the degradation complex, resulting in the 
accumulation of β-catenin, which upon translocation into the nucleus, displaces Groucho 
transcriptional repressors and induces the upregulation of β-catenin target gene expression. Whilst 
the contribution of β-catenin as the main mediator of Wnt-induced gene expression is generally 
accepted, significant debate exists around the precise mechanism by which this is achieved. 
Notably, recent evidence proposes several non-canonical models to explain this effect. One study 
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proposes that the destruction of the degradation complex is an active process facilitated by co-
endocytosis of the Wnt ligand and Frizzled receptor (Taelman et al., 2010), whilst another proposes 
that the degradation complex remains intact, albeit saturated with phosphorylated β-catenin, which 
blocks the degradation of newly synthesised unphosphorylated β-catenin (Li et al., 2012). Further 
studies will be required to fully establish the exact mechanisms by which β-catenin accumulation 
is promoted.  
 
Figure 1.6: Canonical Wnt signalling 
Diagram illustrating the canonical Wnt signalling cascade in the presence or absence of Wnt ligand. 
Alpha, beta and gamma indicate components of the G-protein coupled receptor Frizzled. N and C 
represent the N and C terminals of the β-catenin protein respectively. The axin degradation complex 
consists of axin, GSK3, APC and CK1 and acts to target β-catenin for degradation by the E3 ubiquitin 
ligase β-Trcp (not shown). The Groucho family of transcriptional repressors act to suppress LEF/TCF 
mediated gene expression, and are displaced upon the binding of β-catenin. Adapted and presented 
with permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology, Angers and 
Moon, copyright 2009. 
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As outlined previously, Wnt/β-catenin signalling axis promotes the formation of DE by initially 
cooperating with Nodal to specify the primitive streak (Liu et al., 1999) followed by the 
augmentation of the DE gene transcriptional network. As such, supplementation of Wnt ligands 
together with Activin/Nodal in the early stages of in vitro differentiation may serve to accelerate 
the formation of DE by inducing the rapid formation and transition through the mesendoderm 
stage.  
1.3.3 PI3K/Akt/mTOR  
The PI3K/Akt/mTOR signalling axis constitutes an important pathway that regulates cellular 
growth and metabolism (Fig 1.7). However, the role this pathway plays in the regulation of cellular 
differentiation and development has only recently come to light. Studies refining the molecular 
details have revealed the complex nature of inter-pathway interactions occurring with other 
signalling pathways, defining the PI3K/Akt/mTOR pathway as a key component and modulator 
of the entire intrinsic signalling network. 
1.3.3.1 PI3K and Phospho-inositol (PtdIns) 
The original discovery of PI3K was initially brought about by the intriguing observation that 
hydrolysis of phospholipids resulted in the generation of secondary messengers that were capable 
of activating intracellular kinases such as protein kinase C or PKC (Kishimoto et al., 1980). This 
discovery firmly established the plasma membrane as a key signalling centre and phosphoinositide 
lipids as critical inducers of signalling events, spurring the search for modifiers that could create 
these secondary messengers. One such modifier was identified as a novel kinase with the unique 
ability to phosphorylate the 3-hydroxyl group of the phosphoinositide lipids, and hence named as 
phosphatidylinositol-3-kinase or PI3K (Whitman et al., 1988).  
A range of growth factors activate PI3K, including insulin and insulin-like growth factors (IGFs), 
which suggests that induction of PI3K activity was likely to be an effect of receptor tyrosine kinase 
(RTK) activation and hence may function to regulate cell growth (Traynor-Kaplan et al., 1988; 
Ruderman et al., 1990). PI3K is structurally composed of two distinct proteins of ~110 kDa (p110) 
and ~85 kDa (p85) in size, of which p85 was frequently shown to be bound to activated RTKs 
(Kaplan et al., 1987). Although subsequent work revealed that the p85 protein possessed SRC 
homology 2 (SH2) domains, which facilitated binding to RTKs, it had no inherent kinase activity 
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(Escobedo et al., 1991). Thus, attention was swiftly focused on the p110 subunit, which was shown 
to carry the PI3K activity whilst additionally interacting with the p85 protein (Backer at al., 1992; 
Hiles et al., 1992). Therefore PI3K is a dimeric unit, with p85 serving as a regulatory factor in 
mediating RTK interaction whilst p110 fulfils the kinase function upon phosphoinositide substrate 
binding.  
Further characterisation of PI3K has subsequently uncovered an entire family of kinases, which 
can be subdivided into distinct classes based on their structural and biochemical characteristics. 
Class IA enzymes represent the most studied, classically activated by RTK and consisting of five 
different p85 and three p110 isoforms (α, β, δ). Additionally, the class IB subgroup of enzymes 
utilise a larger regulatory subunit of which there are two isoforms coupled with p110γ and are 
mainly activated by G-coupled receptors. Class I enzymes mainly function to convert PtdIns(4,5)P2 
to PtdIns(3,4,5)P3 by phosphorylating the 3’-hydroxyl of the PtdIns ring which leads to 
downstream signalling events. Class II and Class III enzymes dispense with the need for a 
regulatory subunit, however the stimulus required for the induction of their activity remains 
unknown, although they are functionally thought to catalyse the formation of PtdIns(3)P and 
possibly PtdIns(3,4)P2. Additionally, the discovery of phosphatase and tensin homolog (PTEN) a 
phosphoinositide lipid phosphatase that opposes PI3K function (Maehama et al., 1998; Stambolic 
et al., 1998) provides a mechanism through which PI3K activity is regulated. The positioning of 
PTEN so far upstream of the PI3K/Akt/mTOR signal cascade defines its role as a master 
regulator and tumour suppressor, which is justified given that loss-of-function PTEN mutations 
lead to unrestricted activation of PI3K/Akt/mTOR signalling, resulting in aberrant proliferation 
and tumourigenesis. The need to investigate the functional properties of PI3K spurred the 
development of Wortmannin (Wort) and LY, cell-permeable, pan-PI3K specific inhibitors (Arcaro 
and Wymann, 1993; Vlahos et al., 1994) which facilitated the discovery of many PtdIns(3,4,5)P3-
activated effectors that contribute to the growth enhancing properties of PI3K activation. 
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Figure 1.7: The PI3K/Akt/mTOR Signalling Pathway 
Overview of the PI3K/Akt/mTOR signalling cascade. RTKs and G-coupled receptors act to stimulate 
the induction of PI3K activity, which in turn promotes the formation of the phosphoinositide mediator 
PtdIns(3,4,5)P3 and the recruitment of PDK1, Akt and mTORC2 to the plasma membrane. Full 
activation of Akt is subsequently induced by the kinase activity of PDK1 and mTORC2, which 
phosphorylate Akt at T308 and S473 respectively. Active Akt acts to inhibit TSC1/TSC2 GTPase activity, 
which promotes the activation of the mTORC1 complex. Signalling inputs via AMPK also act to promote 
TSC1/TSC2 activity and inhibit mTORC1 activation. mTORC1 can also be activated by amino acids 
through Rag GTPases, which subsequently induces the growth stimulating activities of ULK1, S6K, and 
4E-BP. PTEN acts to reduce PtdIns(3,4,5)P3 levels which results in negative regulation of the pathway. 
Additionally, activated S6K negatively regulates PI3K/Akt/mTOR signalling by phosphorylating IRS-1.  
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1.3.3.2 Akt/PKB – The first effector 
In identifying the product of PI3K activity as PtdIns(3,4,5)P3, the search was on to find protein 
kinases that could be recruited and activated by this phosphoinositide lipid. Early bioinfomatic 
approaches identified a key domain shared amongst many signalling mediators that facilitates their 
association with membrane proteins, termed the pleckstrin homology (PH) domain (Haslam et al., 
1993), which was subsequently shown to bind PtdIns(4,5)P2 (Harlan et al., 1994). Akt or protein 
kinase B (PKB) was one of the kinases identified to possess a PH domain, and given its close 
relationship with PKC, was suspected to be a downstream effector stimulated by PtdIns(3,4,5)P3. 
Subsequent studies revealed this to be the case, in that Akt binds PtdIns(4,5)P2 and PtdIns(3,4,5)P2 
via its PH domain which localises Akt to the plasma membrane (Burgering and Coffer, 1995; 
Franke et al., 1995). Recruitment of Akt to the membrane alters its protein conformation and 
allows activation by phosphoinositide-dependent kinase 1 (PDK1), another kinase which was 
shown to have PtdIns(3,4,5)P3 binding activity via a PH domain. PDK1 activity is absolutely 
dependent on the presence of either PtdIns(4,5)P2 or PtdIns(3,4,5)P3, and activates Akt by 
phosphorylating the Thr308 residue (Alessi et al., 1997; Stokoe et al., 1997). However, given that 
PDK1 is found to be mostly localised at the membrane prior to PI3K stimulation via binding to 
nascent PtdIns(4,5)P2, and that Akt can also be recruited by PtdIns(4,5)P2, mechanisms must exist 
to prevent constant Akt activation. This is thought to be due to the inherent differences in affinity, 
with PDK1 having a greater affinity for PtdIns(4,5)P2  whilst Akt has a greater affinity for 
PtdIns(3,4,5)P3. Furthermore, full activation of Akt is only achieved when both T308 and S473 
sites are phosphorylated (Figure 1.7), with the latter being mediated by mammalian target of 
rapaymycin complex 2 or mTORC2 (Sarbarssov et al., 2005). 
The physiological role of Akt within cells has been shown to be highly pleiotropic, affecting cell 
survival, proliferation and metabolism. This is demonstrated by the significant body of work 
implicating the hyperactivation of Akt and its downstream mediators in many human cancers. 
Overexpression or activation of Akt promotes anti-apoptotic activities within cells, such as by 
preventing the release of cytochrome C from the mitochondria (Kennedy et al., 1999), and by 
inactivating pro-apoptotic inducers such as pro-caspase 9 and Bad (Datta et al., 1997; Cardone et 
al., 1998), in addition to alleviating the pro-apoptotic and cell cycle suppressive effects of FoxO 
factors (Matsuzaki et al., 2003). Akt also actively promotes cell growth and proliferation by 
inactivating GSK3β by phosphorylation, which in turn prevents the degradation of cyclin D1 
(Diehl et al., 1998), whilst also promoting the degradation of the cell cycle inhibitor p27Kip1 and 
p21cip1/Waf1 (Zhou et al., 2001; Liang et al., 2002). Furthermore, the effect of Akt on GSK3β also 
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extends to the control of glucose transport and metabolism, in that inactivation of GSK3β by Akt 
relieves GSK3β-mediated inhibition of glycogen synthase, promoting the conversion of glucose 
to glycogen (Cross et al., 1995). Additionally, microinjection of an antibody that binds to and 
disrupts Akt function inhibited the insulin-stimulated translocation of glucose transporter 4 
(GLUT4) to the membrane, which therefore prevents uptake of extracellular glucose (Hill et al., 
1999). Given that the above processes still only represents a small fraction of all Akt functions, its 
criticality to all cellular processes including development cannot be understated. 
1.3.3.3 mTOR – New branches of PI3K signalling 
The mammalian target of rapamycin (mTOR) is a protein kinase that exists within two structurally 
distinct complexes that perform different functions pertaining to the induction of PI3K signalling 
and are distinguishable in terms of their core components (Figure 1.7). mTORC1 is activated 
downstream of Akt and consists of the mTOR kinase along with the regulatory-associated protein 
of mTOR (Raptor), and mammalian lethal with SEC thirteen 8 (mLST8), whereas mTORC2 is 
activated upstream of Akt and consists of the mTOR kinase, rapamycin-insensitive companion of 
mTOR (Rictor), mammalian SAPK-interacting 1 (mSin1) and mLST8. Both complexes are also 
distinguishable in their response to rapamycin, an inhibitor that selectively binds to mTORC1 but 
not mTORC2 by forming an inhibitory complex with the FKBP12 immunophilin and hence 
prevent access to the catalytic cleft (Sabers et al., 1995; Benjamin et al., 2011; Yang et al., 2013). 
mTOR complexes serve as sensors of cellular energy and act to diversify the PI3K signalling 
response.  
i. mTORC1 
Activation of mTORC1 activity is conducive to many stimulants, which can be both of 
extracellular and intracellular origin. Canonically, Akt stimulates mTORC1 activation indirectly 
through phosphorylating a heterodimeric protein complex consisting of tuberous sclerosis 1 
(TSC1) and 2 (TSC2). The TSC1/2 complex functions as a GTPase-activating protein for the Ras 
homolog enriched in brain (Rheb) GTPase. GTP-bound Rheb directly interacts with mTORC1 to 
stimulate its activity and as such, inactivation of TSC1/2 via phosphorylation by Akt promotes 
mTORC1 kinase activity (Inoki et al. 2002 and 2003a; Tee et al., 2003). Additionally, Akt can act 
in a TSC1/2 independent manner to activate mTORC1 activity by promoting the disassociation 
of the inhibitory PRAS40 from mTORC1 (Sancak et al., 2007; Vander Haar et al., 2007). The 
ability of TSC1/2 to transduce inputs to mTORC1 is not solely restricted to the PI3K pathway, 
or indeed solely to growth factor induced signalling. Activation of adenosine monophosphate 
___________________________________________________________________________ 
 
42 
 
Chapter One Introduction 
protein kinase (AMPK) in response to hypoxia or high levels of AMP results in the 
phosphorylation of TSC2 as well as Raptor, ultimately leading to the enhancement of TSC2 activity 
and inactivation of mTORC1 (Inoki et al., 2003b; Gwinn et al., 2008). In addition, mTORC1 plays 
a key role in the sensing of intracellular amino acid levels via a class of small G-proteins known as 
the Rag GTPases. RagA/B-RagC/D heterodimers associate directly with mTORC1, which is 
dependent upon the nucleotide-loading state of the Rag proteins, consisting of mainly GTP-bound 
RagA/B and GDP-bound RagC/D in amino acid rich conditions. Rag proteins possess the 
inherent ability to sense amino acid levels which is dependent on their nucleotide loading state, 
promoting the accumulation of GDP-bound RagA/D and GTP-bound RagC/D during starvation 
that cannot bind mTORC1 (Kim et al., 2008; Sancak et al., 2008). However, it appears that the 
Rag proteins do not function to directly stimulate mTORC1 activity, acting more to spatially 
control the localisation and exposure of mTORC1 to Rheb through other accessory proteins 
(Sancak et al., 2010; Bar-Peled et al., 2012).  
In response to an abundance of nutrition, mTORC1 primarily serves to drive anabolic processes 
that result in cell growth and proliferation. Activation of mTORC1 directly regulates the eukaryotic 
translation machinery by phosphorylating the eukaryotic initiation factor 4E (eIF4E), which 
disassociates from the 5’-cap of mRNAs and allows translation to proceed (Gingras et al., 2001). 
Complementarily, activated mTORC1 also drives the phosphorylation and activation of S6 kinase 
(S6K), which activates downstream factors that stimulate ribosome biogenesis (Martin et al., 2002; 
Jastrzebski et al., 2007). S6K is also known to phosphorylate insulin receptor substrate 1 (IRS1), 
inhibiting its ability to activate PI3K and thus forming a negative feedback loop that acts to regulate 
further mTORC1 activation. In addition, mTORC1 also drives the biosynthesis of lipids and 
nucleotides, promoting the expression of several enzymes in the pentose phosphate pathway and 
activating Gln-dependent carbamoyl-phosphate synthase, Asp carbamoyltransferase, 
dihydroorotase (CAD), a key enzyme involved in de novo pyrimidine synthesis (Düvel et al., 2010; 
Ben-Sahra et al., 2013; Robitaille et al., 2013). Further to driving these anabolic processes, 
mTORC1 also positively enforces cell survival and proliferation by inhibiting autophagy via the 
phosphorylation and inhibition of UNC-51 like kinase 1 (ULK1), which is consequently unable to 
activate the vacuolar protein sorting 34 (VPS34)-Beclin 1-ATG14 complex that initiates autophagy 
(Kim et al., 2011).  
ii. mTORC2 
In contrast to mTORC1, the factors and regulative processes driving mTORC2 activation remain 
critically understudied. Unlike mTORC1, activation of mTORC2 appears to occur only upon PI3K 
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stimulation and is driven by association with the ribosome (Zinzalla et al. 2011), however the 
molecular details linking these two events remain unknown. Originally, mTORC2 was determined 
to be the long sought ‘PDK2’, phosphorylating Akt at the hydrophobic tail S473 residue, resulting 
in its full activation (Sarbassov et al., 2005), however further work has revealed other important 
functions for mTORC2. The ribosome-dependent activation immediately suggests that mTORC2 
plays a critical role in the regulation of protein synthesis, and subsequent studies have shown this 
to be true. In addition to phosphorylating Akt at S473, mTORC2 also co-translationally 
phosphorylates Akt at the turn motif T450 residue, which has been demonstrated to promote Akt 
stabilisation and resistance to ubiquitination (Oh et al., 2010). More recently, mTORC2 has also 
been shown to promote stabilisation of the IGF2 mRNA-binding protein 1 (IMP1) via the same 
mechanism, which subsequently enhances the production of insulin-like growth factor 2 (IGF2) 
and cell proliferation (Dai et al., 2013). Thus, co-translational phosphorylation is a hallmark 
mechanism that is directly attributed to mTORC2, which is likely to apply to many other as of yet 
undiscovered substrates.  
1.3.3.4 Relevance of mTOR signalling to development and differentiation 
Given that the PI3K/Akt/mTOR signalling pathway plays a major role in promoting the growth 
and expansion of cells, it is perhaps unsurprising to find that this signalling axis also impinges upon 
many aspects of development and stem cell differentiation. With regards to development, loss of 
various components of the signalling cascade often results in embryonic lethality. Deletion of the 
p110 catalytic subunit in the mouse results in embryonic lethality at E9.5 due to cephalic and 
proliferative defects, (Bi et al., 1999) whilst Akt1/Akt3 double-null mice display embryonic 
lethality a little later at E10.5 due to cardiovascular defects and impaired brain development (Yang 
et al., 2005). Similar phenotypes are observed in TSC1 and TSC2 null embryos, which die around 
stage E10.5-11.5 due to a failure in neural tube closure and anencephaly (Onda et al., 1999; 
Kobayashi et al., 2001). More significantly, mTOR-null and rapamycin treated embryos display 
lethality at an even earlier stage at E5.5-6.5 not long after implantation due to defects in the 
proliferation of ICM and TE cells (Gangloff et al., 2004; Murakami et al., 2004). In taking this 
observation further, Raptor and Rictor knockout mice have also been generated in order to define 
the contributions of mTORC1 and mTORC2 respectively to these defects. Raptor knockout mice 
largely phenocopy that of mTOR-null embryos, in that blastocyst explants show proliferation 
defects in the ICM and trophoblast, whilst deletion of Rictor only results in lethality around E10.5 
due to vascular defects (Guertin et al., 2006b; Shiota et al., 2006). Therefore, it appears that 
mTORC1 is required early on in development mainly to drive cell proliferation, whilst mTORC2 
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is required later during mid-gestation to coordinate tissue vascularisation and consolidate their 
response to growth factors. Furthermore, given that PTEN knockout mice possess more or less 
the same defective features and embryonic lethality observed in p110 knockouts (Suzuki et al., 
1998), the role PI3K/Akt/mTOR signalling plays in modulating developmental processes may 
also depend on an optimal level of signalling, as well as interactions with other key developmental 
pathways.  
Since developmental progression reaches the post-implantation stage in p110, Akt and mTORC-
null mouse mutants, it appears that the PI3K/Akt/mTOR pathway is largely dispensable in germ 
layer specification. However, the fact that all of the above null phenotypes result in embryonic 
lethality suggests that rather than directly driving differentiation, components of the 
PI3K/Akt/mTOR cascade are likely to regulate the differentiation process and promote the 
expansion and homeostasis of differentiated progenitors. This is evident in that LY-mediated 
inhibition of PI3K in mESCs results in the loss of self-renewal and attenuated the expression of 
Nanog (Paling et al., 2004; Storm et al., 2007), whilst PI3K inhibition in hESCs downregulated the 
expression and activity of stage-specific embryonic-antigen 4 (SSEA4) and alkaline phosphatase 
respectively, which is indicative of pluripotency loss (Armstrong et al., 2006). Moreover, 
expression of constitutively active Akt is sufficient in preserving the pluripotency of mouse and 
primate ES cells (Watanabe et al., 2006), whilst treatment of hESCs with the mTORC1 inhibitor 
rapamycin induced the loss of pluripotency and the induction of definitive endoderm (Zhou et al., 
2009). Furthermore, siRNA-mediated knockdown of PTEN in hESCs promoted self-renewal at 
the expense of differentiation potential, with a greater bias towards the formation of 
neuroectoderm over mesendoderm (Alva at al., 2011). This is in agreement with previous findings 
that demonstrated the need to inhibit PI3K/Akt/mTOR signalling in hESCs in order to achieve 
efficient differentiation towards the definitive endoderm, (McLean et al., 2007), as well as the ability 
of insulin to redirect endoderm and mesoderm progenitors during in vitro cardiogenesis towards 
the neuroectoderm (Freund et al., 2008). Therefore, efficient specification of the DE in vitro is 
likely to require a combinatorial approach that takes into consideration the regulatory 
contributions of PI3K/Akt/mTOR signalling. 
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1.4 Modelling DE development using hESCs 
1.4.1 Derivation of hESC lines 
Although developmental studies have undoubtedly been a success as an ideological springboard 
from which to investigate human development, there are both ethical and technological difficulties 
in performing similar experiments using human embryos. Furthermore, the complex environment 
cells reside in the embryo precludes any meaningful investigation of the molecular underpinnings, 
making a complete characterisation of the mechanisms responsible impossible. Once again in 
turning to the mouse model, seminal work performed by two independent groups demonstrated 
that cells from the ICM could be isolated and cultured from mouse blastocysts in vitro (Evans and 
Kaufman, 1981; Martin, 1981). These cells, termed mESCs were shown to possess a normal 
karyotype and could self-renew indefinitely in culture, whilst being able to be differentiated into 
cells derived from all three germ layers but not the placenta, much like the cells of the ICM. This 
powerful property of pluripotency is strikingly evident in that when these cells were injected into 
blastocysts, they were able to produce chimeras, contributing to the formation of all tissues, 
including germ cells and thus generating entire embryos via germline transmission. Furthermore 
when injected into developmentally compromised tetraploid blastocysts, some of these mESCs 
were able to generate the intact embryo by themselves; the most stringent definitive test of 
pluripotency (Nagy et al., 1990 and 1993). In addition to mESCs, another population of stem cells 
have been isolated from the post-implantation epiblast known as epiblast stem cells or EpiSCs 
(Brons et al., 2007; Tesar et al., 2007). These cells retain the self-renewing and pluripotent 
characteristics of mESCs in that they are able to be cultured indefinitely and form teratomas 
respectively, but critically, are unable to form chimeras unless directly reprogrammed to do so 
(Tesar et al., 2007; Guo et al., 2009). Although this suggests that EpiSCs may therefore represent 
a more primed stem cell population that are unable to completely recapitulate pluripotency to the 
same degree as the more naive mESCs, several findings contradict this argument. For example, 
EpiSCs retain the ability to give rise to TE, which is not observed in mESCs unless they are 
cultured under specific conditions (Schenke-Layland et al., 2007, Morgani et al., 2013). Therefore 
it can be argued that EpiSCs are in this respect more naive than mESCs in terms of their 
differentiation potential and that the pluripotent efficacy of all embryonic stem cells is likely to be 
heavily dependent on their culture conditions. Furthermore, the ability to form chimeras may be a 
species-dependent effect rather than a true reflection of stem cell naivety, since chimera formation 
from embryo-derived stem cells has only been demonstrated in the laboratory mouse and rat 
strains, but not in wild-type mouse, farm animals and primates (Nagy et al., 1993; Buehr et al., 
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2008; Li et al., 2008; Tachibana et al., 2012). Thus, it is impossible to distinguish whether the failure 
of chimera formation in other species is truly due to a loss of naivety or simply due to 
immunological incompatibility with the host embryo. Nevertheless, the derivation of several 
embryonic stem cell populations allowed for the generation of transgenic organisms with relative 
ease, and thus offered a model through which the effect of genetic manipulation could be 
examined on an organism-wide scale, albeit with a significant caveat in place in terms of 
interspecies relevance (Robertson et al., 1986).  
Several decades later, successful isolation of primate and human embryonic stem cells swiftly 
followed utilising refined techniques developed from their initial isolation in mice (Thomson et al., 
1995 and 1998). These cells, much like their mouse counterparts, are karyotypically stable, and can 
give rise to cells originating from the three germ layers evidenced by teratoma formation in 
immunocompromised mice, whilst also being able to be propagated indefinitely in culture. 
However whether hESC could contribute to the formation of chimeras remains unknown due to 
ethical constraints, although recent success in forming chimeras by combining primate embryos at 
the 4-cell stage but not from primate ESCs provides compelling evidence to suggest that the same 
situation applies to human derived pluripotent cells (Tachibana et al., 2012). Although the inability 
of primate ESCs and likely hESCs to successfully form chimeras suggests that the isolated cells 
may represent a more primed population which has already lost some efficacy in terms of 
pluripotency, this again could equally be regarded as a consequence of species to species variation, 
as chimera generation has only been formally demonstrated in rodents. Furthermore, studies in 
atypical animal models such as cattle have begun to reveal species-dependent differences pertaining 
to the specification and maintenance of the TE (Berg et al., 2011), which is likely to also apply 
when translating findings from mouse and primate ESCs to human ESCs. As such, there remains 
ample scope for the use of hESCs in order to study human development, given that findings in 
mice and other vertebrate models may not necessarily correlate completely to that of humans.  
1.4.2 Maintenance of pluripotency 
The retention of pluripotency is a key hallmark demarcating embryonic and pluripotent stem cells 
from other cell types, and is governed by coordinated regulation of intrinsic and extrinsic factors. 
Intrinsic factors are transcription factors, represented by the key trio of Oct4, Sox2 and Nanog 
(OSN) that form a distinct core transcriptional circuitry to activate the expression of pluripotent 
genes, including themselves, whilst also acting to repress the expression of lineage-specific genes 
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and maintain the pluripotent state (Boyer et al., 2010). Expression of these core transcription 
factors is additionally subject to regulation by extrinsic signalling pathways (Figure 1.8). 
 
Figure 1.8: Differences in signalling requirements for human and mouse ESC maintenance 
and differentiation.  
Summary of the shared and divergent actions of signalling pathways in mediating mouse and human 
ESC self-renewal, pluripotency and differentiation. In hESCs, FGF2 signalling is able to prevent 
differentiation by suppressing BMP4 and stimulating PI3K activity in combination with low amounts 
of Activin/Nodal and Wnt signalling. Conversely, mESCs depend upon LIF combined with BMP4 to 
suppress differentiation due to MEK1/2 and GSK3β activity. Adapted and presented with permission 
from John Wiley and Sons: Stem Cells, Schnerch, copyright 2010. 
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1.4.2.1 Intrinsic factors 
i. Oct4 
Oct4, encoded by the Pou5f1 allele, is a member of the Pit-Oct-Unc (POU) family of 
homeodomain proteins whose expression is initially found in the blastomeres and later becomes 
restricted to the epiblast and primordial germ cells (Palmieri et al., 1994; Pesce et al., 1998). As 
such, hESCs isolated from the ICM also express Oct4 at high levels, which points to the 
involvement of this factor in the maintenance of the pluripotent state. Loss of Oct4 in mice 
embryos results in the complete absence of ICM, with only TE present (Nichols et al., 1998), 
whilst overexpression in ESCs triggers the formation of PrE and mesoderm (Niwa et al., 2000). 
Interestingly, the same study also noted that different levels of Oct4 expression resulted in 
different cell fates, ranging from TE to mesoderm at lower and higher than ESC levels of Oct4 
respectively. More recent evidence suggests this lineage specifying property of Oct4 also applies 
to both mESC and hESC cultures, whilst also extending the same properties to Sox2 and Nanog 
(Hay et al., 2004; Wang et al., 2012). As such, Oct4 possesses multifaceted roles during the course 
of development, acting initially to preserve pluripotency by guarding against TE differentiation, 
whilst also playing a major role in the latter germ layer specification of endoderm and mesoderm 
before becoming restricted to the germ cells of the adult organism.  
ii. Sox2 
Sox2, a member of the HMG group of transcription factors is also implicitly involved in the 
preservation of the pluripotent state. Much like Oct4, Sox2 is initially detected at the morula stage, 
before being confined to the ICM of the pre-implantation epiblast, with the loss of Sox2 abolishing 
ICM formation (Avilion et al., 2003). As such, loss of Sox2 in ESCs results in the rapid loss of 
pluripotency markers and differentiation to primarily TE tissues (Ivanova et al., 2006; Masui et al., 
2007). The remarkable similarity between Oct4-null and Sox2-null mutants led to the suspicion 
that both factors act to regulate a redundant set of genes necessary in preserving pluripotency. 
This is further evidenced by the fact that forced expression of Oct4 in Sox2-null mice is able to 
rescue the loss of pluripotency in these cells (Masui et al., 2007; Fong et al., 2008). Agreeably, both 
Sox2 and Oct4 have been shown to reciprocally occupy their respective enhancer regions, as well 
as co-occupying sites upstream of many genes that have been shown to be important for regulating 
pluripotency (Boyer et al., 2005; Loh et al., 2006; Chen et al., 2008), which further suggests mutual 
regulation of their expression and hence function. Furthermore, Sox2 has also been shown to 
suppress the expression of primitive streak markers (Wang et al., 2012), which implies that Sox2 
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acts to regulate the expression of Oct4, preventing both the formation of TE and mesendoderm, 
whilst also acting in conjunction with Oct4 to consolidate the pluripotent state. The powerful 
pluripotent inducing and consolidating properties of both Oct4 and Sox2 are strikingly evident in 
that transgenic overexpression in conjunction with Krüppel-like factor 4 (Klf4) and c-myc is 
capable of reprogramming fully differentiated fibroblasts back into an embryonic stem cell-like 
state (Takahashi and Yamanaka, 2006).  
iii. Nanog 
The third component of the pluripotency triad is Nanog, a homeobox protein that was originally 
discovered using a genetic screen for factors that could maintain mESC pluripotency in the 
absence of LIF, (Chambers et al., 2003; Mitsui et al., 2003). In vivo, Nanog expression is first 
detectable in the compacted morula, which like Oct4 and Sox2, becomes progressively restricted 
first to the ICM and latterly to the germ cells post-implantation (Mitsui et al., 2003). Subsequently, 
loss of Nanog results in the concurrent cessation of post-implantation development, however 
unlike the loss of Oct4 or Sox2, structures resembling the ICM is still evident in Nanog-null 
blastocysts. Although ESCs can be successfully isolated and propagated from these blastocysts, 
they are more prone to differentiate into primarily TE tissues (Mitsui el al., 2003). Concurrently, 
conditionally Nanog-null ESC lines are able to contribute to the formation of all somatic lineages 
with the exception of germ cells, which implies that Nanog is ultimately dispensable for ESC 
pluripotency (Chambers et al., 2007). Thus, it appears that Nanog plays a critical role in the 
establishment of the pluripotent state rather than strictly promoting its maintenance. However, 
given that Nanog itself is a Sox2/Oct4 target (Rodda et al., 2005), concurrent expression of all three 
factors acts to fully consolidate and maintain the pluripotent transcriptional program (Loh et al., 
2006; Chen et al., 2008).  
1.4.2.2 Extrinsic factors  
The culture and maintenance of embryonic stem cells require specific combinations of signalling 
ligands that act to stimulate the transcriptional machinery necessary in preventing spontaneous 
differentiation, which appear to differ between human and mouse (Figure 1.3). In the case of 
mouse ESCs (mESCs), co-culture with mitotically inactivated embryonic fibroblasts in the 
presence of serum was sufficient in supplying the extrinsic cues needed to maintain the pluripotent 
state (Evans and Kaufman, 1981; Martin, 1981). This was further refined upon the discovery that 
LIF and BMP4 could replace both serum and feeders, allowing the development of more defined 
culture conditions (Smith et al., 1988; Williams et al., 1988; Ying et al., 2003). Recent evidence has 
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taken this even further, in that mESCs can be isolated and cultured in the absence of BMP4, but 
in the presence of GSK3 and MAPK inhibitors supplemented together with LIF (termed 2i/LIF), 
(Ying et al., 2008). The fact that ESCs can exist under different signalling environments posits the 
existence of a spectrum of cell states that reflect the differentiation capacity of the cells. This is 
evident in that mESCs when cultured under 2i/LIF conditions are able to form extraembryonic 
tissues (Morgani et al., 2013), which does not occur in feeder-dependent mESCs and is suggestive 
of a conversion to a more naive state, termed the ground-state. In contrast, EpiSCs whilst still 
retaining the pluripotent features of mESCs, fail to significantly contribute to chimeras and the 
germline, which is indicative of a loss in pluripotent efficacy (Brons et al., 2007; Tesar et al., 2007). 
However, isolation of a subpopulation within EpiSC cultures that resemble cells of the early 
epiblast is able to restore chimera formation (Han et al., 2010), which again highlights the inherent 
heterogeneity of ESC cultures in their propensity for differentiation and that culture conditions 
can act to determine the efficacy of differentiation. 
The idea that embryonic stem cells can exist in varying states of differentiation efficacy becomes 
even more evident when considering the culture conditions that permit the propagation of hESCs. 
Whilst both mESCs and hESCs were originally isolated and propagated in similar ways, it quickly 
became evident that hESCs differed in many respects. Firstly, in terms of morphology, hESC 
colonies are flatter, opposed to the more domed appearance of mESCs and are more reminiscent 
of EpiSCs. Secondly, whilst mESCs can be propagated as single cells independent of feeder, hESCs 
undergo apoptosis when disassociated and rapidly differentiate in the absence of feeders. However, 
hESCs can be successfully cultured feeder-free if passaged onto Matrigel-coated plates 
supplemented with mouse embryonic fibroblast conditioned media (MEF-CM), and as single cells 
if the media is supplemented with Rho kinase inhibitor or ROCKi (Watanabe et al., 2007). Finally, 
and perhaps most importantly, hESCs differ in their response to extrinsic signalling cues. hESCs 
do not require LIF for propagation or maintenance, but instead requires fibroblast growth factor 
2 (FGF2), (Dahéron et al., 2004; Dvorak et al., 2005). FGF2 is thought to exert both direct and 
indirect effects that positively enforce the pluripotent state. Provision of exogenous FGF2 to 
hESCs reduces spontaneous differentiation, promotes cell adhesion, survival and proliferation 
whilst also indirectly stimulating the secretion of AA from the feeder layer (Greber et al., 2007; Li 
et al., 2007; Eiselleova et al., 2009). Low levels of AA act to drive the expression of Nanog, a key 
pluripotency factor and hence act in tandem with the other pleiotropic effects of FGF2 to maintain 
hESC self-renewal and pluripotency (Vallier et al., 2005; Xu et al., 2008). Contrastingly, unlike in 
mESCs, the presence of BMPs in hESC cultures act to promote differentiation of hESCs, in that 
hESCs cultured in defined media containing the native BMP antagonist Noggin retain pluripotency 
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(Xu et al., 2005). The similarity in the signalling response between hESCs and EpiSCs rather than 
mESCs, coupled with the inability of primate derived ESCs to form chimeras suggests that hESCs 
are more equivalent to the primed EpiSCs than mESCs (Tesar et al., 2007). This has recently been 
supported by the successful derivation of naive hESCs by several groups, which retain molecular 
and functional properties that are more akin to mESCs but with different extrinsic culture 
conditions (Gafni et al., 2013; Takashima et al., 2014; Theunissen et al., 2014). However, hESCs 
do not express the EpiSC marker, FGF5, but retain expression of the mESC marker Rex1, 
indicating that the difference between hESCs and mESCs could also be attributed to distinct 
species to species differences. Nevertheless, the relative ease by which naive and primed hESCs 
can be propagated under increasingly more defined conditions makes them excellent cell models 
from which to interrogate molecular mechanisms governing directed differentiation. 
1.4.3 Interaction of extrinsic and intrinsic factors in hESCs 
Given that mouse and human ESCs differ significantly in their response to extrinsic cues necessary 
for the maintenance of self-renewal and pluripotency, the mechanism by which signalling pathways 
establish the OSN network must also differ. Although it is generally accepted that FGF2 and 
Activin/Nodal signalling are the two key pathways needed to maintain hESC pluripotency, 
unravelling the exact molecular mechanisms involved in this process have proved difficult and 
poorly characterised when compared to mESCs. This is due to the inherent pleiotropic effects 
attributed to FGF2 signalling and the multitude of culture conditions in which hESCs are 
propagated. Whilst it has been suggested that FGF2 may act via ERK to prevent differentiation to 
extra embryonic lineages (Li et al., 2007), it appears that this alone is insufficient in that both FGF2 
and Activin/Nodal signalling are required to maintain hESCs in the absence of MEF-CM or 
feeders via the upregulation of Nanog (Vallier et al., 2005 and 2009). This has been supported by 
chromatin immunoprecipitation (CHIP) experiments which show the direct association of Smads 
with the Nanog proximal promoter (Xu et al., 2008) as well as with other pluripotency genes such 
as Oct4, Telomerase reverse transcriptase (TERT) and myc (Brown et al., 2011), thereby 
underscoring the critical importance of Smad2/3 and Nodal/Activin signalling to the maintenance 
of pluripotency.  
The contentious issue of hESCs representing a more primed pluripotent population akin to that 
of EpiSCs has been recently reinforced by the successful derivation of naive hESCs, which may 
serve to account for the difference in extrinsic factors required for the propagation of mESCs and 
hESCs. The induction of naivety in conventional hESCs via the expression of Klf2 and Nanog 
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transgenes results in global changes in DNA methylation, gene transcription and metabolic output 
that is more similar to mESCs (Takashima et al., 2014). This coupled with the ability of these cells 
to retain pluripotency under culture conditions which completely lack exogenous growth factors 
strongly suggests that the maintenance of pluripotency in conventional hESC cultures require 
FGF2 and Activin/Nodal signalling simply because the transcriptional circuitry requires greater 
reinforcement in order to be stably propagated. Moreover, the existence of this ground-state is 
evident in that transient transgene expression is sufficient to revert conventional hESCs into a 
more naive state albeit their propagation requires reinforcement via culture with 2i/LIF and the 
PKC inhibitor Gö6983. Together, these finding may reflect the transient nature of pluripotency in 
vivo, as well as the intrinsic propensity towards differentiation during development. 
1.4.4 Differentiation of hESCs to definitive endoderm and hepatocytes 
1.4.4.1 Combinatorial approaches to in vitro DE specification 
As demonstrated in the mouse and ESCs, the induction of DE formation principally requires the 
presence of Activin/Nodal signalling. However, given that low levels of Activin/Nodal are 
conducive to preserving pluripotency in vitro (Vallier et al., 2005) and for specifying mesoderm in 
vivo (Vincent et al., 2003), the induction of DE should therefore require high or sustained levels of 
Activin/Nodal stimulus. AA serves as an effective surrogate for Nodal in the in vitro induction of 
DE as it is more stable in storage and in culture unlike Nodal whilst still inducing the same 
downstream signal cascade. Effective endoderm specification utilising high dose Activin was first 
demonstrated in mESCs, which when cultured under low attachment conditions in serum-free 
media containing AA readily forms embryoid bodies which contain brachyury-positive cells that 
formed endoderm structures when purified and transplanted into mouse kidney capsules (Kubo 
et al., 2004). This process was subsequently refined in the derivation of DE cells from hESCs, 
utilising monolayer cultures to maximise the exposure of the cells to the signalling ligand. Under 
these conditions, hESCs progressed through a primitive streak-like phase, recapitulating the in vivo 
developmental program and resulting in a greater number of Sox17-positive cells (D’Amour et al., 
2005). Furthermore, the same study found that the presence of serum drastically reduced the 
efficiency of this specification, and a subsequent study would implicitly link the PI3K pathway to 
this inhibitive effect, in that dual treatment of hESCs with both Activin and the PI3K inhibitor 
LY promoted a more efficient Activin-induced DE differentiation (McLean et al., 2007). Thus, the 
conditions favouring efficient endoderm formation include high or sustained Activin coupled with 
low PI3K signalling, although the exact underlying mechanisms remain unknown.  
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Evidently from developmental studies, although Activin/Nodal signalling is critical in the 
formation of any mesendodermal tissue, the Wnt/β-catenin pathway also functions to 
cooperatively aid in the specification of the primitive streak and mesendoderm (Conlon et al., 1994; 
Liu et al., 1999). As such, modulation of the Wnt/β-catenin signalling in hESCs coupled with 
TGFβ signalling should also positively reinforce the formation of endoderm. Several studies have 
reported this effect, in that inducible expression of constitutively active β-catenin or 
supplementation with active Wnt3a ligand together with BMP or Activin in hESCs promoted the 
formation of mesoderm and endoderm respectively (Hay et al., 2008; Sumi et al., 2008). 
Furthermore, recent studies employing the use of GSK3β inhibitors that largely mimic the effects 
seen when Wnt/β-catenin signalling is activated also improved the derivation of Activin-induced 
DE to similar levels as that of directly supplying Wnt3a (Kunisada et al., 2012; Teo et al., 2014). 
In addition to signalling ligands, the application of epigenetic modifiers has also been shown to 
improve the derivation of DE when combined with high dose Activin. For example, use of sodium 
butyrate is known to improve the homogeneity of DE specification in hESCs by inhibiting the 
action of histone deacetylases (Jiang et al., 2007; Hay et al., 2008b). However this method also 
resulted in high levels of cell death and permanent modifications to the epigenetic landscape that 
impacted further differentiation from the DE stage. As such, the predominant method for deriving 
DE from hESCs is still very much a growth factor and small molecule inhibitor driven process, 
although the molecular mechanisms behind this process remains largely incomplete. 
1.4.4.2 Derivation of hepatocytes from hESC-derived DE for therapeutic use 
Liver disease represents a major health concern, given that over 1 million people die globally each 
year from acute or chronic liver failure (Gonzalez and Keeffe, 2011) and that the only effective 
therapeutic intervention in most cases is transplantation. Evidently, this has resulted in a significant 
number of patients dying whilst waiting for donor organs to become available, constituting a 
significant bottleneck in preventing liver disease associated mortality. Efforts to develop alternative 
therapeutic options using cells isolated from native sources such as foetal hepatocytes or using 
adult livers to derived hepatic cell lines have been largely unsuccessful due to their functional 
immaturity and limited capacity for expansion to levels required for therapeutic use respectively.  
As such, efforts made to circumvent these limitations have resulted in the use of pluripotent stem 
cells as a platform from which to derive functional hepatocytes, since stem cells are able to be 
cultured indefinitely while possessing the inherent ability to form any cell constituting the adult 
organism. 
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The efficient derivation of a highly homogenous population of DE from hESCs or iPSCs 
represents the first stage from which more specialised and therapeutically useful hepatocytes can 
be derived (Figure 1.8). As outlined in the previous section, several different methods exist by 
which to achieve this, mainly utilising high dose Activin in combination with inhibitors or growth 
factors that serve to improve the homogeneity of the final culture. However, the culture conditions 
driving the commitment of DE cells to hepatocyte progenitors are generally conserved in most 
protocols, in that BMP2/4 and FGF2 are either sequentially applied or given in combination to 
the culture (Cai et al., 2007; Song et al., 2009; Si-Tayeb et al., 2010; Touboul et al., 2010). The 
hepatic specifying activities of BMP2/4 and FGF2 are also well characterised in the mouse, and 
are consequently able to enforce the commitment of hESC and iPSC derived DE towards the 
hepatic lineage (Jung et al., 1999; Rossi et al., 2001). Following the formation of hepatocyte 
progenitors known as hepatoblasts, further culture is required to achieve functional maturation, 
involving treatment with hepatocyte growth factor (HGF), oncostatin M (OSM) and 
dexamethasone which have been shown to drive the maturation of foetal hepatocytes (Kamiya et 
al., 2001; Suzuki et al., 2003). The resultant cells are morphologically similar to that of primary 
hepatocytes, notably in being polygonal in shape, highly vacuolarised and possessing prominent 
nucleoli.  
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Figure 1.9: Hepatic differentiation from DE  
Schematic depicting the most commonly used culture conditions in converting ESCs to hepatocyte-like 
cells. High dose Activin treatment converts ESCs to DE, which is accompanied by progressive 
downregulation of Oct4 coupled with the induction of Sox17 and FoxA2. DE cells are directed towards 
the hepatic lineage upon exposure to FGF and BMP signalling, resulting in the expression of AFP, 
albumin and HNF4α. Further maturation with HGF, OSM and Dex results in hepatocyte maturation, 
accompanied by increased albumin secretion and the gain of detoxification activities. Image taken and 
adapted from Zorn, 2008. 
 
The progression from hESC/iPSC to mature hepatocyte-like cells is accompanied by distinctive 
changes in gene expression profiles that are characteristic of each stage of differentiation (Figure 
1.9), which also largely mimics what is observed in vivo. Much like the cells of the ICM, 
hESCs/iPSCs express high levels of Oct4, Sox2 and Nanog, which become progressively 
downregulated upon DE conversion. This is accompanied by a transient upregulation of primitive 
streak markers such as Brachyury, which is rapidly downregulated upon continued culture as the 
cells adopt a more endoderm fate opposed to the mesoderm. The DE fate is consolidated by the 
increasing upregulation of factors such as MixL1, Eomes, Sox17 and FoxA2, which also serve as 
markers defining the successful formation of DE in culture. Sox17 expression is progressively lost 
during the maturation stages, whilst FoxA2 persists throughout (Si-Tayeb et al., 2010). However, 
in the early stages of DE specification, many of these profiles are shared with the extraembryonic 
endoderm. The DE identity is demarcated by the ability of DE to form cells of hepatic origin upon 
further culture, and serves as important test by which to verify the successful formation of DE 
over extraembryonic endoderm. Transition of DE to hepatoblast cells is marked by an increase in 
the expression of genes that are characteristic of the foetal liver such as alpha-fetoprotein (AFP), 
which is progressively downregulated as the hepatoblasts are matured into hepatocyte-like cells 
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concomitant with increased albumin secretion. Much like primary hepatocytes, these hepatocyte-
like cells express several genes that strongly correlate with the acquisition of a functional 
hepatocyte phenotype, such as the expression of albumin and detoxification enzymes such as 
cytochrome P450 (CYP450), which can be further assessed on a functional level by specialised 
assays to determine the degree of maturation achieved by different protocols (Schwartz et al., 2005; 
Khetani and Bhatia, 2008; Chen et al., 2011).   
Despite the relative ease by which hepatocyte-like cells can be derived from hESC/iPSCs, 
significant hurdles remain to be overcome before they can be used therapeutically. The main 
obstacles concern the inability of these cells to fully recapitulate all the functions associated with 
primary hepatocytes over long term and difficulties in scaling up the differentiation process to 
obtain a sufficient number of cells for therapeutic intervention. Furthermore, although the advent 
of iPSCs has made the prospect of autologous derivation and transplantation of hepatocytes 
possible, there are questions surrounding the genomic stability of these derived cells. Many of 
these problems stem from an inefficient derivation of DE, producing cells which although 
competent in converting to hepatic fates, are nonetheless already functionally compromised due 
to either partial conversion or exposure to toxic factors required to drive the initial exit from the 
stem cell state. As such there is an inherent need for a more complete molecular characterisation 
of this initial stage of differentiation, in an effort to improve the functional properties of resultant 
hepatocytes. 
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1.5 Aims and Hypothesis 
Whilst Activin/Nodal signalling has been shown to be the critical pathway in driving DE 
formation, the importance of PI3K signalling in driving the proliferation and consolidation of 
differentiated tissues has firmly established this pathway as a key modulator of DE specification. 
Although previous studies have demonstrated the antagonistic effect of PI3K signalling upon DE 
differentiation, the use of undefined culture conditions precludes any attempt at defining the 
molecular basis for this effect (D’Amour et al., 2005; McLean et al., 2007). Although several groups 
have proposed a range of molecular mechanisms by which to explain why PI3K activity 
antagonises TGFβ-induced apoptosis and cell cycle arrest (Conery et al., 2004; Remy et al., 2004; 
Song et al., 2006), it is questionable whether these mechanisms apply to hESCs and their 
differentiation, given that all of these studies were performed in tumour lines that are known to 
possess abnormal signalling responses. Although one recent study attributed the antagonistic effect 
of PI3K/mTOR signalling on DE differentiation in hESCs to an indirect effect of Wnt/β-catenin 
inhibition (Singh et al., 2012), they could not explain the origin of the increase in Smad2/3 
activation observed in their study, which hinted at a more direct mechanism through which 
PI3K/mTOR signalling impacts R-Smad activity (Chen et al., 2012).  
As such, this study posits the existence of a direct mechanism through which components of the 
PI3K pathway interact to regulate the activity of Activin-induced R-Smads. Specifically this study 
aims to assess this hypothesis in the following manner: 
1) Verify the relationship between PI3K mediators and R-Smad activity during DE 
differentiation in hESCs under chemically defined conditions. 
2) Fully characterising and robustly testing the molecular mechanisms involved in mediating 
this crosstalk through inhibitor assays and gain or loss-of-function approaches. 
3) Develop new methods by which to differentiate hESCs to DE utilising new insights gained 
from the molecular model in order to improve hepatocyte differentiation.  
Completion of this study will hence contribute to a greater understanding of the crosstalk 
mechanisms governing DE formation, from which new methods can be developed to improve 
the efficiency of hESC to DE differentiation and ultimately improve the procurement of 
functionally competent hepatocytes.  
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2.1 Cell Culture 
2.1.1 Materials 
2.1.1.1 Cell Lines 
All cells were cultured at 37 oC with 5% CO2.  
Cells Source 
H1 hESC (WA-01) Male human ES cell line isolated by Thomson et al., 
1998, distributed by WiCell. 
PC-3 Prostate adenocarcinoma cell line derived from a 
metastatic site in the bone, kind gift from Dr. Robert 
Krypta. 
Hep3B Liver cell line derived from hepatocellular carcinoma, 
obtained from the European Collection of Cell 
Cultures (ECACC). 
HEK293T Kidney cell line immortalised by T-antigen delivered 
by adenovirus, obtained from the ECACC. 
Mouse Embryonic Fibroblasts (MEFs) Wild-type MEFs isolated from E13.5 CD-1 mouse 
embryos. 
Rictor-Control MEFs Control MEFs for Rictor-null kind gift from Prof. 
Mark Magnuson (Shiota et al., 2006). 
Rictor-Null MEFs Immortalised MEFs with knockout of Rictor gene 
also from Prof. Mark Magnuson (Shiota et al., 2006). 
 
2.1.1.2 Growth Factors and Inhibitors 
All growth factors reconstituted in Dulbecco’s Phosphate Buffered Saline (DPBS) supplemented 
with 0.2% BSA as carrier, all inhibitors reconstituted in DMSO with the exception of 
chloroquine, puromycin, ascorbic acid and ROCKi which were reconstituted in TC grade H2O.  
Reagent Supplier Working Concentration 
Activin A (AA) Peprotech 100 or 10 ng/ml 
Ascorbic Acid Sigma-Aldrich 50 μg/ml 
Bone Morphogenetic Protein 2 (BMP2) Peprotech 20 ng/ml 
Chloroquine Sigma-Aldrich 25 µM 
Flavopiridol Selleck Chemicals 1 µM  
Hepatocyte Growth Factor (HGF) Peprotech 10 ng/ml 
Heregulin (H) Peprotech 10 ng/ml 
Basic Fibroblast Growth Factor (bFGF) R&D 10 ng/ml 
Hydrocortisone-21-hemisuccinate Sigma-Aldrich 10 µM 
Insulin Sigma-Aldrich 1 µM 
LR3-IGF (I) Sigma-Aldrich 100 ng/ml 
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LY294002 (LY) NEB 20 µM 
MG-132 Millipore 10 µM 
Okadaic Acid Millipore 5 nM 
Oncostatin M (OSM) R&D 20 ng/ml 
Puromycin Sigma-Aldrich 1-2.5 µg/ml 
Rapamycin Sigma-Aldrich 100 nM 
Rho Kinase Inhibitor (ROCKi) Sigma-Aldrich 10 µM 
SB203580 R&D/Tocris 20 µM 
SB431542 Sigma-Aldrich 10 µM 
SP600125 Reagents Direct 500 nM 
Torin-2 (Torin/Tor) R&D/Tocris 10 nM 
U0126 Reagents Direct 10 µM 
Wortmannin (Wort) Sigma-Aldrich 300 nM 
 
2.1.1.3 Media Components 
Component Supplier 
200 mM L-Glutamine Sigma-Aldrich 
100X Penicillin-Streptomycin Sigma-Aldrich 
20% Bovine Serum Albumin (BSA) Sigma-Aldrich 
50X B27 Supplement (-vitamin A) Life Technologies 
Dulbecco's Modified Eagle AQ Media (DMEM-AQ) Sigma-Aldrich 
Heat-inactivated Foetal Bovine Serum (FBS) Sigma-Aldrich 
Knockout DMEM Life Technologies 
Knockout Serum Replacement (KSR) Sigma-Aldrich 
Lebovitz's L-15 Media (L-15) Sigma-Aldrich 
Non-essential Amino Acids (NEAA) Life Technologies 
Opti-MEM® Reduced Serum Medium Life Technologies 
Roswell Park Memorial Institute AQ-Media 1640 (RPMI-AQ) Sigma-Aldrich 
Tryptose Phosphate Broth (TPB) Sigma-Aldrich 
50 mM β-mercaptoethanol  Life Technologies 
 
2.1.1.4 Disassociation Enzymes  
Enzyme Supplier 
Accutase Sigma-Aldrich 
Collagenase IV Life Technologies 
Trypsin-EDTA Sigma-Aldrich 
 
2.1.1.5 Chemicals, Kits and Coating Reagents 
Reagent Supplier 
2% Gelatine in PBS Sigma-Aldrich 
Calcium Phosphate Transfection Kit Sigma-Aldrich 
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Chondroitin Sulphate Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Dual-Glo® Luciferase Assay Kit Promega 
Dulbecco's Phosphate Buffered Saline (DPBS) Sigma-Aldrich 
Hexadimethrine bromide (Polybrene) Sigma-Aldrich 
LipofectamineTM LTX with PLUSTM Reagent Life Technologies 
Matrigel® Matrix Growth Factor Reduced BD Bioscience 
Water Tissue Culture Grade (TC-H2O) Sigma-Aldrich 
 
2.1.1.6 Media and Stock solutions  
All media and stocks were filter sterilised and stored at 4 oC. 
MEF/HEK293T/Hep3B medium (D10) DMEM-AQ supplemented with: 
 10% FBS 
 1x NEAA 
 
1x Penicillin-Streptomycin 
 
PC-3 medium (R10) RPMI-AQ supplemented with: 
 10% FBS 
 1x NEAA 
 
1x Penicillin-Streptomycin 
 
Knockout Serum Replacement KO-DMEM supplemented with: 
Medium (KSR-M) 20% KSR 
 1 mM L-glutamine 
 1x NEAA 
 0.1 M β-mercaptoethanol for TC 
 
1x Penicillin-Streptomycin 
 
MEF-conditioned medium  MEF conditioned KSR-M supplemented with: 
for H1 hESCs (MEF-CM) 1 mM L-glutamine 
 
10 ng/ml bFGF 
 
RPMI/B27 medium (DE differentiation) RPMI-AQ supplemented with: 
 1x B27 
 2 mM L-glutamine 
 
1x Penicillin-Streptomycin 
 
Hepatoblast Specification medium KSR-M supplemented with: 
 20 ng/ml BMP2 
 
10 ng/ml bFGF 
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Hepatocyte Maturation medium (L-15) L-15 supplemented with: 
 8.3% TPB 
 8.3% FBS 
 2 mM L-Glutamine 
 10 µM Hydrocortisone-21-hemisuccinate 
 1 µM Insulin 
 50 µg/ml Ascorbic Acid 
 1x Penicillin-Streptomycin 
 20 ng/ml OSM 
 10 ng/ml HGF 
 
2.1.2 Methods 
2.1.2.1 Culture and propagation of hESCs 
i. Isolation of wild-type MEFs from embryos 
Uterine horns from terminated E13.5 pregnant CD-1 mice were washed three times with DPBS 
containing 2X Penicillin/Streptomycin. Embryos were then removed and individually dissected to 
remove the heart and liver, finely minced and disassociated into single cells with trypsin at 37oC in 
Bijou tubes with one embryo per tube. Tissues were periodically vortexed during this incubation 
period to break up any large clumps of cells. MEFs were then isolated following neutralisation 
with D10 medium by allowing any remaining clumps to settle and extracting the overlying cell 
suspension, which was transferred into T75 flasks with each tube contributing to one flask. Cells 
were allowed to plate down overnight and the medium was changed the following day after they 
were checked for contamination. After 2-3 more days of culture, all the flasks were trypsinised and 
combined and cells were frozen down at 1 x 107 cells per cryovial in D10 medium supplemented 
with 10% DMSO and labelled as P0 (passage 0).  
ii. Generation of MEF-CM 
Frozen MEFs were defrosted and passaged 3 to 4 times in order to obtain sufficient numbers to 
seed 5-7 T225 flasks with 2.5 x 107 cells per flask. After trypsinisation, cells were irradiated at 40 
Gy using an IBL 637 Cell irradiator (CIS-Bio International) to abolish replicative potential. 
Irradiated MEFs were then counted and seeded into T225 flasks pre-coated with 0.5% gelatine at 
a density of 2.5 x 107 cells per flask. After 24 hours, cells were rinsed in DPBS and D10 medium 
was replaced with 150 ml KSR-M per flask. The following day, MEF-CM was collected and stored 
at -80 oC until needed. Fresh KSR-M was added back onto the MEFs and the entire collection 
process was repeated for up to 7 days. Upon use, defrosted MEF-CM was filtered to remove 
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cellular debris and additional 2 mM L-glutamine was added to replenish uptake by MEFs during 
the conditioning. MEF-CM was stored at 4 oC following filtration and used for no longer than 1 
week post-thaw. 
iii. Preparation of Matrigel® coated plates 
Stock Matrigel® was thawed overnight on ice at 4 
oC and diluted 1 in 2 with chilled KO-DMEM 
before being aliquoted into 15 ml tubes at 1 ml per tube. Aliquots were stored at -20 oC until use, 
whereby they were again thawed overnight at 4 oC before being further diluted 1 in 15 with chilled 
KO-DMEM. 6 well plates that were used for the routine culture of hESCs were coated with 1 ml 
per well of this new dilution. Plates were allowed to set at 4 oC overnight and warmed to room 
temperature before use. Excess Matrigel® solution was aspirated off just prior to hESC passaging. 
In emergency circumstances, plates were made on the day of passaging and allowed to set for a 
minimum of 4 hours at room temperature before use. 
iv. Routine culture and maintenance of hESCs 
H1 hESCs grow as distinct colonies and were routinely passaged onto Matrigel® coated plates in 
MEF-CM which is supplemented with 10 ng/ml bFGF before use. Medium was changed daily 
and the cells were routinely passaged when confluent as smaller colonies every 5-7 days using 
200U/ml collagenase IV to remove spontaneously differentiated cells followed by mechanical 
disassociation. Cells were routinely split at a 1:2-1:4 ratio depending on the confluency. For 
freezing hESCs, >80% confluent wells were treated with collagenase IV and mechanically 
dissociated in 1 ml cold KSR, after which 10% v/v DMSO was added in a dropwise fashion. Cells 
were then transferred as clumps into cryovials and stored overnight at -80 oC before transfer into 
liquid nitrogen for long-term storage. 
v. Accutase/ROCKi passaging of hESCs 
hESCs which have been disassociated into single cells undergo rapid apoptosis and are prone to 
differentiate in MEF-CM. Thus, routine maintenance requires that these cells be passaged as small 
colonies to permit their expansion. However, cell clumps are not permissive for efficient DNA 
transfection and often form large compacted colonies during culture, which also impedes directed 
differentiation. As such, for these purposes, hESCs were subjected to an Accutase/ROCKi split, 
whereby confluent cultures were disassociated into single cells upon treatment with accutase and 
split at a ratio of 1:3-1:4. The activity of accutase was inhibited upon the addition of media, and 
the associated apoptosis was mitigated by the supplementation of 10 µM ROCKi (Watanabe et al., 
2007) to the MEF-CM as the cells plate down overnight. The following day, ROCKi was removed 
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from the culture upon medium change to minimise chronic effects of Rho kinase inhibition. After 
one day of further culture, the resultant monolayer is hence conducive for efficient transfection 
and differentiation.  
2.1.2.2 Differentiation of hESCs to DE and hepatocytes 
i. AA-LY induced DE differentiation 
High-quality hESC cultures were characterised based on their morphology to determine the 
feasibility of differentiation. Cultures contained less that 5% clearly differentiated or stromal cells, 
with a corresponding abundance of undifferentiated, non-compacted colonies making up at least 
80% of the well. Alternatively, hESCs were passaged as single cells via Accutase/ROCKi split or 
re-split to provide a differentiation competent monolayer should the colonies become too 
compacted. In wells which fulfilled these criteria, MEF-CM was exchanged with RPMI/B27 
supplemented with 100 ng/ml AA and 20 µM LY for 24 hours. Medium was refreshed for the 
following 2 days, however the concentration of LY was reduced by half to mitigate LY-induced 
cytotoxicity. Cells differentiated to the DE are morphologically distinguishable, being spiky and 
irregular in shape.  
ii. Hepatic specification and maturation from DE 
DE cultures were further specified to the hepatic lineage by exchanging the RPMI/B27 DE 
specifying medium with hepatoblast specification medium supplemented with 20 ng/ml BMP2 
and 10 ng/ml bFGF for 3-5 days. Hepatoblasts were further matured into hepatocyte-like cells 
upon medium exchange with L-15 hepatocyte maturation medium supplemented with 20 ng/ml 
OSM and 10 ng/ml HGF for a further 3-5 days until the emergence of polygonal, binucleated cells 
that typify successful maturation and gain of hepatic functions.  
2.1.2.3 Culture and propagation of HEK293T, Hep3B and PC-3 cells 
Tumour cell lines were routinely cultured in either D10 (HEK293T and Hep3B) or R10 (PC-3) 
media and regularly passaged twice a week at a 1:3 to 1:10 splitting ratio using trypsin-EDTA. Cells 
were typically frozen at 1 x 106 cells per vial in fresh growth media supplemented with 10% DMSO.   
2.1.2.4 Culture and propagation of Rictor-Control and Rictor-Null MEF 
Both control and transgenic MEFs that had been spontaneously immortalised after their initial 
isolation from control and Rictor knockout mice were cultured in D10 and passaged regularly prior 
to confluence. Rictor-Control MEFs displayed growth rates that are not dissimilar to that of wild-
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type MEFs and were consequently passaged at 1:3 to 1:10 splitting ratio. However, Rictor-Null 
MEFs had a markedly reduced proliferative rate and were therefore split at a ratio no greater than 
1:3 to reduce senescence associated cell death. Both MEF lines were frozen at 3 x 106 cells per vial 
in enriched D10 media supplemented with 50% FBS and 10% DMSO.  
2.1.2.5 Growth Factor and Inhibitor assays 
Cells were treated with growth factors and/or inhibitors at the indicated working concentrations 
above typically for 1, 3 or 6 hours in the absence of serum unless otherwise indicated.  
2.1.2.6 Genetic manipulation of cell lines 
i. Lipofection  
Transfection of hESCs and tumour cell lines with plasmid DNA was conducted via a modified 
lipofection protocol (Ma et al., 2012). For 1 x 106 cells, 1.6 µg of kit purified plasmid DNA was 
suspended in 50 µl of OptiMEM® supplemented with 1.6 µl of PLUSTM Reagent. In another tube, 
4 µl of LipofectamineTM LTX reagent was re-suspended in another 50 µl of OptiMEM®. Both 
tubes were incubated at room temperature for 5 min before being mixed together and incubated 
for a further 25 min. During this time, target cells were trypsinised, counted and pelleted before 
being directly resuspended in the transfection mix and incubated for 15 min. The transfection 
process was stopped upon the addition of growth media and cells were allowed to plate down 
overnight in the appropriate culture vessel. Cells were typically split 1:2-1:3 following transfection. 
Reagents were scaled up accordingly depending on the number of cells to be transfected. For 
MEFs, lipofection was conducted following the accompanying manufacturer’s instructions with a 
DNA to LipofectamineTM LTX ratio of 1:10.  
ii. Lentiviral Transduction  
Low passage HEK293T packaging cells were seeded at 1.5 x 107 cells per T225 flask and allowed 
to reach a confluency of 80-90% prior to transfection. On the morning of transfection, the media 
was refreshed and transfection was performed late afternoon by the calcium phosphate method 
with the following DNA ratios: 60 µg lentivector: 40 µg pCMV∆8.91 helper: 40 µg VSV-G 
envelope according to the manufacturer’s instructions. Cells were transfected overnight in the 
presence of 25 µM chloroquine in order to inhibit endosomal DNA degradation during 
endocytosis of the DNA. Medium was changed 18 hours post-transfection and supernatant 
containing viral particles was collected 48 and 72 hours post transfection and stored at -80 oC. 
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Viral particles within the harvested supernatant were concentrated prior to use in transduction. 
Supernatants were defrosted and filtered through a 0.45 µM unit into Ultra-ClearTM Beckman 
centrifuge tubes after which polybrene and chondroitin sulphate was added at 120 µg/ml each to 
precipitate the particles. Following a brief vortex, tubes were sealed with parafilm and incubated 
for 30 min at 37 oC. Tubes were then centrifuged at 10000 xg for 1.5 hours in a Beckman Coulter 
Avanti J-20 centrifuge at 4 oC to pellet the virus-chondroitin-polybrene complexes. Pellets were 
then dislodged from the tube wall in 200 µl cold DPBS by light tapping and the viral particles were 
allowed to dissolve into the solution at 4 oC for 2 hours. Concentrated virus solutions were then 
aliquoted into cryovials at 40 µl per vial and frozen at -80 oC. To create stable hESC and PC-3 
lines, cells were dissociated with accutase or trypsin respectively and were infected overnight with 
concentrated viral particles as they were plating down. 48 hours post-infection, cells were selected 
with 2 µg/ml puromycin for stable transgene expression. 
iii. hESC Luciferase Assay 
High quality hESCs were accutase/ROCKi split 1:6 into 12 well plates and allowed to reach 70-
80% confluence prior to transfection. hESCs were co-transfected with both firefly (pGL3-
CAGA12-MLP-luc) and renilla (pRL-T7-renilla) plasmids as an internal control at a ratio of 10:1 
respectively using Lipofectamine 2000 (Life Technologies) following standard lipofection 
procedures with modifications. Both DNA and LipofectamineTM were resuspended separately in 
equal volumes of OptiMEM® before being mixed together and incubated at room temperature for 
20-30 min to allow transfection complexes to form. Transfection mixtures were applied to the 
cells in a dropwise fashion and media was changed 6 hours post-transfection to maintain hESC 
survival. 42 hours post transfection, cells were differentiated for 6 hours, harvested using accutase 
and each well dispensed equally into 3 corresponding wells of a 96-well luminometer plate. 
Luciferase assay was performed using Dual-Glo® luciferase assay kit, whereby cells were lysed 
using Dual-Glo® luciferase assay reagent for 10 minutes before luciferase luminescence was 
recorded using a Perkin Elmer Victor II luminometer. Following this, lysate was treated with Dual-
Glo® Stop & Glo reagent to quench firefly luciferase activity and stimulate renilla luciferase-
mediated luminescence recorded on the same luminometer. Firefly luminescence readings were 
normalised with corresponding renilla luminescence readings to give representative luciferase 
expression values that are independent of transfection efficiency and cell number. 
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2.2 Molecular Biology - DNA/RNA techniques 
2.2.1 Materials 
2.2.1.1 Reagents, Chemicals and Kits 
Reagent Supplier 
1 kb Full Scale DNA ladder Thermo Fisher 
100 bp ladder NEB 
6X DNA loading buffer NEB 
Acetic Acid Sigma-Aldrich 
Agarose (molecular biology grade) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Bacto-tryptone Sigma-Aldrich 
Boric Acid Sigma-Aldrich 
Chloroform:Isoamyl alcohol 24:1 Sigma-Aldrich 
DH5α Competent E. coli Active Motif 
Deoxynucleotide mix (dNTP) Sigma-Aldrich 
Ethanol VWR 
Ethidium Bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Glucose Sigma-Aldrich 
HiSpeed Maxiprep Kit Qiagen 
HiSpeed Midiprep Kit Qiagen 
Hydrochloric acid (37%) Sigma-Aldrich 
Isopropanol VWR 
Magnesium chloride (MgCl2), anhydrous Sigma-Aldrich 
Molecular Grade Water Sigma-Aldrich 
Murine RNAse Inhibitor NEB 
Oligo(dT)12-18 Thermo Fisher 
Potassium chloride (KCl) Sigma-Aldrich 
Q5 Site Directed Mutagenesis Kit NEB 
QIAprep Gel Extraction Kit Qiagen 
Sodium chloride (NaCl) Sigma-Aldrich 
Sodium hydroxide Sigma-Aldrich 
SYBR® Green JumpstartTM Taq Ready Mix Sigma-Aldrich 
Tri Reagent® Sigma-Aldrich 
Tris Base Sigma-Aldrich 
UltraCleanTM Low Melting Sieve Agarose Mobio 
Yeast Extract Sigma-Aldrich 
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2.2.1.2 Buffers and Solutions 
10X Tris-Borate-EDTA Buffer (TBE) 108 g Tris Base 
 55 g Boric Acid 
 
9.3 g EDTA 
Autoclaved water to 1 L 
  
50X Tris-Acetate-EDTA Buffer (TAE) 242 g Tris Base 
 57.1 ml Acetic Acid 
 
18.6 g EDTA 
Autoclaved water to 1 L 
 
Tris-EDTA Buffer (TE) 1 ml Tris-HCL pH 8.0 (10 mM) 
 200 μl of 0.5M EDTA pH 8.0 (1 mM) 
 
Autoclaved water to 100 ml 
 
Lysogeny Broth (LB) Medium 10 g Bacto-tryptone 
 5 g Yeast extract 
 10 g NaCl 
 
Autoclaved water to 1 L 
 
LB Agar 5 g Bacto-tryptone 
 2.5 g Yeast extract 
 5 g NaCl 
 7.5 g Agar 
 
Autoclaved water to 500 ml 
 
SOC Media 20 g Bacto-tryptone 
 5 g Yeast extract 
 2 ml of 5 M NaCl 
 2.5 ml of 1 M KCl 
 10 ml of 1 M MgCl2  
 20 ml of 1 M glucose 
 
Autoclaved water to 1 L 
 
P1 Resuspension Buffer (Qiagen) 50 mM Tris-HCl pH 8.0 
 10 mM EDTA 
 
100 μg/ml RNAse A 
 
P2 Lysis Buffer (Qiagen) 200 mM NaOH 
 
1% Sodium Dodecyl Sulphate (SDS) 
 
P3 Neutralisation Buffer (Qiagen) 3M Potassium acetate pH 5.5 
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Oligos annealing buffer 400 µl Tris-HCl pH 7.5 (10 mM) 
 80 µl of 0.5 M EDTA pH 8.0 (1 mM) 
 
400 µl of 5 M NaCl (50 mM) 
Molecular grade water to 50 ml 
 
2.2.1.3 Plasmids 
All plasmids stored in TE buffer or molecular grade water and stored at -20 oC. For subcloned 
plasmids, detailed cloning strategies are available in the Appendix section. 
Plasmid Source 
pBluescript II KS Stratagene (C4) 
pcDNA3-Flag-mTOR-wt Addgene 26603 
pcDNA3-Myr-HA-Akt1 Addgene 9008 
pcDNA3-Myr-HA-Akt1-S473A Subcloned from Addgene 9031 and 9008 
pcDNA3-T7-Akt1-K179M/T308A/S473A Addgene 9031 
pCMV-VSV-G Gift from Dr. Anil Chandrashekran 
pCMV-Δ8.91-helper Gift from Dr. Anil Chandrashekran 
pCS2-Flag-Smad2-T220V Mutagenesis of Addgene 14042 (L57) 
pCS2-Flag-Smad2-WT Addgene 14042 
pGEX-6P-2-GST GE Healthcare (C45) 
pGEX-6P-2-GST-Smad2-T220V Subcloned from C45 and L57 
pGEX-6P-2-GST-Smad2-WT Subcloned from C45 and Addgene 14042 
pHyg-Puro-2A-EGFP Lab owned (L18) 
pLKO.1-Puro-shGFP shGFP insertion into Addgene 10878 
pLKO.1-Puro-shNedd4L2 Subcloned from Addgene 10878 
pLKO.1-Puro-shRictor1 Addgene 1853 
pLKO.1-Puro-shRictor2 Addgene 1854 
pLKO.1-Puro-TRC  Addgene 10878 
pLVTHM-EGFP Addgene 12247 
pLVTHM-EGFP-shNedd4L1 shNedd4L insertion into Addgene 12247, (L54) 
pLVTHM-Puro-2A-EGFP-shNedd4L1 Subcloned using L54 and L18 
pLVTHM-Puro-2A-Smad2-T220V Subcloned from L51 and L57 
pLVTHM-Puro-2A-Smad2-WT Subcloned from L51 and Addgene 14042 
pLVTHM-Puro-2A-Sox2 Lab owned (L51) 
pGL3-CAGA12-MLP-luc Gift from Dr. Vasso Episkopou 
pRK-myc-Rictor Addgene 11367 
pRL-TK-Renilla Promega, GenBank® no. AF025846  
 
 
  
___________________________________________________________________________ 
 
70 
 
Chapter Two Materials and Methods 
2.2.1.4 Primers and shRNA  
All primers and shRNA reconstituted as 100 µM in molecular grade water and stored at -20 oC. 
Primer Forward strand Reverse strand 
Brachyury TGCTTCCCTGAGACCCAGTT GATCACTTCTTTCCTTTGCATCAAG 
CLIC4 TGAAAGCATAGGAAACTGCCC GGTCAACAGTCGTCACACTAAA 
Eomes AGGAATTCTTGCTTTGCTAATTCTG CGAAGAAACAGCAAGAGCAGC 
Flag-Smad2 GGACTACAAGGACGACGATGA TCACTGCTTTCTCACACCACT 
FoxA2 GGGAGCGGTGAAGATGGA TCATGTTGCTCACGGAGGAGTA 
Goosecoid GAGGAGAAAGTGGAGGTCTGGTT CTCTGATGAGGACCGCTTCTG 
MixL1 CCGAGTCCAGGATCCAGGTA CTCTGACGCCGAGACTTGG 
Nanog TGATTTGTGGGCCTGAAGAAAA GAGGCATCTCAGCAGAAGACA 
Nedd4L TCCAATGGTCCTCAGCTGTTTA ATTTTCCACGGCCATGAGA 
Oct4 TCGAGAACCGAGTGAGAGGC CACACTCGGACCACATCCTTC 
Pax6 TCCGTTGGAACTGATGGAGT GTTGGTATCCGGGGACTTC 
PPM1A AGGGGCAGGGTAATGGGTT GATCACAGCCGTATGTGCATC 
RPL22 TCGCTCACCTCCCTTTCTAA TCACGGTGATCTTGCTCTTG 
Smad2 ATTCCAGAAACGCCACCTCC GCTATTGAACACCAAAATGCAGG 
Sox17 ACGCCGAGCTCAGCAAGAT TCCACGTACGGCCTCTTCTG 
Sox2 GCCGAGTGGAAACTTTTGTCG GCAGCGTGTACTTATCCTTCTT 
β-actin TGTCTGGCGGCACCACCATG AGGATGGAGCCGCCGATCCA 
 
shRNA Sense strand Anti-sense strand 
Nedd4L1 GCTAGACTGTGGATTGAGT ACTCAATCCACAGTCTAGC 
Nedd4L2 AGAGTCCTATCGGAGAATTAT ATAATTCTCCGATAGGACTCT 
Rictor1 ACTTGTGAAGAATCGTATCTT AAGATACGATTCTTCACAAGT 
Rictor2 CAGCCTTGAACTGTTTAA TTAAACAGTTCAAGGCTG 
shGFP CTACGTCCAGGAGCGCACC GGTGCGCTCCTGGACGTAG 
 
2.2.1.5 DNA Modifying Enzymes 
Enzyme Source 
Antarctic Phosphatase NEB 
DNAse I Sigma 
JumpstartTM Taq Polymerase Sigma 
ProtoScript II Reverse Transcriptase NEB 
Q5® High Fidelity Polymerase NEB 
Restriction endonucleases NEB 
T4 ligase NEB 
T4 polynucleotide kinase (PNK) NEB 
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2.2.2 Methods 
2.2.2.1 Plasmid manipulation and cloning 
i. Bacterial Transformation 
Competent DH5α E.coli cells were thawed on ice to which plasmid DNA was added to no greater 
than 10% of the total volume and mixed gently with tapping. Transformation reactions were 
incubated on ice for 30 min after which the cells were subjected to heat shock upon immersion in 
a 42 oC water bath for 40 sec. Cells were allowed to recover on ice for 2 minutes before the aseptic 
addition of 250 µl of SOC media per reaction. Tubes were incubated for 1 hour at 37 oC with 
shaking at 225-250 rpm to allow the outgrowth of transformants. Bacteria were then pelleted by 
centrifugation at 3000 rpm for 5 min, before being resuspended in 50 µl of the SOC supernatant 
and plated onto LB agar plates supplemented with 100 µg/ml ampicillin. Plates were inverted and 
incubated overnight at 37 oC to allow outgrowth and selection of transformants. Plates were 
inspected the following day for transformed colonies. 
ii. Plasmid Amplification and Purification 
For small scale DNA amplification for use in subcloning, transformed colonies were picked from 
LB agar plates and cultured in 5 ml of LB broth supplemented with 100 µg/ml ampicillin overnight 
at 37 oC with 230 rpm shaking. The following day, cultures were centrifuged for 15 min at 6000 
xg to pellet the bacteria cells. The supernatant was then discarded and the tubes were inverted to 
remove all traces of LB broth, after which the pellets were resuspended in 300 µl of P1 
resuspension buffer. An equal volume of P2 lysis buffer was added to initiate alkaline lysis of the 
cells for no longer than 5 min before the addition of 300 µl of P3 neutralisation buffer to neutralise 
and precipitate out the bacterial debris. The debris was removed via centrifugation for 5 min at 
14000 rpm, and the supernatant containing solubilised plasmid DNA was transferred into fresh 
tubes. 600 µl of isopropanol was added to the extract, which was in turn immediately centrifuged 
to pellet and precipitate out the DNA. Pellets were washed with 1 ml of 70% ethanol before 
undergoing a final centrifugation. After removal of the ethanol, pellets were allowed to air-dry for 
5 min before resuspension in 50 µl of molecular grade water. The concentration of plasmid DNA 
was measured by nanodrop spectrometer 1000 (Thermo Fisher) at A260 and is of sufficient purity 
for use in subcloning and sequencing procedures. 
For large scale DNA amplification required for transfection and lentiviral production, transformed 
colonies were picked from LB agar plates and cultured in 2 ml of LB broth supplemented with 
100 µg/ml of ampicillin and incubated for 6-8 hours at 37 oC with shaking. This starter culture was 
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used to inoculate 50 ml (Midiprep), 150 ml (Maxiprep, high copy no.) or 250 ml (Maxiprep, low 
copy no.) LB broth supplemented with 100 µg/ml of ampicillin and incubated overnight at 37 oC 
at 230 rpm shaking. Typically, lentiviral vectors and plasmids over 10 kb in size were treated as 
low copy number given that more time is required to replicate large plasmids. The following day, 
plasmid DNA was isolated using the HiSpeed Midiprep or Maxiprep kits, with the final elution of 
the DNA in 500 µl of sterile TE buffer. DNA was quantified via nanodrop and stored at -20 oC 
until use. 
iii. Restriction digests and gel extraction 
Plasmid DNA was subjected to restriction endonuclease digests either for sequence verification or 
for subcloning purposes utilising the NEB restriction enzyme system. In brief, reactions were 
typically set up in a 10-20 µl total volume containing 500 to 1000 ng of plasmid DNA and no more 
than 10% v/v restriction enzyme, which typically equates to 10-20 U enzyme/reaction together 
with the appropriate buffer. For verification purposes, plasmids were digested for a minimum of 
30 min while digestion is allowed to proceed for 2 hours or more for subcloning. Reactions were 
terminated upon the addition of 6X loading buffer and are analysed via agarose gel electrophoresis. 
Samples are typically run along with the appropriate DNA ladder at 100V for 30 min through a 
0.8-1.5% agarose gel dissolved in either 1X TAE or TBE buffer, containing 0.5 μg/ml ethidium 
bromide depending on the size of the fragments to be resolved. Fragments for use in subcloning 
were typically run through a 1% w/v low melt TAE agarose gel after which they were excised 
using a sharp scalpel and purified using the QIAprep Gel Extraction Kit. DNA fragments are 
typically eluted in 30 µl to maximise the concentration for ligation.  
iv. DNA dephosphorylation  
After purification, digested vectors were typically dephosphorylated by Antarctic phosphatase to 
eliminate any chance of religation of singly digested plasmids. Typically 1/10th volume of 10X 
Antarctic phosphatase buffer and 5 U Antarctic Phosphatase was added to 1-5 µg of digested 
vector and incubated for 30 to 60 min to dephosphorylate 5’ or 3’ extensions respectively. Enzyme 
was heat inactivated for 5 min at 70 oC before use in ligation reactions. 
v. Oligo annealing and phosphorylation 
Equal volumes of both sense and antisense strands for were mixed at an equimolar ratio to achieve 
annealing reaction volume of 100 µl of annealing buffer containing 10 µM of each oligo. Reactions 
were placed onto a heating block set at 95 oC for 5 min after which the entire block was removed 
from the heating plate and allowed to slowly cool to room temperature to allow the strands to 
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anneal. The concentration of the now double-stranded fragments was determined by nanodrop 
after which up to 300 pM 5’ ends were phosphorylated with 10 U of T4 PNK in 1X T4 ligase 
buffer with ATP according to the conversion equation: 1 µg of 20 bp oligo = 150 pM 5’ ends. 
Reactions were incubated for 30 min at 37 oC and heat inactivated at 65 oC for 20 min before use 
in ligation reactions. 
vi. Ligation 
Ligations were performed with T4 ligase according to manufacturer’s guidelines. Typically, a vector 
to insert molar ratio of 1:3 was incubated in a 10 to 20 µl total volume containing 20 U of T4 ligase 
in 1X T4 ligase buffer supplemented with ATP and incubated for 1 hour at 22 oC. Care was taken 
to ensure that total DNA concentration in the reactions did not exceed 10 ng/µl and more difficult 
ligation reactions that required blunt ended or triple fragment ligations were incubated overnight 
at 16 oC. After ligation, 5 to 10 µl of the reaction was used to transform bacteria as indicated in 
above in order to select for positive transformants.  
vii. Site-directed mutagenesis 
Using pCS2-Flag-Smad2 (Addgene 14042) as a template, non-overlapping primers were first 
designed with 5’ ends annealing back-to-back, through which a substitution was created by 
designing a mismatch in the centre of the forward primer, with 19 complementary base pairs before 
and after the mismatch. The 5’ end of the anti-sense primer begins at the base adjacent to the 5’ 
end of the sense primer and continues in the opposite direction on the complementary strand. The 
anti-sense primer is fully complementary to the plasmid sequence. Primers sequences were 
designed using the NEBaseChangerTM online too and are as follows:   
Sense: 5'-GAGTAATTATATTCCAGAAGTGCCACCTCCTGGATATATC-3’ 
Anti-sense: 5' TGTGGCTCAATTCCTGCTGG 3' 
Mutagenesis was carried out essentially as outlined in the procedures accompanying the Q5 Site 
Directed Mutagenesis Kit. Briefly, 1.25 µl of each 10 µM primer stock was added to a thin walled 
PCR tube containing 12.5 µl of Q5 Hot Start High Fidelity 2X Master mix and 25 ng of template 
DNA. Reaction was performed in a Bio-Rad Dyad DNA Engine thermocycler with the following 
cycling conditions: 
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 1: 98 oC 30 sec   Initial denaturation 
 2: 98 oC 10 sec  Cycling denaturation 
     69 oC 30 sec  Primer annealing (Ta) 
     72 oC 3 min  Extension 
 Repeat from step 2 for 25 cycles. 
 3: 72 oC 2 min  Final extension 
 4: 4 oC  Forever Hold 
The amplified PCR product was added directly to the Kinase-Ligase-DpnI (KLD) enzyme mix to 
digest the template and circularise the new plasmid. Reactions were incubated at room temperature 
for 5 min after which 5 to 10 µl was directly used for bacterial transformation to amplify the new 
plasmid. Clones were confirmed via sequencing using a CMV universal primer supplied by 
Beckman Coulter Genomics. Primer designs and generation of this plasmid was performed by Mr. 
Nick Murphy, a master student under my supervision.  
2.2.2.2 Gene expression analysis 
i. RNA Isolation and extraction 
For gene expression analysis, typically 1 x 106 cells or one fully confluent well of hESCs or their 
derivatives were lysed in 1 ml of TRI Reagent® and stored at -80 oC until further processing. To 
isolate the RNA, samples were defrosted at room temperature and allowed to stand for 5 min to 
equilibrate. For each 1 ml of TRI Reagent® used, 200 µl of chloroform:isoamyl alcohol was added 
and the tube vigorously shaken and allowed to stand at room temperature for 15 min to extract 
the RNA via phase separation. Following centrifugation at 12000 xg for 15 min at 4 oC, the aqueous 
top layer containing the RNA was transferred into a new tube. 500 µl of isopropanol was added 
and the tubes allowed to stand at room temperature for 10 min to precipitate the RNA. 
Precipitated RNA was pelleted upon centrifugation at 12000 xg for 10 min at 4 oC before the 
supernatant was removed and the pellet washed in 1 ml of 75% ethanol. A final centrifugation was 
perform at 7500 xg for 5 min to pellet the washed RNA pellet and upon the removal of the ethanol, 
tubes were allowed air-dry for 10 to 15 min before being resuspended in 20 µl of molecular grade 
water to re-dissolve in RNA. Samples were further subjected to DNAse I treatment in order to 
remove any residual genomic DNA contamination. 2 µl of 10X reaction buffer along with 2 U of 
DNAse I was added to each sample, which was incubated at room temperature for 15 min before 
the addition of 2 µl of stop solution and heating at 70 oC to fully inactivate the DNAse I. The final 
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RNA concentration was measured via nanodrop after which 500 ng to 1 µg of total RNA was used 
for cDNA synthesis.   
ii. cDNA Synthesis 
Typically 1 μg of total RNA was used as template to generate cDNA for use in gene expression 
analysis. RNA was initially incubated with 2 µl of 50 µM Oligo(dT)12-18 and 1 µl of 10 mM dNTP 
in a total volume of 12 µl and incubated in a thermocycler at 65 oC for 5 min to fully denature the 
RNA and anneal the Oligo(dT)12-18 primers to the template. After the initial annealing reaction, 
tubes were placed promptly back on ice to which 4 µl of 5X ProtoScript II RT reaction buffer, 2 
µl 0.1 M DTT, 40 U of murine RNAse inhibitor and 200 U of ProtoScript II reverse transcriptase 
was added to each reaction to a final volume of 20 µl. Additionally, samples also had a ‘minus RT’ 
counterpart reaction in which no reverse transcriptase was added to ensure that all genomic 
contamination has been removed. Reactions were incubated at 42 oC for 1 hour followed by 5 min 
at 80 oC to inactivate the enzyme. The newly generated cDNA solutions were diluted 1 in 10 with 
the addition of 180 µl of molecular grade water and stored at -20 oC until use. 
iii. Semi-quantitative Polymerase Chain Reaction (PCR) 
Prior to quantitative real-time analysis, cDNA samples were subjected to standard PCR reactions 
with known housekeeping markers such as RPL22 and β-actin to ensure that cDNA synthesis was 
successful. Furthermore, newly designed primers were also subjected to the same test to ensure 
their specificity and effectiveness for use in quantitative reactions. Typically, 2 to 3 µl of diluted 
cDNA solution was used as template, to which 1X JumpstartTM Taq reaction buffer, 200 µM dNTP, 
200 nM of forward and reverse primer, and 1.25 U of JumpstartTM Taq polymerase was added to 
a total volume of 25 µl. Assembled reactions were incubated in the thermocycler with the following 
cycling conditions: 
 1: 94 oC 2 min  Initial denaturation 
 2: 94 oC 30 sec  Cycling denaturation 
     58 oC 30 sec  Primer annealing (Ta) 
     72 oC 45 sec  Extension 
 Repeat from step 2 for 25-35 cycles depending on primer used. 
 3: 72 oC 5 min  Final extension 
 4: 4 oC  Forever Hold 
Primers are typically designed with a melting temperature (Tm) of between 60 to 65 
oC with the Ta 
of the annealing step adjusted accordingly to around 3 to 5 oC lower than the primer with the 
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higher Tm value. Reactions were stopped following the addition of 6X loading buffer and half the 
reaction was typically loaded and run through a 1.5% TBE gel to resolve the PCR fragments in 
the same manner as outlined above. PCR products are typically 100 to 200 bp in size.  
iv. Quantitative Real-Time PCR (qRT-PCR) 
Once efficacy has been verified by standard PCR, cDNA samples are subjected to quantitative 
real-time assessment to measure gene expression. 2 µl of cDNA template was used per reaction to 
which 15 µl of SYBR® Green JumpstartTM Taq Ready Mix, 300 nM of forward and reverse primer 
was added to a final volume of 30 µl per reaction. Each reaction was setup up in triplicate for each 
gene, with each cDNA sample analysed twice on two different occasions to generate n=6 Ct values 
for each sample and for each gene analysed. Reactions were run on a Bio-Rad Opticon2TM DNA 
Engine Real-time fluorescence thermocycler with the following conditions: 
 1: 94 oC 2 min    Initial denaturation 
 2: 94 oC 15 sec   Cycling denaturation 
     60 oC 30 sec   Primer annealing (Ta) 
     72 oC 30 sec   Extension 
     75 – 84 oC    +3 oC/sec  Real-time fluorescence read/sec  
 Repeat from step 2 for 40 cycles depending on primer used. 
 3: 67 – 91 oC +0.3 oC/sec  Melting curve read/sec 
Production of double stranded product was tracked in real-time by measuring the SYBR® green 
fluorescence. Melting curve was performed at least once for each primer set to ensure the 
formation of a single PCR product. Analysis was performed using accompanying software and 
using the 2∆∆Ct method as outlined by Livak and Schmittgen, 2001. In brief, raw Ct values were 
normalised to either RPL22 and β-actin values for each sample by subtraction giving the ∆Ct value. 
∆∆Ct values were obtained via normalisation with control samples, after which the relative gene 
expression was obtained by taking the ∆∆Ct value as the exponential function of 2. Students t test 
was used to assess significance in changes observed in gene expression. 
  
___________________________________________________________________________ 
 
77 
 
Chapter Two Materials and Methods 
2.3 Molecular Biology – Protein techniques 
2.3.1 Materials 
2.3.1.1 Reagents, Chemicals and Kits 
Reagent Supplier 
30% Acrylamide/Bis Sigma 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Sigma 
4’,6 diamidino-2-phenylindole (DAPI) Sigma 
Adenosine triphosphate (ATP) Sigma 
Ammonium persulphate (APS) Sigma 
Bicinchoninic Acid Assay (BCA) Protein Quantification Kit Thermo Fisher 
BL-21 strain E.coli for recombinant protein synthesis GE Healthcare 
Bromophenol blue Sigma 
Bovine Serum Albumin (BSA) Sigma 
CL-Xposure film Scientific Labs 
Dithiothreitol (DTT) Sigma 
Enhanced chemiluminescence substrate (ECL) Thermo Fisher 
Ethylene glycol tetraacetic acid (EGTA) Sigma 
Glutathione magnetic beads Thermo Fisher 
Glycerol  Sigma 
Glycine Sigma 
Goat serum Sigma 
Guanidine hydrochloride (GnHCl) Sigma 
Immobilon® polyvinylidene fluoride (PVDF) membrane Millipore 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Sigma 
Lambda phosphatase NEB 
Luminate Forte Enhanced ECL substrate Millipore 
Methanol VWR 
Mowiol 4-88 Sigma 
Nonidet P-40 (NP-40) Anachem 
PageRuler Plus Protein Ladder Thermo Fisher 
Paraformaldehyde NEB 
Phenylmethanesulfonylfluoride (PMSF) Sigma 
Phosphatase Inhibitor Cocktail 2 Sigma 
Potassium acetate Sigma 
Protease Inhibitor Cocktail Sigma 
Protein G Dynabeads® Life Technologies 
Recombinant active Erk2 kinase NEB 
Recombinant GST-GSK3 fusion protein NEB 
Recombinant His-6-tagged Akt1 Millipore 
Reduced L-glutathione Sigma 
Skim milk powder Sigma 
Sodium azide (NaN3) Sigma 
Sodium deoxycholate Sigma 
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Sodium dodecyl sulphate (SDS) Sigma 
Sodium fluoride (NaF) Sigma 
Sodium orthovanadate (Na3VO4) Sigma 
Tetramethylethylenediamine (TEMED) Sigma 
Tetrasodium pyrophosphate (Na4O7P2) Sigma 
Triton X-100 Sigma 
Tween-20 Sigma 
Ubiquitin aldehyde R&D/Boston Biochem 
β-glycerophosphate Sigma 
β-mercaptoethanol Sigma 
 
2.3.1.2 Buffers and Solutions 
Immunoblotting  
  
Radio Immunoprecipitation Assay  25 ml 1 M Tris-HCl pH 8.0 (50 mM) 
Buffer (RIPA) 15 ml 5 M NaCl (150 mM) 
 5 ml NP-40 (1% v/v) 
 2.5 g Sodium deoxycholate (0.5% w/v) 
 0.5 g SDS (0.1% w/v) 
 
Autoclaved water to 500 ml 
 
2X Sample buffer 2.5 ml 0.5 M Tris-HCl pH 6.8 (125 mM) 
 2 ml glvcerol (20% v/v) 
 4 ml 10 % SDS (4% w/v) 
 160 µl 1.25% bromophenol blue (0.02 % w/v) 
 500 µl β-mercaptoethanol (715 mM) 
 
Autoclaved water to 10 ml 
 
Sodium Orthovanadate stock 183.9 mg Na3VO4 (200 mM) 
 Adjust pH to 10.0  
 Boil solution until colourless 
 Cool and readjust pH back to 10 
 Repeat boil/cool cycles until solution remains  
 
colourless at pH 10.0 
 
5X Sample buffer 1.25 ml 0.5 M Tris-HCl pH 6.8 (50 mM) 
 2.5 ml glycerol (25 % v/v) 
 2 ml 10% SDS (2% w/v) 
 400 µl 0.5% bromophenol blue (0.02 % w/v) 
 500 µl β-mercaptoethanol (715 mM) 
 
Autoclaved water to 10 ml 
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4% Polyacrylamide Stacking Gel  2.5 ml 0.5 M Tris-HCl pH 6.8 (125 mM) 
 1.3 ml 30% Acrylamide/Bis (4% v/v) 
 100 µl 10% SDS (0.1 % w/v) 
 50 µl 12% APS (0.06 % w/v) 
 12 µl TEMED (0.12 % v/v) 
 
Autoclaved water to 10 ml 
 
8% Polyacrylamide Running Gel 2.5 ml 0.5 M Tris-HCl pH 6.8 (125 mM) 
 2.7 ml 30% Acrylamide/Bis (6% v/v) 
 100 µl 10% SDS (0.1 % w/v) 
 75 µl 12% APS (0.075 % w/v) 
 18 µl TEMED (0.18 % v/v) 
 
Autoclaved water to 10 ml 
 
10X SDS Running Buffer 30.3 g Tris base (250 mM) 
 144.2 g Glycine (1.9 M) 
 50 ml 20% SDS (1%)  
 
Autoclaved water to 1 L 
 
Transfer Buffer 5.82 g Tris base (48 mM) 
 2.93 g Glycine (39 mM) 
 3.75 ml 10% SDS (0.04% w/v) 
 200 ml methanol (20% v/v) 
 
Autoclaved water to 1 L 
 
Tris Buffered Saline with Tween-20 20 ml Tris-HCl pH 7.6 (20 mM) 
(TBS-T) 26 ml NaCl (130 mM) 
 1 ml Tween-20 (0.1 % v/v) 
 
Autoclaved water to 1 L 
 
Blocking buffer 5 g BSA or Skim milk (5% w/v) 
 
1 L 1X TBS-T 
 
Stripping buffer 10 ml Tris-HCl pH 7.5 (20 mM) 
 286.6 g GnHCl (6 M) 
 1 ml NP-40 (0.2% v/v) 
 3.5 ml β-mercaptoethanol (0.1 M) 
 
 
Autoclaved water to 500 ml 
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Cytoplasmic/Nuclear Fractionation  
  
Cytoplasmic extraction buffer 5 ml 0.5 M HEPES-NaOH pH 7.5 (10 mM) 
 50 µl 0.5 M EDTA pH 8.0 (0.1 mM) 
 200 µl 0.125 EGTA pH 8.0 (0.1 mM) 
 2.5 ml 1 M KCl (10 mM) 
 125 µl 1 M DTT (0.5 mM) 
 Autoclaved water to 250 ml 
 
Adjust pH to 7.9 with 10 M NaOH 
 
Nuclear extraction buffer 10 ml 0.5 M HEPES-NaOH pH 7.5 (20 mM) 
 500 µl 0.5 M EDTA pH 8.0 (1 mM) 
 2 ml 0.125 EGTA pH 8.0 (1 mM) 
 250 µl 1 M DTT (1 mM) 
 20 ml NaCl (400 mM) 
 Autoclaved water to 250 ml 
 
Adjust pH to 7.9 with 10 M NaOH 
 
 
Immunoprecipitation  
  
HEPES lysis buffer  476.6 mg HEPES (40 mM) 
 1 ml 0.5 M EDTA pH 8.0 (10 mM) 
 5 ml glycerol (10% v/v) 
 Autoclaved water to 50 ml 
 
Adjust pH to 7.4 with 10 M NaOH 
 
2X Non-denaturing CS lysis buffer  1 ml 1 M Tris-HCl pH 7.5 (20 mM) 
 1.5 ml 5 M NaCl (150 mM) 
 100 µl 0.5 M EDTA ph 8.0 (1 mM) 
 400 µl 0.125 EGTA pH 8.0 (1 mM) 
 500 µl NP-40 (1% v/v) 
 
Autoclaved water to 25 ml 
 
mTORC Co-IP lysis buffer 8 ml 0.5 M HEPES-NaOH pH 7.5 (40 mM) 
 2.4 ml 5 M NaCl (120 mM) 
 200 µl 0.5 M EDTA pH 8.0 (1 mM) 
 4 ml 0.25 M Na4P2O7 (10 mM) 
 10 ml 0.5 M NaF (50 mM) 
 10 ml 3% NP-50 (0.3% v/v) 
 Autoclaved water to 100 ml 
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6% Stacking Gel (High MW proteins) 2.5 ml 0.5 M Tris-HCl pH 6.8 (125 mM) 
 2.0 ml 30% Acrylamide/Bis (6% v/v) 
 100 µl 10% SDS (0.1 % w/v) 
 75 µl 12% APS (0.075 % w/v) 
 18 µl TEMED (0.18 % v/v) 
 
Autoclaved water to 10 ml 
 
 
Protein elution buffer 750 mg glycine 
 100 ml autoclaved water 
 
Adjust pH to 2.5 with 9.61 M HCl acid 
 
 
Kinase Assay  
  
10X Akt kinase assay buffer 1.25 ml 1 M Tris-HCl pH 7.5 (250 mM) 
 500 µl 0.5 M β-glycerophosphate (50 mM) 
 100 µl 1 M DTT (20 mM) 
 500 µl 1 M MgCl2 (100 mM) 
 
Autoclaved water to 10 ml 
 
10X mTORC kinase assay buffer 2.5 ml 0.5 M HEPES-NaOH pH7.5 (250 mM) 
 2.5 ml 2 M Potassium acetate (1 M) 
 200 µl MgCl2 (10 mM) 
 
Autoclaved water to 10 ml 
 
10X Erk2 kinase assay buffer (NEB) 500 mM Tris-HCl pH 7.5 
 100 mM MgCl2 
 1 mM EDTA 
 20 mM DTT 
 
0.1% Brij 35 
 
10X NEBuffer for PMP (NEB) 500 mM HEPES pH 7.5 
 1 M NaCl 
 20 mM DTT 
 
0.1% Brij 25 
 
 
Immunocytochemistry  
  
Fixation buffer 4 g paraformaldehyde dissolved in  
 90 ml autoclaved water at 60 oC 
 10 M NaOH added dropwise till solution clears 
 10 ml 10X DPBS  
 Adjust pH to 7.2 with 9.61 M HCl acid 
 Adjust volume to 100 ml with autoclaved water 
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Blocking/permeablising buffer 1 ml goat serum (10% v/v) 
 0.25 g BSA (2.5% w/v) 
 30 µl Triton X-100 (0.3% v/v) 
 
DPBS to 10 ml 
 
Mowiol mounting solution 12 ml 200 mM Tris-HCl pH 8.5 (135 mM) 
 6 g glycerol 
 2.4 g Mowiol 4-88 
 6 ml autoclaved water 
 
Heat tubes at 60 oC to dissolve Mowiol  
 
 
2.3.1.3 Antibodies 
All antibodies stored according to manufacturer’s instructions and reconstituted in blocking buffer 
supplemented with 0.01% NaN3 for long term storage and use. 
Antigen Supplier Application and dilution  
Akt NEB/Cell Signaling: 9727 IB: 1:1000 
Akt-pS473 NEB/Cell Signaling: 4060 IB: 1:2000 
Akt-pT308 NEB/Cell Signaling: 9275 IB: 1:1000 
Brachyury R&D: AF2085 IB: 1:500 
CLIC4 Santa Cruz: 130723 IB: 1:500 
Erk1/2 NEB/Cell Signaling: 9102 IB: 1:1000 
Erk1/2-pT202/Y204 NEB/Cell Signaling: 9106 IB: 1:1000 
Flag Sigma: F1804 IB: 1:1000, IP: 1:100 
FoxA2 Abcam: ab60721 IB: 1:200 
Goat IgG-HRP Santa Cruz: 2020 IB: 1:5000 
GSK3α/β-pS21/9 NEB/Cell Signaling: 9331 IB: 1:1000 
GST Sigma: G7781 IB: 1:2000 
Lamin B Santa Cruz: 365962 IB: 1:500 
Mouse IgG-HRP Santa Cruz: 2005 IB: 1:5000 
Mouse IgG-HRP light chain specific Stratech: 211-032-174 IB: 1:10000 
mTOR NEB/Cell Signaling: 2972 IB: 1:1000 
Nedd4L Abcam: ab131167 IB: 1:5000 
Normal mouse IgG2a Santa Cruz: 2025 IP: µg equivalent to Flag 
Normal rabbit IgG Santa Cruz: 2027 IP: µg equivalent to Smad 
P70S6K NEB/Cell Signaling: 2972 IB: 1:1000 
P70S6K-pT421/S424 NEB/Cell Signaling: 9204 IB: 1:1000 
PPM1A Santa Cruz: 56956 IB: 1:500 
Rabbit IgG-Alexa Fluor® 488 Life Technologies: A11055 IF: 1:400 
Rabbit IgG-HRP Santa Cruz: 2004 IB: 1:2000 
Rabbit IgG-HRP light chain specific Stratech: 211-032-171 IB: 1:10000 
Rb-pS780 NEB/Cell Signaling: 9307 IB: 1:1000 
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Rictor Bethyl Labs: A300-459A IB: 1:5000, IP: 1:100 
JNK-pT183/Y185 NEB/Cell Signaling: 4668 IB: 1:1000 
Smad2 NEB/Cell Signaling: 3122 IB: 1:1000, IP: 1:100 
Smad2/3 NEB/Cell Signaling: 3102 IB: 1:1000 
Smad2/3-pT220/179 Abgent: AP3675a IB: 1:500 
Smad2-pS245/250/255 NEB/Cell Signaling: 3104 IB: 1:1000 
Smad2-pS465/467 NEB/Cell Signaling: 3108 IB: 1:1000, IF: 1:100 
Smad3-pS423/425 Millipore: EP823Y IB: 1:1000 
Smad4 NEB/Cell Signaling: 9515 IB: 1:1000 
Sox17 R&D: MAB1924 IB: 1:500 
Ubiquitin NEB/Cell Signaling: 3936 IB: 1:1000 
β-actin Sigma: A5316 IB: 1:5000 
β-tubulin Abcam: ab6046 IB: 1:200 
   
2.3.2 Methods 
2.3.2.1 Immunoblotting 
For standard immunoblotting, cells were lysed using RIPA buffer supplemented with phosphatase 
(Na3VO4, 1:100 or phosphatase inhibitor cocktail 2) and protease inhibitors (PMSF in ethanol or 
protease inhibitor cocktail, 1:100). Protein was purified from cell debris via centrifugation at 14000 
rpm for 20 min at 4 oC. Total protein content in cell lysates was quantified using the BCA Assay 
Protein Quantification Kit following manufacturer’s instructions, with the protein absorbance read 
at a wavelength of 562 nm on an Optimax Tuneable microplate reader (Bio-Rad). Typically, 5 to 
25 µg of protein was loaded per lane, with lysates being diluted in either 2X or 5X sample buffer 
and resolved at 180 V for 1 hour through 6-8% Tris-Bis acrylamide gels immersed in SDS running 
buffer before being transferred onto PVDF membranes via electroblotting. Proteins were typically 
transferred using the semi-dry method at 20 V for 75 min, with the classical wet method being 
employed for the transfer of proteins greater than 150 kDa in size at 120 V for 90 min at 4 oC. 
Both methods utilised the same transfer buffer. Blots were blocked for 20 min with the appropriate 
blocking buffer before being probed with primary antibody overnight. Blots were washed 3x with 
1X TBS-T the following day followed by a 1 hour incubation with the appropriate horse radish 
peroxidase (HRP)-conjugated secondary antibody diluted in blocking buffer. Membranes were 
washed a further 3x with TBS-T after incubation with secondary antibody before the addition of 
ECL substrate and exposure onto CL-Xposure film. Films were developed using an Optimax X-
ray film processor (Thermo Fisher).   
2.3.2.2 Cytoplasmic/nuclear fractionation 
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Cells were harvested in cytoplasmic buffer supplemented with protease and phosphatase inhibitors 
as per immunoblotting and allowed to swell on ice for 20 min, after which NP-40 was added to a 
final concentration of 0.5%, Samples were immediately vortexed for 10 sec and centrifuged at 
13000 rpm for 30 sec to pellet the cell nuclei. The supernatant was extracted and retained as the 
cytoplasmic fraction. The nuclear pellet was washed 3X with cytoplasmic buffer without NP-40 
to remove residual cytoplasmic contamination before being resuspended in nuclear buffer and 
vigorously shaken for 15 min at 4 oC. Nuclear lysates were then centrifuged for 5 min at 13000 
rpm to remove nuclear debris and the supernatant extracted as the nuclear fraction. Samples were 
quantified and analysed as per immunoblotting. 
2.3.2.3 Co-immunoprecipitation  (Co-IP) 
Cells were harvested in HEPES lysis buffer supplemented with protease and phosphatase 
inhibitors as per immunoblotting. Due to the absence of salt and detergents, cell lysis was induced 
mechanically by repeated passaging of lysate through a 25G needle on ice. Proteins within the 
lysate were purified and extracted via centrifugation at 12000 rpm for 10 min to preserve the 
integrity of protein complexes. Total protein was quantified as per immunoblotting with 1-2 mg 
of protein being used in the subsequent immunoprecipitation (IP) step. Smad2 antibody was 
incubated with 1-2 mg total protein in a 200 µl total volume for 90 min at 4 oC with rotation, after 
which 100 µl of protein-G conjugated Dynabeads® was added per IP reaction and incubated for a 
further hour under the same conditions. Precipitated immunocomplexes were separated from the 
lysate using a magnetic stand, and washed 3 times with cold HEPES lysis buffer to remove non-
specific binding prior to elution with 2X sample buffer. Elutes were subjected to immunoblotting 
and the co-IP assessed with the relevant antibodies. Light chain specific HRP-conjugated 
secondary antibodies were used to eliminate the background signal associated with the heavy chain 
contamination from the use of 2X sample buffer as the elution buffer.  
2.3.2.4 Smad2 ubiquitination assay 
Cells were harvested in 1X non-denaturing CS lysis buffer supplemented with protease and 
phosphatase inhibitors as per immunoblotting. Lysates were additionally supplemented with 2 µM 
ubiquitin aldehyde to prevent the action of deubiqutinating enzymes. Proteins within lysates were 
purified and quantified as per immunoblotting, with 1-2 mg being used in the subsequent IP with 
Smad2 antibody as per co-IP. Immunocomplexes were washed 3x with cold CS lysis buffer to 
remove non-specific binding and eluted with 2X Sample buffer. Elutes were subjected to 
immunoblotting and the degree of ubiquitination assessed using anti-ubiquitin antibody.  
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2.3.2.5 Generation/purification of recombinant GST-Flag-Smad2/Smad2-T220V 
Wild-type and mutant T220V Flag-Smad2 sequences were cloned into pGEX-6p2 plasmids 
containing the GST sequence and transformed as per bacterial transformation protocol. Single 
colonies were picked and expanded as per miniprep bacteria culture protocol, with 5 ml used to 
inoculate a 50 ml LB supplemented with 100 µg/ml ampicillin the following day. This larger culture 
was allowed to grow until mid-log phase (OD550-600 ~0.6-1.0) before the addition of isopropyl β-
D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM. Growth was continued for 
a further 6 hours at 37 oC, after which the bacteria were pelleted by centrifugation at 2500 xg for 
15 min at 4 oC. Bacterial pellets were resuspended in 2.5 ml PBS (1/20th original volume) and 
sonicated on a Diagenode Bioruptor sonicator on medium setting for 2X 15 sec cycles. Triton X-
100 was added to a final concentration of 1% and incubated for 30 min at room temperature to 
release and solubilise the recombinant protein from inclusion bodies. Crude extracts were 
subjected to a final centrifugation at 10000 xg for 5 min at 4 oC before being aliquoted and stored 
at -80 oC. A fraction of the purified extract was subjected to immunoblotting with anti-GST 
antibody to verify successful expression of the recombinant protein. Recombinant proteins were 
further purified and concentrated via IP with glutathione-imbued magnetic beads. Beads were 
washed thrice with 3X volume of 50 mM Tris-HCl pH8.0 wash buffer before the addition of 
purified bacterial extract. Immunoprecipitation was conducted at 4 oC for 2 hours with rotation. 
Beads were separated from the bacterial lysates using a magnetic stand and washed 3x with wash 
buffer before recombinant proteins were eluted in 200 µl wash buffer containing 10 mM reduced 
glutathione. Elution was performed at 4 oC for 10 min with rotation after which protein solutions 
were aliquoted and stored at -80 oC. Typically, 3 to 6 µl of the final elution was used in subsequent 
kinase assays.   
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2.3.2.6 Production/purification and dephosphorylation of recombinant Smad2  
PC-3 cells were transfected with either pCS2-Flag-Smad2-WT or pCS2-Flag-Smad2-T220V using 
lipofection according to the previously outlined protocol and harvested 48 hours post-transfection 
using non-denaturing CS lysis buffer supplemented with protease and phosphatase inhibitors as 
per immunoblotting. Lysates were subjected to IP with anti-Flag antibody in the same manner as 
outlined previously to precipitate Flag-Smad2-WT/Flag-Smad2-T220V. Immunocomplexes were 
washed 4X with lysis buffer to remove non-specific binding and subjected to dephosphorylation 
on bead by resuspending in 50 µl of 1x NEBuffer for PMP provided by NEB supplemented with 
1000 U of lambda phosphatase and 1 mM MnCl2. Samples were incubated for 90 min at 30 
oC 
with agitation, after which the phosphatase was washed off the beads with 2X washes with non-
denaturing CS lysis buffer followed by 2X washes with 1X Akt kinase buffer. Finally, 
dephosphorylated recombinant proteins were eluted off the beads via incubation with elution 
buffer for 10 min at 4 oC with rotation and immediately neutralised with 1/10th volume of 1 M 
Tris-HCl pH 8.2 to prevent hydrolysis of the proteins. Solutions containing the recombinant 
protein were aliquoted at -80 oC. Typically 6 to 12 µl of the final elution was used in subsequent 
kinase assays. 
2.3.2.7 Akt/Erk2 kinase assay 
HEK293T or PC-3 cells were grown in in serum containing cultures after which they were 
harvested in non-denaturing lysis buffer supplemented with protease and phosphatase inhibitors 
as per immunoblotting. Active Akt was immunoprecipitated as previously using anti-Akt-pS473 
antibody and washed 3X with non-denaturing CS lysis buffer followed by 1X wash with 1X Akt 
kinase buffer. Preservation of kinase activity was tested via incubation with 1 µg recombinant GST-
GSK3 fusion protein and phosphorylation assessed via immunoblotting with anti-GSK3α/β-
pS9/21 antibody. 25 µl beads carrying active Akt was used per kinase reaction, to which 1X kinase 
assay buffer, substrate, 200 mM ATP and molecular grade water were added to a final volume of 
30 µl. Reactions were incubated at 30 oC for an hour with agitation after which an equal volume 
of 2X sample buffer was added to stop the reaction. Phosphorylation was then assessed by 
immunoblotting with the appropriate phospho-specific antibodies. As a positive control, GST-
Flag-Smad2-WT/Smad2-T220V proteins were incubated with Erk2 kinase in 1X Erk kinase buffer 
supplemented with 200 mM ATP and assessed for phosphorylation via immunoblotting with anti-
Smad2-pT220/T179 and anti-Smad2-pS245/S250/S255 antibodies after the reaction is 
terminated. 
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2.3.2.8 mTORC2 kinase assay 
HEK293T cells were grown in serum containing cultures after which they were harvested in 
mTORC lysis buffer supplemented with protease and phosphatase inhibitors as per 
immunoblotting. Cells were gently lysed with rotation for 20 min at 4 oC, after which 1.2 mg of 
total protein was used in the subsequent IP with 3 µg of anti-Rictor antibody to selectively isolate 
mTORC2 over mTORC1. Immunoprecipitation was performed in the same manner as outlined 
previously. Immunocomplexes were washed 3X with mTORC lysis buffer with a gradually 
decreasing NP-40 series from the initial 0.3% to 0.15% and finally 0% to preserve mTOR kinase 
activity. Complexes were subjected to a further wash in 1x mTORC kinase assay buffer to 
completely remove all traces of detergents and incubated with 250 ng phosphatase treated his-6-
tagged Akt1 to verify the preservation of kinase activity using anti-Akt-pS473 antibody. 25 µl beads 
carrying mTORC2 was used per kinase reaction, to which 1X mTORC kinase assay buffer, 
substrate, 400 nM ATP and molecular grade water were added to a final volume of 30 µl. Reactions 
were incubated at 37 oC for an hour with agitation after which an equal volume of 2X sample 
buffer was added to stop the reaction. Phosphorylation was then assessed by immunoblotting with 
the appropriate phospho-specific antibodies.  
2.3.2.9 Immunostaining of hESCs 
hESCs were split and cultured on Matrigel® coated coverslips until the desired confluency was 
reached. Cells were then washed with DPBS and fixed for 10-20 min with 4% fresh 
paraformaldehyde solution. Excess paraformaldehyde was removed via 3X wash with DPBS and 
the coverslips were the incubated with blocking/permeablisation buffer for 1 hour followed by an 
overnight incubation with primary antibody at the appropriate dilution at 4oC with tilting. The 
following day, coverslips were subjected to 3X 10 min washes with DPBS followed by 40 min 
incubation with the appropriate fluorophore-conjugated secondary antibody in the dark. 
Coverslips were then subjected to a further 2X 10 min DPBS wash followed by 1X 10 min 
DPBS+DAPI wash with DAPI at a final concentration of 1 µg/ml to counterstain the nuclei also 
in the dark. Slides were mounted onto microscope slides using Mowiol 4-88 solution and allowed 
to dry overnight. Slides were visualised using a Leica SP5 II confocal fluorescent microscope 
typically at 64X magnification.  
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2.4 Software and Online Tools 
Computer Software   
A Plasmid Editor (ApE)  
Adobe Photoshop CS5  
Leica LAS AF Lite  
Microsoft Office 2013 (Word, Excel, Powerpoint)  
Opticon Monitor 3  
Quantity One 1D Gel Analysis Software  
Serial Cloner 2.6 
 
 
Online Tools Website 
Addgene Plasmid Repository https://www.addgene.org/ 
Basic Local Alignment Search Tool (BLAST) http://blast.ncbi.nlm.nih.gov/Blast.cgi 
BioGRID3.4 Protein Interaction Repository http://thebiogrid.org 
Clustal OMEGA Protein Alignment Tool 
http://www.ebi.ac.uk/Tools/msa/clustalo
/ 
Endnote Web 
https://www.myendnoteweb.com/EndNot
eWeb.html 
Genebank® DNA Sequence Database http://www.ncbi.nlm.nih.gov/genbank/ 
Molarity Calculator 
http://www.graphpad.com/quickcalcs/Mo
larityform.cfm 
NEB Double Digest Finder 
https://www.neb.com/tools-and-
resources/interactive-tools/double-digest-
finder 
NEBaseChangerTM for Site-directed mutagenesis http://nebasechanger.neb.com/ 
Pubmed http://www.ncbi.nlm.nih.gov/pubmed 
REBASE® Restriction Enzyme database 
https://www.neb.com/external-
links/rebase 
UniProt Protein Database http://www.uniprot.org/ 
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prolonging the Activin-induced activation of Smad2/3 
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3.1 Introduction 
It has been well established that the specification of DE both in vivo and in vitro requires high levels 
of TGFβ signalling, either through endogenously secreted Nodal or by exogenous 
supplementation of Activin ligands respectively (Lowe et al., 2001; Vincent et al., 2003; Kubo et 
al., 2004). However, model systems used by these studies are not conducive for the interrogation 
of the underlying molecular mechanisms. In the case of in vivo studies, the tissue complexity and 
inherent redundancy of development preclude investigations at the molecular level, whilst early in 
vitro hESC to DE differentiation protocols were conducted in the presence of serum, an undefined 
media component containing milieu of signalling ligands whose effects overwhelm those supplied 
exogenously. The chance discovery that serum components actually interfere with Activin-induced 
DE differentiation in feeder-free hESCs cultures (D’Amour et al., 2005) partially resolved this 
issue, in that advantageously, efficient hESC to DE conversion could be and should be performed 
in the absence of serum, which together with the use of defined media, is conducive for molecular 
interrogation. A following study into the inhibitive action of serum on DE also uncovered for the 
first time the involvement of PI3K signalling in modulating this process, in that supplementation 
of hESC cultures with the PI3K inhibitor LY promoted efficient DE formation much like the 
removal of serum (McLean et al., 2007). Although it has recently been proposed that the negative 
effects of PI3K signaling upon DE differentiation are an indirect effect attributed to the inhibition 
of Wnt-β-catenin pathway (Singh et al., 2012), a more direct mechanism in which PI3K signaling 
impacts R-Smad activity itself cannot be completely dismissed (Chen et al., 2012), and provides 
further scope for fuller molecular interrogation of this process. 
Although efforts to develop a completely defined hESC culture condition have been successful in 
terms of eliminating the need for the majority of serum components (Ludwig et al., 2006; Vallier 
et al., 2005; Singh et al., 2012), such media often contains high amounts PI3K/mTOR stimulators 
such as insulin, which have been shown to promote the maintenance of hESC self-renewal and 
pluripotency (Armstrong et al., 2006; Watanabe et al., 2006). As such, there is currently no culture 
media that has been shown to support the expansion of hESCs in the absence of PI3K stimulators. 
In order to interrogate the effect of PI3K signalling upon Activin-induced DE differentiation, our 
laboratory has developed a defined protocol in which to perform this differentiation. Given that 
hESCs cannot be propagated in the absence of PI3K stimulators, there was no obvious advantage 
in utilising defined media in hESC cultures and as such, I maintained our lines in undefined MEF-
CM. However, since the focus of the study is to interrogate the molecular events surrounding DE 
conversion from hESCs, I ensured that the DE differentiation conditions were fully defined 
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(Figure 3.1A). Although the original B27 formulation does contain insulin (Brewer and Cotman, 
1989, 4 µg/ml), this is less when compared to other types of defined media (Thomson’s mTeSR1: 
10 µg/ml, Vallier’s CDM: 7 µg/ml) and is required to maintain the survival of differentiated DE 
cells (Hay et al., 2008b). Our protocol also encompassed further differentiation to hepatocyte-like 
cells, which can only be derived from the DE and hence offer verification of DE identity and 
effectiveness of differentiation (Figure 3.1E). Each stage of differentiation in marked by distinct 
morphological changes accompanied by the expression of stage specific proteins (Figure 3.1B, C). 
With the defined protocol established, I utilised LY inhibitor in combination with AA (AA-LY) to 
drive the DE differentiation and compared these cells to ones that have been differentiated with 
AA alone in order to dissect the contribution of PI3K signalling. As expected, AA-LY treatment 
promoted a more effective DE formation as evidenced by increased Sox17 expression and 
hepatocyte formation (Figure 3.1C, D and E) 
 
  
___________________________________________________________________________ 
 
92 
 
Chapter Three Results 
Figure 3.1: Defined DE and hepatic differentiation protocols from hESC 
(A) Overview of differentiation protocol, full details available in section 2.1.2.2. (B) Phase contrast 
microscopy depicting morphological changes associated with DE differentiation over 3 days. (C) 
Immunostaining depicting increased expression of mesendoderm (Brachyury) and DE (Sox17) markers 
upon AA-LY treatment. (D) Verification of 20 µM LY efficacy over time as indicated by decrease Akt-
pS473/pT308 phosphorylation. (E) Morphological changes associated the formation of hepatocyte-like 
cells following the end of the protocol marked by increased alpha-fetoprotein (AFP) and albumin 
expression (B, C and E by Ramasamy 2012). 
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3.2 Results 
3.2.1 PI3K signalling antagonises the duration of Smad2/3 activation 
With the establishment of a defined system by which we can investigate the molecular 
underpinning governing the inhibitory effects of PI3K on AA-induced DE specification, I next 
asked whether PI3K signalling interferes with the activation of the downstream mediators of the 
TGFβ pathway. Modulation of the PI3K signalling using both LY inhibitor and stimulators such 
as heregulin (Her) and IGF-1 (IGF) under serum-free conditions in the absence of AA stimulation 
in hESCs revealed that activation of endogenous Smad2-pS465/S467 (Smad2-pTail) is largely 
inversely reciprocal to that of PI3K activity as indicated by Akt-pS473 activation and by 
densitometric measurements (Figure 3.2A). Furthermore, replacement of undefined MEF-CM 
with defined RPMI/B27 medium induced an increase in Smad2 activation, which is likely a 
consequence of the removal of serum components and transfer into a pro-differentiation medium. 
Consistent with this, time-course analysis revealed that although LY had no effect on the initial 
activation of Smad2/3 by AA, cells treated with LY exhibited a slower decline of activated 
Smad2/3, which became more apparent 6 hours post-treatment (Figure 3.2B). The experiment 
was repeated several times in which a greater abundance of active Smad2/3 (>1.5 folds) in the 
AA-LY treated cells compared with those treated with Activin alone was observed in all cases at 6 
hours post-treatment, despite there being no effect on total Smad2/3 and Smad4 expression 
(Figure 3.2C).  
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Figure 3.2: Effect of PI3K/mTOR signalling on Smad2/3 activation 
(A) hESCs were treated with activators or inhibitors of the PI3K/mTOR pathway for 1 hour and 
analysed by immunoblot. Densitometry of bands is shown below blot in which densities of 
phosphoproteins was normalised to total protein. (B) Time-course analysis of hESCs treated with AA 
or AA-LY for 1, 3, and 6 hours depicting the levels of Smad2-p465/467 and Smad3-p423/S425 
(Smad2/3-pTail) phosphorylation. Arrow indicates Smad3. Numbers indicate quantification of 
activated Smad2 and Smad3. Experiment was repeated twice and representative image shown.(C) 
Treatment of hESCs with RPMI/B27 or with RPMI/B27 supplemented with LY/AA/AA-LY for 1 and 6 
hours as indicated. Proteins were analysed by immunoblot and densitometry of three independent 
experiments are represented below as relative fold change in Smad2-pTail compared to RPMI/B27 
treated cells. Error bars represent standard deviation (SD) of three independent experiments and ** 
indicates p<0.001 by Student’s t test.  
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3.2.2 Prolonged activated Smad2/3 accumulate primarily in the nucleus and 
drives mesendoderm and DE gene expression 
In observing that inhibition of PI3K with LY prolongs or sustains the Activin-induced activation 
of Smad2/3 in hESCs, I next explored whether this population of activated Smad2/3 persists long 
enough to contribute to the improved DE specification associated with AA-LY treatment. 
Cytoplasmic-nuclear fractionation and immunostaining of hESCs treated for 3 or 6 hours revealed 
the predominant localisation of activated Smad2/3 within the nuclear compartment, particularly 
in hESCs treated with AA-LY (Figure 3.3A, B). This accumulation is also suggestive of an increase 
in transcriptional function, and a luciferase assay was performed to assess this. hESCs transfected 
with a luciferase expression vector controlled by twelve repeated CAGA Smad binding elements 
revealed that AA-LY treated hESCs had a significant increase in luciferase activity when compared 
to LY and AA treated cells (Figure 3.3C, D). Remarkably, gene expression analysis revealed that 
even at this early stage into the differentiation process, mesendoderm markers such as Brachyury, 
Eomes, and Goosecoid were already increased in AA-LY treated cells when compared with AA 
treated, whilst the DE marker also showed an increase albeit to a lesser extent than the 
mesendoderm markers (Figure 3.3E). Although the pluripotency markers Oct4 and Nanog showed 
little difference between AA and AA-LY treated cells, the expression of Sox2 was already reduced 
in cells of both treatments, further suggesting that there is preferential bias towards the formation 
of mesendoderm fated cells opposed to the neuroectoderm. 
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Figure 3.3: Localisation and transcriptional efficacy of Smad2/3 in treated hESCs 
(A) hESCs were treated with either RPMI/B27 alone or supplemented with LY/AA/AA-LY for 6 hours 
after which lysates were subjected to cytoplasmic-nuclear fractionation and analysed by immunoblot. 
Lamin B and β-tubulin were used to assess levels of nuclear and cytoplasmic contamination respectively 
in opposing fractions. (B) Immunostaining of activated Smad2 in hESCs treated for 3 hours with either 
AA or AA-LY. Control coverslip was incubated with secondary antibody alone to distinguish 
background from true staining. Scale bar represents 30 µm. (C) Schematic of the luciferase construct 
used showing the placement of the CAGA12 Smad binding elements upstream of the major late promoter 
(MLP) which drives Smad-dependent expression of luciferase. (D) Luciferase assay performed on 
hESCs co-transfected with luciferase and renilla constructs treated as in (A) for 6 hours. Data obtained 
from three independent experiments, error bars represent SD. * and ** indicates p<0.05 and p<0.001 
by Student’s t test respectively. (E) Gene expression analysis by qRT-PCR in hESCs treated as in (A) 
from two independent experiments with the qRT-PCR reaction performed in triplicate (n=6). Graphs 
indicate relative fold change with respect to day 0 hESCs maintained in MEF-CM. Error bars represent 
SD. * indicates p<0.05 by Student’s t test. All experiments repeated at least twice with representative 
image depicted unless otherwise stated. 
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3.2.3 DE differentiation induced by AA-Wort mimics AA-LY treatment  
To ensure that the enhance of DE differentiation by LY was solely due to its inhibitive effects on 
PI3K rather than any off target effects, I utilised Wort, an alternative PI3K inhibitor, in 
combination with AA to induce DE differentiation for 3 days to replicate the normal 
differentiation procedure with AA-LY.  Effects upon signalling were assessed at 6 hours into the 
differentiation, which revealed an identical prolonged Smad2/3 activation in AA-Wort treated cells 
compared to cells treated with AA alone as previously seen in AA-LY treated cells (Figure 3.4A 
vs. Figure 3.2C). Furthermore, gene expression analysis of hESCs differentiated for 2 days under 
these conditions showed that AA-Wort derived DE cells exhibited substantial increases in all 
mesendoderm and DE markers with the exception of Brachyury, which is however known to be 
drastically downregulated 2 days into the differentiation and routinely signifies a conversion to a 
more endoderm fate over mesoderm (Hay et al., 2008b; Teo et al., 2011).  
Figure 3.4: Induction of DE differentiation with AA-Wort 
(A) hESCs were treated with either RPMI/B27 alone or supplemented with Wort/AA/AA-Wort for 6 
hours after which lysates were analysed by immunoblot. Like LY, Akt-pS473 was used to assess 
inhibitive efficacy of Wort. Experiment repeated twice with representative image depicted.(B) Gene 
expression analysis of AA/AA-Wort differentiated cells by qRT-PCR. Graphs indicate relative fold 
change as per Figure 3.3E. Error bars indicate SD from two independent experiments with qRT-PCR 
reaction conducted in triplicate for each (n=6). * and ** indicates p<0.05 and p<0.001 by Student’s t 
test respectively.   
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3.3 Discussion and Conclusions 
A full description of the molecular underpinnings in how PI3K signalling negatively impacts 
Activin-induced DE differentiation of hESCs has been hampered by the inability to interrogate 
the cross-interaction of both pathways without interference from serum. Here, we have established 
a defined culture condition that facilitates the efficient conversion of hESC to DE in the absence 
of serum, which additionally allows for a fuller interrogation of the process on a molecular level. 
Initial experiments revealed that the basal level of Smad2 activation appears to be quite low in the 
MEF-CM condition, supporting previous findings which indicate that low levels of TGFβ 
stimulation is beneficial in maintaining pluripotency by driving the expression of Nanog (Paling et 
al., 2004; Storm et al., 2007; Vallier et al., 2009). However, low levels of Smad2 activation may not 
necessarily be due to the lack of Activin/Nodal ligand present in the MEF-CM. As evidenced by 
the amount of Akt activation, MEF-CM contains potent stimulators of PI3K signalling, which in 
turn acts to reduce the activation of Smad2. This supports the findings of previous studies in which 
PI3K signalling was shown to promote the maintenance of pluripotency and self-renewal 
(Armstrong et al., 2006), and acts to keep Activin/Nodal signalling low to prevent aberrant 
differentiation. This negative influence of PI3K upon Smad2 activation becomes more apparent 
upon medium exchange with defined RPMI/B27, in that reduction in the stimulation of PI3K 
promotes increased Smad2 activation even in the absence of exogenous Activin/Nodal 
stimulation. Furthermore, the negative effects of PI3K activation can be further enhanced when 
stimulators such as IGF-1 and Heregulin are supplemented into the RPMI/B27 base media, which 
when applied together, act to suppresses Smad2 activation to a similar extent as with MEF-CM. 
Therefore, PI3K signalling negatively affects the activation of Smad2/3 in a reciprocal manner, 
with a higher PI3K activation resulting in a greater reduction of Smad2/3-pTail phosphorylation 
and hence a reduction in their functional output. Full manifestation of this effect is evident when 
DE differentiation conditions are applied to the hESCs. When PI3K is inhibited by LY in the 
presence of high AA supplementation, a prolonged accumulation or increased activation of 
Smad2/3 was observable between 3 and 6 hours into the process that is entirely independent of 
total Smad2/3 and Smad4 levels. Given that Smad2/3 activation is similar at 1 hour into the 
differentiation, two explanations can be offered; either Smad2/3 activation by the receptors is 
being sustained or that the pool of activated Smad2/3 persists for longer following maximal 
activation at 1 hour and are somehow resistant to PI3K-induced deactivation. In order to 
distinguish which explanation is true, further experimentation was performed which will be 
described in subsequent chapters.  
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The prolonged activation of Smad2/3 upon PI3K inhibition by LY immediately suggests an 
explanation as to why AA-LY treated hESCs ultimately differentiate better in terms DE and 
hepatocyte formation efficacy when compared to AA treated hESCs. Given that activated 
Smad2/3 together with Smad4 function as transcription factors upon entry into the nucleus, I next 
asked whether this prolonged population of activated Smad2/3 are able to drive a more robust 
transcriptional response when compared to the levels observed in AA treated cells. In this regard, 
I found that not only was this prolonged population of activated Smad2/3 present mainly in the 
nucleus, but that they were also transcriptionally active as indicated by the luciferase reporter assay. 
Furthermore, as several mesendoderm genes are known to be direct Smad2/3 targets (Teo et al., 
2011), I also found that these genes were upregulated in AA-LY treated cells albeit may not 
necessarily be statistically relevant at this early stage of differentiation. Notably, as the same 
enhancement in Smad2/3 activation was observed in both cytoplasmic and nuclear fractions upon 
AA-LY treatment, this suggests that the underpinning molecular events leading to this effect are 
likely to take place in the cytoplasm prior to the nuclear translocation of activated Smad2/3. As a 
whole, this data reflects two intriguing findings from which to move forward with; firstly in that 
PI3K signalling appears to directly influence Smad2/3 activation, and secondly, in that this effect 
may explain why DE conversion from hESC is enhanced upon the inhibition of PI3K by LY. 
However, whether this is truly an effect of PI3K signalling alone, or via an indirect mechanism as 
outlined previously (Singh et al. 2012), will be explored further into this study, although 
experiments with Wort encouragingly indicate the involvement of at least PI3K in mitigating this 
effect.   
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4.1 Introduction 
Evidence acquired from the experiments performed in the previous chapter suggests that the 
negative impact of PI3K signalling on AA-induced DE differentiation is primarily due to a PI3K-
mediated downregulation of Smad2/3 activation, which is also independent of total Smad2/3 
turnover. This represents the first line of evidence linking PI3K activity with the regulation of 
Smad2/3 activity, which is well supported given that inhibition of PI3K with either LY or Wort 
enhances Smad2/3 activation in the presence of AA (Figure 3.2C and 3.4A). This could be as a 
result of either prolonged receptor kinase activity or sustained stabilisation of the activated 
Smad2/3 pool. However, given that levels of activated Smad2/3 are stoichiometrically related to 
levels of receptor activation (Inman et al., 2002), and that supplementation of the culture with 100 
ng/ml AA ensures that activating ligands are initially available in abundance, if LY did affect 
receptor activation, a difference in the activation of Smad2/3 by AA would have been observed 
at an earlier point before 1 hour of treatment. The fact that the difference was observed 3 hours 
into the treatment and peaked at 6 hours indicates that it is less likely that effect of PI3K inhibition 
is due to an effect upon the receptor activity. Thus it is more likely that the second scenario, 
whereby the activated Smad2/3 pool is sustained for longer periods of time in the presence of LY 
is true.  
In considering how to experimentally verify this scenario, one must first understand the 
mechanisms by which active Smad2/3 is regulated. Upon the cessation of transcriptional activity 
within the nucleus, activated Smad2/3 are subjected to dephosphorylation by phosphatases such 
as PPM1A and protein phosphatase 5 (PP5), which in turn triggers their export back into the 
cytoplasm (Lin et al., 2006; Bruce et al., 2012). Alternatively, activated Smad2/3 may also to bind 
proteins such as chloride intracellular channel 4 (CLIC4), which function to preserve their 
activation and prevent phosphatase-mediated deactivation (Shukla et al., 2009). As such, LY-
mediated inhibition of PI3K could also in turn inhibit or promote the action of nuclear 
phosphatase or activated Smad2/3 stabilisation proteins respectively.  
Equally, another mechanism by which activated Smad2/3 can be subjected to deactivation is via 
the ubiquitin-mediated proteasomal degradation pathway. Several E3-ubiquitin ligases such as 
Smurf2, Nedd4L and Arkadia have been shown to bind and target Smad2/3 for degradation (Lin 
et al., 2000; Alarcón et al., 2009; Gao et al., 2009; Mavrakis et al., 2007) and represents a critical 
mechanism by which Smad2/3 activity is regulated. Given that most of these ubiquitin ligases are 
rather appropriately, expressed ubiquitously, regulation of their activity upon Smad2/3 is mediated 
through the substrate such as phosphorylation of the Smad linker region (Gao et al., 2009) or 
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Smad2/3 interaction with Smad7 (Hayashi et al., 1997). As such, it can be envisaged that PI3K 
signalling could act to mediate ubiquitin ligase recruitment simply by modulating the Smad linker 
region, and thus directly control their turnover via degradation.  
 
4.2 Results 
4.2.1 LY-mediated stabilisation of activated Smad2/3 is not through affecting 
PPM1A and CLIC4 expression nor PPP activity 
Since phosphatase-mediated deactivation is thought to represent the most effective mechanism by 
which Smad2/3 signalling activity is terminated, I questioned whether LY-mediated inhibition of 
PI3K affects the expression or activity of any Smad2/3-specific phosphatases or active Smad2/3 
binding proteins. I first examined the expression of PPM1A, which was up until recently the only 
Smad2/3 phosphatase reported to exist along with its modulator CLIC4 by qRT-PCR and 
immunoblotting, which revealed no obvious changes on both mRNA and protein levels in relation 
to the presence or absence of LY (Figure 4.1A, B). More importantly, PPM1A was detected 
exclusively in the cytoplasmic fraction, which is incompatible with its role as a nuclear localised 
Smad2/3 phosphatase (Lin et al., 2006). I further extended my investigations to other phosphatase 
families including phosphoprotein phosphatases (PPP) of which one family member; PP5 has been 
recently shown to be a Smad2/3 phosphatase (Bruce et al., 2012). In order to track the degradation 
kinetics of activated Smad2, I designed an experimental protocol whereby cells were pulse treated 
with high dose AA before subsequent incubation with SB431542 (SB), a potent ALK receptor 
inhibitor that prevents further activation of Smad2 (Figure 4.1C). Co-treatment of the cells with 
SB and Okadaic acid (OA), a pan-specific inhibitor of PPPs, revealed no significant differences in 
terms of the decay kinetics of activated Smad2 when compared to SB treated cells (Figure 4.2B), 
which suggests that phosphatase-mediated deactivation of Smad2/3 is not the mechanism by 
which PI3K antagonises Smad2 activity. 
  
___________________________________________________________________________ 
 
103 
 
Chapter Four Results 
Figure 4.1: Effect of PPM1A, PPP family and CLIC4 in the regulation of Smad2/3 activity 
(A) hESCs were treated with either AA or AA-LY for 1, 3 and 6 hours after which gene expression was 
analysed by qRT-PCR. Graphs indicate relative fold change in relation to hESCs in MEF-CM. Error 
bars indicate SD from two independent biological replicates with qRT-PCR reaction conducted in 
triplicate for each (n=6). (B) Cytoplasmic/nuclear fractionation of lysates treated as indicated, with 
Lamin B and β-actin used contamination and loading control respectively. (C) Schematic depicting 
setup of experiments used to track the degradation of activated Smad2 over 6 hours in the presence of 
SB ± OA. (D) Immunoblot of cells treated according to schematic in C. Zero time-point indicates levels 
of Activin-induced Smad2-pTail following 20 min of incubation. Graphs indicate relative activated 
Smad2/3 levels normalised to total Smad2 and β-actin. Error bars indicate SD from three independent 
biological replicates. All experiments repeated twice with representative image depicted. 
 
4.2.2 LY inhibits the ubiquitin-mediated proteasomal degradation of activated 
Smad2 by preventing the recruitment of Nedd4L 
As the antagonistic effect of PI3K upon Smad2/3 activation appears to be independent of 
phosphatase activity, and given that ubiquitin-mediated proteasomal degradation has also been 
reported to regulate active Smad2/3 signal termination, I next asked whether LY-mediated 
inhibition of PI3K acts to prevent the degradation of activated Smad2. By replicating the 
experiment outlined in Figure 4.1C but substituting OA with LY or the proteasome inhibitor 
MG132, I found that LY reduced the active Smad2 degradation much like MG132 albeit not with 
the same efficacy (Figure 4.2A, B). Additionally, SB treatment did not appear to affect the rate of 
active Smad2 degradation, although the LY-mediated resistance of Smad2 against degradation was 
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now observable earlier at 1 hour into the treatment (Figure 4.2A). This again suggests that the 
inhibition of PI3K activity affects Smad2 activity independent of receptor activity and that it may 
act to suppress ubiquitin-mediated proteasomal degradation of active Smad2/3. Although Nedd4L 
has been previously identified as a Smad2/3 ubiquitin ligase (Gao et al., 2009), the presence of LY 
had no discernable effect on Nedd4L expression (Figure 4.2C). However, LY treatment 
substantially reduced the binding of Nedd4L to Smad2 (Figure 4.2D), which consequently resulted 
in the decreased ubiquitination of Smad2 (Figure 4.2E). Notably, LY treatment also appeared to 
reduce the phosphorylation of the Smad2 T220 linker residue, which has been shown to be 
required for Nedd4L recruitment (Gao et al., 2009). Therefore, downregulation of this 
phosphorylation by LY treatment could account for the reduction of Nedd4L recruitment, which 
in turn prevents Smad2 ubiquitination and prolongs its activation.  
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Figure 4.2: Effect of ubiquitin-mediated proteasomal degradation in the regulation of 
Smad2/3 activity 
(A) and (B) Immunoblot of hESCs treated according to schematic in Figure 4.1C, but with OA 
substituted with either LY or MG132 (MG). Zero time-point indicates levels of Activin-induced Smad2-
pTail following 20 min of incubation. Graphs indicate relative activated Smad2/3 levels normalised to 
total Smad2 and β-actin. Error bars indicate SD from three independent biological replicates. (C) 
hESCs were treated as indicated for 1, 3, and 6 hours as indicated and analysed by immunoblot. (D) 
Co-IP of Smad2 with Nedd4L and Smad4 in hESCs treated for 1 hour as indicated. (E) Ubiquitination 
assay of immunoprecipitated Smad2 from hESCs treated for 1 hour as indicated. All experiments 
repeated at least twice with representative image depicted. 
 
4.2.3 shRNA-mediated knockdown of Nedd4L enhances the stabilisation of 
activated Smad2 and promotes DE induction in the absence of LY  
It has been shown in the previous sections that inhibition of PI3K promotes Activin-induced DE 
differentiation of hESCs by reducing the recruitment of Nedd4L to activated Smad2/3, which 
enhances their activity. Thus, I next sought to verify this mechanism by diminishing Nedd4L in 
cells via genetic means. If the hypothesised mechanism is correct, the reduction of Nedd4L levels 
will increase Activin-induced Smad2/3 activity and promote the DE differentiation of hESCs. 
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Furthermore, as PI3K signalling promotes Nedd4L binding, loss of Nedd4L itself will lead to the 
stabilisation of activated Smad2/3 regardless of LY treatment. In utilising lentiviral delivery of 
shRNA-containing constructs, I was able to obtain both PC-3 and hESC knockdown lines 
(shNedd4L-PC-3/hESCs) possessing over ~50% knockdown as assessed by qRT-PCR and 
immunoblotting (Figure 4.3C) 
A). PC-3 cells were chosen as a surrogate cell line to initially perform this experiment due to its 
hESC-like responsiveness to Activin stimulation. Indeed, decreased Nedd4L expression mitigates 
the antagonistic effect of PI3K upon Smad2/3 activation, resulting in their enhanced resistance to 
ubiquitin-mediated proteasomal degradation with LY treatment having no effect upon Smad2/3 
activation. This is clearly demonstrated in shNedd4L-PC-3 cells whereby Smad2 activity was 
enhanced regardless of the presence or absence of LY unlike that observed in control cells (Figure 
4.3B). Notably, the same downregulation of Smad-T220 linker phosphorylation was also observed 
in the presence of LY, indicating that this effect is attributed to the presence of LY. Since Nedd4L 
knockdown serves to enhance Smad2 activity, I next assessed whether it enhances the induction 
of DE in hESCs. In complete agreement with the effects observed in PC-3 cells, shNedd4L-hESCs 
when treated with AA alone showed higher levels of mesendoderm and endoderm gene expression 
when compared to control cells (Figure 4.3C). Therefore, regulation of the ubiquitination activity 
of Nedd4L by PI3K signalling has a direct impact upon the differentiation of hESCs to DE.  
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Figure 4.3: Effect of Nedd4L knockdown on Smad2 activity and DE induction 
(A) Verification of shRNA-mediated Nedd4L knockdown in PC-3 and hESCs by qRT-PCR and 
immunoblot. Graphs indicated percentage of knockdown when compared to controls infected with 
shGFP-containing virus. Error bars indicate SD from two independent experiments from which PCR 
reaction was performed in triplicate (n=6). * and ** indicates p<0.05 and p<0.001 by Student’s t test 
respectively. (B) shGFP control and shNedd4L-PC-3 cells treated for 1 hour as indicated before lysis 
and assessment by immunoblot. AA dosage was reduced to 10 ng/ml. Graphs depict densitometry 
measurements of activated Smad2 normalised to total Smad2 and β-actin in AA and AA-LY treated 
cells. Experiment repeated twice with representative image depicted. (C) Gene expression analysis of 
shGFP control and shNedd4L-hESCs differentiated for three days with AA alone. Graphs indicate 
relative fold change when normalised with day 0 shGFP/shNedd4L-hESCs in MEF-CM. Error bars 
indicate SD from two independent experiments from which PCR reaction was performed in triplicate 
(n=6). * and ** indicates p<0.05 and p<0.001 by Student’s t test respectively.   
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4.3 Discussion and Conclusions 
In establishing that PI3K signalling negatively affects the duration of Smad2/3 activity, two 
different mechanisms were posited to induce this effect. Given that the duration of the Smad2/3 
response is directly related to its activation (Inman et al., 2002), I reasoned that PI3K may act to 
modulate the activity of Smad2/3-specific phosphatases or proteins that stabilise activated 
Smad2/3. Subsequent experimentation served to discount this mechanism, in that LY treatment 
did not result in any significant changes in PPM1A or CLIC4 expression on both mRNA and 
protein levels. Furthermore, my study has found PPM1A expression to be largely restricted to the 
cytoplasmic fraction, whilst the majority of Smad2/3 are shown to rapidly translocate into the 
nucleus post-activation (Chacko et al., 2001). These results were initially very surprising as PPM1A 
had been the only phosphatase identified to be responsible to dephosphorylate C-terminal 
Smad2/3 serine residues (Lin et al., 2006). However, a recent report (Bruce et al., 2012) has 
demonstrated a similar pattern of PPM1A expression in HaCaT cells, utilising the same cell type 
as in the original paper (Lin et al., 2006), which is additionally in line with my results and indicates 
the cell line independency of this effect. Furthermore, PPM1A does not appear to be in the right 
cellular compartment to perform its phosphatase function, and given that it has also been shown 
to promiscuously act upon cytoplasmic targets such as PI3K and axin (Yoshizaki et al., 2004; 
Strovel et al., 2000), it is hence questionable whether PPM1A truly is a bona fide nuclear 
phosphatase.  
Although Bruce et al. provided convincing evidence to suggest that PP5 rather than PPM1A is the 
Smad2/3 phosphatase, treatment of hESCs with the pan-PPP inhibitor OA had no effect on the 
decay kinetics of activated Smad2, which together with the previous lines of evidence, discounts 
the involvement of phosphatases in mediating the LY-dependent stabilisation activated Smad2/3. 
However, despite the characterisation of OA as a pan-PPP inhibitor, it is known that certain 
phosphatases are inhibited to a greater degree than others, even amongst the same family. Notably, 
PP2A is preferentially inhibited to a greater extent than PP1, although both at the nanomolar 
range, whilst PP2B requires much higher concentrations for effective inhibition (Bialojan and 
Takai, 1988). Therefore OA treatment alone cannot comprehensively rule out the involvement of 
all PPP family members, although these results almost certainly rule out the involvement of PP5 
due to its inherent sensitivity to OA inhibition to the same extent as that of PP2A (Chen et al., 
1994). The use of improved pan-phosphatase inhibitors such as calyculin A that potently inhibits 
both PP1 and PP2A should allow future studies to address this issue with greater confidence (Resjö 
et al., 1999).  
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In comparing the decay kinetics of LY-treated with MG-treated cells, I observed that although the 
pattern of decay was similar to each other, in that both prolonged the activation of Smad2, the 
effect was more pronounced in MG-treated cells. This is perhaps unsurprising given that MG acts 
to prevent the degradation of both total and activated Smad2 regardless of the identity of the E3 
ligase, whilst LY only acts specifically to prevent Nedd4L-mediated Smad2 degradation. However, 
it is notable that the total Smad2 levels did not show a great deal of increase even in the presence 
of MG for extended periods of time, which suggests that the rate at which total Smad2 undergoes 
ubiquitin-mediated turnover is rather slow, although whether MG treatment affects global protein 
synthesis is debatable. Nonetheless, this data indicates that the effect of LY treatment in the 
stabilisation of activated Smad2 might be manifested via the inhibition of their ubiquitin-mediated 
proteasomal degradation. In pursuing this line of enquiry, I identified Nedd4L as a likely candidate 
for investigation, as it was reported to be the most effective E3 ubiquitin ligase acting upon 
activated Smad2/3 (Gao et al., 2009). Experimentation along these lines revealed that as 
characteristic of most E3 ubiquitin ligases, Nedd4L is ubiquitously expressed in hESCs and 
unaffected by either AA or AA-LY treatment. However, I reasoned that although LY may not 
affect Nedd4L expression, it could still interfere with Nedd4L recruitment to Smad2/3. Enticingly, 
this was proven to be the case, in that less Nedd4L was bound to Smad2 in cells that were treated 
with LY to suppress PI3K activity, which was corroborated with a reduction in their overall 
ubiquitination. Therefore, the experiments have demonstrated that PI3K signalling antagonising 
Activin-Smad signalling could be through regulation of the recruitment of Nedd4L to Smad2/3.  
In establishing the involvement of Nedd4L in the regulation of Smad2 activity by PI3K, I then 
sought to verify whether this mechanism accounts for the inhibitive effects of PI3K signalling on 
DE induction using a loss of function approach to target Nedd4L using shRNA. As predicted, 
reduction in Nedd4L expression resulted in prolonged Smad2 activation, dispensing with the need 
for LY, which additionally resulted in a more effective DE differentiation in hESCs when supplied 
with AA alone. As a whole, this body of evidence suggests that PI3K/Akt signalling acts to 
promote the phosphorylation the Nedd4L-mediated degradation of activated Smad2/3 and 
curtails the AA-induced DE differentiation of hESC.  
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5.1 Introduction 
Emerging evidence has lent weight to the idea that the linker region of Smad2/3 serves as an 
important site at which their activity is regulated. This region contains multiple phosphorylation 
sites that are targeted by various proline-directed kinases stemming from other signaling pathways 
and thus can additionally be considered as a key site for inter-pathway crosstalk. Phosphorylation 
of this region controls the interactions between Smad2/3 and other proteins, which consequently 
affects active Smad2/3 stability, nuclear translocation and transcriptional activity (Guo et al., 2009; 
Wrighton et al., 2006). In particular, it has been demonstrated that recruitment of Nedd4L to the 
Smad2/3 linker PPxY motif requires the phosphorylation of the upstream linker threonine residue 
lying adjacent to the PPxY sequence, Smad2-T220 and Smad3-T179 (Figure 5.1A and Figure 1.5). 
In previously observing that LY-treatment acts to reduce the phosphorylation of these residues 
(Figure 4.2D and 4.3B), it remains however unknown whether this effect is contributory in 
promoting Smad2/3 activation or DE differentiation. Nonetheless, if this is indeed the case, 
genetic manipulation of the T220/T179 residue should be able to replicate the positive effects of 
LY-mediated PI3K inhibition in terms of promoting Smad2/3 activation and consequently DE 
differentiation in the absence of LY, not too dissimilar to the effects observed with Nedd4L 
knockdown.  
It is also unclear as to whether this effect is a direct or indirect consequence of PI3K signalling, 
since several kinases have been definitively shown to act upon the Smad2/3 linker residue such as 
Erk1/2 (Kretzschmar et al., 1999) and CDK (Alarcón et al., 2009). Conceptually, should targeted 
inhibition of such kinases recapitulate the effects seen with LY or Wort treatment, one could at 
least partially resolve this issue. Whilst it might be evidently more likely that PI3K may exert its 
influence upon Smad2/3 activity via the modulation of linker region kinases, the direct 
involvement of kinases along the PI3K signalling axis itself cannot be completely discounted. The 
following experiments in this chapter aimed to address these issues, firstly in verifying whether 
LY-mediated regulation of the T220/T179 residue is sufficient in driving improved DE, and 
secondly, whether this modulation is a direct or indirect effect of PI3K signalling. 
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5.2 Results 
5.2.1 LY treatment specifically inhibits the phosphorylation of the T220 residue 
and promotes the prolonged activation of Smad2 
The linker region of Smad2 is characterised by Ser and Thr residues adjacent to Pro residues that 
are the target of various proline-directed Ser/Thr kinases. Nedd4L recruitment is mediated by the 
phosphorylation state of the T220/T179 residue lying adjacent to the PPxY binding site (Figure 
5.1A and Figure 1.5), (Gao et al., 2009). In observing the downregulation of the T2220 
phosphorylation in LY treated hESCs and the possibility that this could account for the reduced 
association of Smad2 with Nedd4L, it is conceivable that PI3K may affect Smad2/3 activation 
through regulating the phosphorylation of the Smad2/3 linker threonine residue that subsequently 
affects Smad2/3 interaction with Nedd4L. In addition to T220/T179, the Smad2/3 linker region 
also contains three other Ser residues that can also be phosphorylated. These residues are denoted 
as S245/S250/S255 in Smad2 (Smad2-LS, Figure 5.1A) and S204/S208/S213 in Smad3 (Smad3-
LS, Figure 1.5). Therefore it was important to ascertain whether PI3K signalling specifically 
regulates the threonine residue of the Smad2/3 linker region, or whether it affects the linker region 
more generally by regulating the phosphorylation of the other Ser residues. Furthermore, given 
that phosphorylation of these linker sites have been shown to alter the efficacy of endoderm 
specification in Xenopus (Grimm and Gurdon, 2002), it was also important to assess how their 
phosphorylation status changes during the course of in vitro DE differentiation in response to AA 
or AA-LY treatment. 
A time course experiment in hESCs analysing the dynamics of Smad2-T220 and Smad-LS revealed 
that T220 phosphorylation was increased upon AA treatment, which was downregulated in the 
presence of LY, most evidently at 6 hours post-treatment (Figure 5.1B, C). In contrast, 
phosphorylation of the LS residues showed no changes in response to either AA or LY treatment, 
indicating that the phosphorylation of the T220/T179 and LS residues are regulated by different 
mechanisms. Interestingly, hESCs that were transferred to RPMI/B27 medium supplemented 
with SB to block TGFβ/Activin signalling also exhibited high levels of Smad2/3-T220/T179 
phosphorylation, which could be inhibited by LY treatment, thereby demonstrating that PI3K-
mediated T220/T179 phosphorylation is independent of TGFβ/Activin signalling (Figure 5.1D). 
The effect of LY in downregulating the phosphorylation of Smad2-T220 also corresponds exactly 
with the time point at which Smad2 activation is also increased (Figure 5.1E, F), suggesting that 
these two events are related each other. Furthermore, when subjecting PC-3 cells to similar 
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treatment, albeit with a lower dosage of AA, similar effects were observed at 1 hour post-treatment 
(Figure 5.1G). Independent observation of the same effect in two different cell lines suggests that 
PI3K is involved in the regulation of the Smad2/3 linker Thr residue and that this occurs solely 
upon the T220 residue in Smad2. Moreover, it is probable that this is a more general effect that is 
not dependent on the cell line used. This data causatively links the downregulation of T220 
phosphorylation with the prolonged activation of Smad2 and offers a mechanism by which PI3K 
activity can influence Smad2/3 function.  
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Figure 5.1: LY-mediated downregulation of T220 phosphorylation prolongs Smad2 
activation 
(A) Schematic illustrating the structure of the Smad2 linker region. (B) hESCs were treated with either 
AA or AA-LY for 1, 3 and 6 hours after which cell lysates were analysed by immunoblotting. (C) 
Densitometric measurements of linker T220 and LS phosphorylated Smad2 normalised to total Smad2 
and β-actin levels depicting LY-dependent downregulation in AA-LY treated cells as per B. (D) hESCs 
pre-treated with AA followed by incubation with RPMI/B27+SB as indicated (E) hESCs treated for 6 
hours with the indicated treatments and analysed by immunoblotting. (F) Densitometric measurements 
of T220 phosphorylated Smad2 normalised to total Smad2 and β-actin levels from repeated experiments 
of E. Graph represents data from three independent experiments, error bars indicate SD. Statistical 
analysis was performed via Student’s t test where * indicates P<0.05. (G) PC-3 cells treated as in B 
but with reduced AA dosage (10 ng/ml) and duration (1 hour) and analysed by immunoblotting. All 
experiments repeated twice with representative image depicted. 
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5.2.2 Ectopic expression of mutant Smad2-T220V promotes LY-independent 
prolonged activation of Smad2 and induces DE differentiation in hESCs 
Previously, I have found that Nedd4L knockdown serves to enhance the resistance of activated 
Smad2 to degradation and thereby promote DE induction irrespective of the T220 
phosphorylation status. This provided corroborating evidence to support the notion of PI3K 
affecting Smad2/3 activity and DE differentiation through the proposed mechanism in which 
Nedd4L-mediates Smad2/3 degradation. Similarly, I anticipated that if this mechanism is indeed 
regulated by PI3K via the modulation of the Smad2/3 linker Thr, mutation of this residue to a 
non-phosphorylatable Val residue by genetic manipulation could serve to further corroborate this 
data in producing a similar effect.  
To these means, a construct was generated via site-directed mutagenesis in which the T220 residue 
in the Flag-tagged wild-type Smad2 (Smad2-WT) coding sequence was mutated to V220 (Smad2-
T220V). Substitution of the Thr residue with Val generates a mutant form of Smad2 that is 
effectively permanently dephosphorylated and hence incapable of recruiting Nedd4L. This mutant 
sequence along with the wild-type were further subcloned into lentiviral expression vectors 
downstream of a PuroR-2A sequence in order to generate puromycin-resistant cell lines that also 
express Smad2-WT/T220V protein (Figure 5.2A). A lentiviral vector encoding for PuroR alone 
was used as an empty vector control. Transgenic cells were generated from both PC-3 and H1 
hESC lines via lentiviral transduction, which express either Smad2-WT or Smad2-T220V. 
Treatment of transgenic PC-3 cells with AA or AA-LY revealed that Smad2-T220V cells treated 
with AA exhibited similar levels of activated Smad2 as that of the AA-LY treated, indicating that 
the activation of these cells is independent of the presence of LY (Figure 5.2B), whilst both control 
and Smad2-WT cells showed a much higher Smad2 activation only in the presence of AA-LY as 
observed in experiments previously. In addition to the differential activation of Smad2 between 
Smad2-WT and Smad2-T220V transgenic lines, AA-induced DE differentiation over 2 days in 
transgenic hESCs also revealed an upregulation of mesendoderm and DE markers in Smad2-
T220V expressing cells when compared to WT (Figure 5.2C). These effects in both PC-3 cells and 
hESCs were not due to the differential expression of Smad2 as both total and transgenic Smad2 
levels in the two transgenic lines were shown to be largely equal as indicated by Smad2 and Flag 
levels assessed via immunoblot and qRT-PCR. These results have demonstrated the effect of 
Smad2/3 activity and DE differentiation by PI3K signalling is regulated through the 
phosphorylation of Smad2/3 linker Thr phosphorylation.  
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Figure 5.2: Ectopic expression of mutant Flag-Smad2-T220V into PC-3 and hESCs 
(A) Schematic illustrating three lentiviral constructs used ectopically express Puro, Puro-2A-Flag-
Smad2(WT) and Puro-2A-Flag-Smad2(T220V). Infected cells were selected with puromycin and 
propagated as stable cell lines. (B) Transgenic PC-3 cells were treated with either AA or AA-LY for 1 
hour after which cell lysates were analysed by immunoblotting. Experiment repeated twice with 
representative image depicted. (C) Gene expression analysis of transgenic Smad2-WT and Smad2-
T220V expressing hESCs differentiated for 2 days in the presence of AA alone. Graphs represent data 
from 2 independent experiments from which RT-PCR was performed in triplicate for each (n=6). Error 
bars indicate SD. F-Smad2 refers to expression of Flag-tagged Smad2 expressed via transgene.  
 
5.2.3 Known linker kinases do not contribute to the PI3K-mediated 
downregulation of T220 phosphorylation  
In verifying that T220 phosphorylation regulates the activity of Smad2/3 via recruitment of 
Nedd4L, I next sought to uncover the kinase responsible for this phosphorylation. Specifically, I 
questioned whether the regulation of this phosphorylation by PI3K occurs indirectly through 
affecting the activity of known linker kinases such as Erk1/2, CDK and other MAPKs. Given that 
LY and Wort treatments are shown to be effective in downregulating the PI3K-dependent T220 
phosphorylation, inhibition of the target kinase should equally be able to recapitulate the effects 
of LY treatment upon the T220 residue. To these means, I applied various inhibitors that are 
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known to specifically act against these linker kinases (Figure 5.3A) to hESCs and assessed their 
efficacy by analysing their canonical downstream targets (Figure 5.3B). MEK1/2, PI3K and CDK 
were effectively inhibited as indicated by the downregulation of Erk1/2-pT202/Y204, Akt-p473 
and Rb-pS780 phosphorylation respectively, whilst the effectiveness of the JNK inhibitor was 
demonstrated by the downregulation of its own pT183/Y185 phosphorylation due its ability for 
autophosphorylation. I was unfortunately unable to assess the effectiveness of the p38 inhibitor, 
owing to the lack of a working MAPKAPK-2 antibody. However, of the currently reported linker 
kinases, Erk1/2 and CDK appear to be the best characterised (Kretzschmar et al., 1999; Grimm 
and Gurdon, 2002; Alarcón et al., 2009; Gao et al., 2009) and therefore became the main focus of 
my investigations. hESCs pulse treated with high-dose Activin were subjected to a further 1 hour 
treatment with the various inhibitors in combination with SB to prevent further activation of 
Smad2/3 via Activin. Analysis via immunoblot following treatment revealed that although all the 
inhibitors did reduce T220 phosphorylation to some degree, none was as effective as LY treatment 
(Figure 5.3C). Notably, T220 phosphorylation persisted even in the presence of the Activin 
receptor inhibitor SB, supporting the previous notion of T220 phosphorylation being independent 
of Activin stimulation. Furthermore, extending the treatment time to 6 hours also revealed that 
only LY treatment was able to maintain the suppression of T220 phosphorylation (Figure 5.3D). 
Surprisingly, treatment with the CDK inhibitor flavopiridol enhanced T220 phosphorylation, 
whilst simultaneously reducing Smad2-pLS and total Smad2 levels, which was particularly evident 
in the prolonged treatment. These results suggest that CDK may affect Smad2/3 signalling by a 
mechanism that is completely different from that mediated by PI3K.  
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Figure 5.3: Effect of various linker kinase inhibitors on T220 phosphorylation 
(A) Table outlining the inhibitors used, direct targets and affected downstream targets. (B) hESCs were 
pulse treated 100 ng/ml Activin after which they were further incubated with inhibitors for 1 hour as 
indicated and assessed by immunoblotting. (C) hESCs treated as in B and assessed by immunoblotting. 
Numbers indicate densitometric measurements of Smad2-pT220 and Smad2-pLS normalised to total 
Smad2 and β-actin levels. (D) hESCs treated as in C but for 6 hours, total Smad2 levels were assessed 
by both short and long exposure as indicated. All experiments repeated twice with representative image 
depicted. 
 
5.2.4 Erk1/2 kinase does not contribute to the LY-mediated downregulation of 
T220 phosphorylation  
As Erk1/2 has been previously demonstrated to be a key linker kinase implicated in the regulation 
of Smad2/3 activity (Grimm and Gurdon, 2002) and more recently, induction of DE 
differentiation (Singh et al., 2012), I performed further experiments to further verify the hypothesis 
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of PI3K-mediated inhibition of Smad2 activity being both a CDK and Erk-independent effect. 
Analysis of Erk in hESCs treated with AA or AA-LY for 1, 3 and 6 hours revealed no significant 
LY-dependent changes in Erk activation (Figure 5.4A). Since heregulin and IGF-1 (HI) could 
potentially activate Erk via non-canonical activation of PI3K signalling, I treated hESCs in 
RPMI/B27 supplemented with both factors and compared the Erk activity levels from cells 
supplemented with RPMI/B27 alone or in combination with LY (Figure 5.4B). Notably, under 
these conditions, both LY and HI treatment actually enhanced Erk activity, with LY treatment 
being the more effective. Importantly, despite the LY-dependent increase in Erk activation, no 
substantial increase in Smad2-T220 or Smad2-LS phosphorylation was observed, indicating that 
Erk1/2 does not function as the PI3K-induced linker kinase responsible for the inhibition of 
Smad2 activity. In fact, PI3K acts to inhibit Erk activity under these culture conditions, which is 
similar to findings in previous studies (Singh et al., 2012). Although HI treatment enhanced PI3K 
signalling as evidenced by Akt activation and P70S6K-pT389 phosphorylation, no difference in 
T220 phosphorylation was observed between untreated and HI treated samples, which was 
surprising. However, it is worth noting that even though Smad2-T220 phosphorylation did not 
increase upon HI treatment, it was dramatically reduced when PI3K activity was inhibited by LY 
treatment as assessed by Akt-p473 levels. This suggests that a low level of PI3K activity is sufficient 
to maximally phosphorylate Smad2/3 at the T220/T179 residue, meaning that increasing PI3K 
activity via HI would have no further effect as phosphorylation of this residue was already 
saturated. It is plausible that this low level PI3K activity is due to the insulin component of the 
B27 supplement. This hypothesis was subsequently confirmed upon the treatment of hESC with 
HI in the absence of B27, which evidently increased the phosphorylation of the T220 residue when 
compared to untreated cells (Figure 5.4C), additionally demonstrating the inherent sensitivity of 
this residue to PI3K-induced phosphorylation. Therefore, this data shows that none of the 
reported linker kinases appear to be responsible for mediating the PI3K-dependent inhibition of 
Smad2 activity via the T220 residue, which strongly suggests that this function is solely restricted 
to a kinase with the PI3K signalling pathway itself or is directly regulated by PI3K activation. 
Nevertheless, the involvement of these linker kinases in regulating Smad2/3 activity through 
mechanisms beyond the one examined cannot be fully discounted based on these experimental 
observations.  
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Figure 5.4: Effect of Erk1/2 to the PI3K-mediated downregulation of T220 
phosphorylation 
(A) hESC treated with AA/AA-LY for 1, 3, and 6 hours after which Erk activity was assessed by 
immunoblotting. (B) hESCs treated with RPMI/B27 alone or supplemented with LY or HI for 1 hour 
and assessed by immunoblotting. (C) hESCs treated as in B, but in the absence of B27 supplement and 
assessed by immunoblotting. All experiments repeated twice with representative image depicted. 
 
5.2.5 Nedd4L recruitment requires both receptor-mediated activation and 
phosphorylation of Smad2 at the linker region 
I have thus far shown that LY treatment acts to prevent the recruitment of Nedd4L to Smad2/3 
via the downregulation of the T220/T179 phosphorylation and that this PI3K-mediated 
phosphorylation does not require the activation of Smad2/3 nor their nuclear translocation. 
However, given that Nedd4L is an E3 ubiquitin ligase that is primarily localised in the cytoplasm 
(Gao et al., 2009), immediate questions arise as to whether Nedd4L only targets active Smad2/3 
for degradation and if so, how it distinguishes activated Smad2/3 from the inactive form. It is 
plausible that Nedd4L either possesses some inherent mechanisms to detect the activation state 
of Smad2/3 or that access to the binding site differs between active and inactive Smad2/3. To 
resolve these issues, I performed a co-IP experiment to assess the degree of Nedd4L recruitment 
to populations of Smad2 with different phosphorylation states on their SxS and T220 residues 
(Figure 5.5). PC-3 cells were chosen as the model to perform this particular experiment due to 
their intrinsic hyperactivation of the PI3K pathway even after starvation due to a PTEN mutation 
that enhances the duration of PI3K signalling via prolonging the half-life of the 
phosphatidylinositide mediator PtdIns(3,4,5)P3. Thus, upon overnight starvation in base medium, 
the majority of the signalling pathways in PC-3 cells are repressed with the exception of PI3K, 
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which would result in the phosphorylation of Smad2/3 at the linker T220/T179 residue but not 
at the SxS motif. In these cells, AA treatment would thus result in both sites becoming 
phosphorylated, whereas AA-LY treatment would result in phosphorylation mainly at the SxS site 
alone. In comparing the three treatments in terms of their ability to recruit Nedd4L, it is notable 
that both maximal Nedd4L binding and ubiquitination is present only when both the linker 
T220/T179 and SxS residues are phosphorylated (AA treated), which is substantially reduced in 
cells where Smad2 phosphorylation at the T220 is reduced and SxS activation is sustained (AA-
LY treated) or in cells with high T220 phosphorylation alone (starved). This suggests that T220 
phosphorylation is insufficient in inducing maximal Nedd4L recruitment, merely serving to prime 
Smad2 for Nedd4L binding upon activation via SxS phosphorylation.  
Figure 5.5: Effect of different Smad2 phosphorylation states on Nedd4L recruitment 
Co-IP experiment whereby starved PC-3 cells were pre-treated for 1 hour with MG132 followed RPMI 
base medium alone or supplemented with AA/AA-LY for a further hour as indicated before lysates were 
subjected to IP with Smad2 antibody. Immunoprecipitates were assessed for Nedd4L binding and also 
degree of ubiquitination. Input samples were assessed by immunoblot to determine the effectiveness of 
the treatments in modulating the T220 and SxS phosphorylation states. Experiment was repeated twice 
with representative image depicted. 
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5.3 Discussion and Conclusions 
In finding that the prolonged activation of Smad2 is attributed to a reduction in Nedd4L 
recruitment which is mediated by a downregulation of linker T220 phosphorylation, experiments 
in this chapter has comprehensively established the importance of this residue in controlling the 
Smad-dependent induction of DE from hESCs and has stringently corroborated the 
phosphorylation of this residue as a direct result of PI3K signalling. The intriguing finding that 
downregulation of T220 phosphorylation coincided with prolonged activation of Smad2 
immediately suggested that these two events are linked and related to each other. Correspondingly, 
and complementary to the Nedd4L knockdown experiments in the previous chapter, ectopic 
expression of degradation-resistant Smad2-T220V prolonged the activation of Smad2 independent 
of LY, which in turn bolstered the DE induction in transgenic hESCs. Therefore, much like the 
downregulation of Nedd4L, reduction of T220 phosphorylation is itself sufficient in driving 
effective DE formation regardless of the presence of PI3K signalling. This experiment served as 
the acid test by which the phenotypic outcome of the proposed mechanism is verified, in that 
modulation of T220 phosphorylation by PI3K affects Smad2 turnover and activity, resulting in 
the inhibitive effects of PI3K upon AA-induced DE differentiation. This therefore concretely 
establishes ubiquitin-mediated proteasomal degradation as a critical mechanism in the control and 
termination of Smad2 activity.   
Another missing link in the derivation of a complete mechanism characterising the inhibitive 
effects of PI3K signalling upon TGFβ activities concerns the relationship between PI3K activity 
and T220 phosphorylation. Given the pleiotropic properties of PI3K, I envisaged that this could 
be mediated via PI3K-mediated activation of various linker kinases that have been shown to 
regulate the phosphorylation of this residue. However, inhibition of these known linker kinases 
failed to recapitulate the downregulation of T220 phosphorylation to the same degree as LY 
treatment, implying that although they do act to regulate the phosphorylation state of this residue, 
none are involved in regulating Smad2 activity via the proposed mechanism. This is particularly 
true of CDK. Several members of the CDK family have been reported to be capable of modulating 
the phosphorylation of the Smad2/3 linker residues and subsequently inhibiting tis transcriptional 
activity (Matsuura et al., 2004; Gao et al., 2009). CDK2 and CDK4 were found to regulate the 
phosphorylation of the Smad3 linker at all four residues without specifically distinguishing them 
individually (Matsuura et al., 2004). More recently, CDK8 and CDK9 were identified as linker 
kinases in mediating Nedd4L recruitment via T220 phosphorylation (Gao et al., 2009). However, 
in my study, although flavopiridol treatment reduced the Smad2-LS phosphorylation as observed 
___________________________________________________________________________ 
 
123 
 
Chapter Five Results 
in the original study, T220/T179 phosphorylation demonstrated either no obvious change or 
notably increased with prolonged treatment accompanied by a decrease in total Smad2 levels. It is 
unclear whether the upregulation of the T220/T179 phosphorylation is attributed to the inhibition 
of CDK or an effect of flavopiridol itself, however, flavopiridol treatment has been reported to 
upregulate the phosphorylation of Akt-S473, which is in line with my own findings detailing the 
involvement of the PI3K signalling pathway in mediating T220/T179 phosphorylation (Caracciolo 
et al., 2012). The decrease in total Smad2 is likely a result of the unforeseen inhibition of RNA 
polymerase II activity, which requires CDK activity for its own activation and hence induces a 
global downregulation of gene expression (Chao et al., 2001). Although inhibition of Erk did not 
fully recapitulate the effect of LY, I nonetheless persevered to assess its effects upon hESC 
differentiation given that PI3K has been shown to stimulate Erk activity and hence drive DE 
specification (Singh et al., 2012). In finding that both LY and HI treatments stimulated Erk activity 
without any effect on the linker phosphorylation, I comprehensively ruled out the role of PI3K-
induced Erk activity in the mechanism. This was further evidenced by subsequent experiments in 
hESCs, in that T220 phosphorylation could only be increased by PI3K stimulation alone and 
further corroborated in that although the study by Singh et al. identified a LY-dependent increase 
in both Erk and Smad2 activation, no mechanism was proposed to explain this effect, which is 
likely to be in actuality a consequence of the mechanism I have currently outlined.  
The role of the E3 ubiquitin ligase-mediated degradation of activated Smad2/3 in regulating TGFβ 
signalling has been a contentious issue with differing opinions as to whether this mechanism plays 
a key role in mediating TGFβ activities. Whilst there is evidence to suggest that Smad2/3-SxS 
dephosphorylation is a critical mechanism by which TGFβ signalling is terminated (Inman et al., 
2002; Xu et al., 2002; Lin et al., 2006), a wealth of studies support the notion of E3 ubiquitin ligase-
mediated Smad2/3 degradation as the primary means by which this is achieved (Lo and Massagué, 
1999; Lin et al., 2000; Mavrakis et al., 2007; Gao et al., 2009). In the previous chapters, I have 
provided evidence to support this idea, in that LY-mediated enhancement of the duration and 
intensity of Smad2/3 activity is not dependent on C-terminal phosphatases, but rather dependent 
on Nedd4L-mediated Smad2/3 degradation, which was associated with and regulated by the 
phosphorylation of the Smad2/3-T220/T179 residue. In originally uncovering the role of Nedd4L 
in mediating Smad2/3 degradation via the T220/T179 residue, Massagué and colleagues have 
proposed a mechanism by which Smad2/3 activity is terminated. Upon ligand-induced activation, 
Smad2/3 translocates into the nucleus whereupon it becomes phosphorylated at the T220/T170 
site by CDK8/9, which in turn induces the export of activated Smad2/3 back into the cytoplasm 
by an as of yet uncharacterised mechanism. Once in the cytoplasm, Nedd4L is recruited to 
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Smad2/3 by virtue of the CDK8/9-mediated phosphorylation of T220/T179, which induces the 
ubiquitination and subsequent proteasome-mediated degradation of Smad2/3 (Gao et al., 2009). 
However, in exploring the mechanisms that regulate Smad2/3 linker phosphorylation, I found that 
AA-induced activation of Smad2/3 was not required in sustaining their T220/T179 
phosphorylation, and that CDK-mediated linker phosphorylation plays no part in regulating the 
LY-induced prolonging of Smad2/3 activation. This presented a new problem in that Nedd4L 
must therefore be able to recognise activated Smad2/3 in order to selectively degrade it over 
inactive forms to produce the resultant effect, given that T220/T179 phosphorylation can occur 
independent of AA-induced Smad2/3 activation. In finding that Nedd4L recruitment is maximal 
only when both T220 and SxS residues are phosphorylated, I propose a new mechanism by which 
Nedd4L acts to selectively distinguish activated Smad2 for degradation, which is likely to occur 
even prior to the nuclear translocation of activated Smad2/3. Although PI3K-dependent 
phosphorylation of the linker T220/T179 residue primes Smad2/3 for degradation even prior to 
their activation, Nedd4L binding to the PPXY motif is prevented by steric hindrance, which is 
resolved upon Smad2 activation via SxS phosphorylation. However, as the rate of Smad2/3 
activation is likely to outpace that of its degradation, the effect is negligible under conditions 
whereby the total pool of Smad2/3 is maximally activated, yet this effect becomes gradually more 
evident with time or under low Activin conditions as an increasing proportion of activated 
Smad2/3 undergoes degradation (Figure 4.2B verses Figure 4.4B). In this way, Nedd4L-mediated 
degradation serves as an ever more potent mechanism by which activated Smad2/3 signalling 
activities are downregulated upon ligand exhaustion, allowing for stringent and rapid termination 
of Activin/Nodal signalling. This results in clear phenotypic changes with regards to DE 
specification in that interference with the mechanism via Nedd4L knockdown or ectopic 
expression of Smad2-T220V serves to enhance the AA-induced DE differentiation of hESCs, 
which is due to attenuated Smad2/3 signal termination.  
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6.1 Introduction 
In considering the results obtained from the previous chapter, the modulation of Smad2/3-
T220/T179 linker phosphorylation appears to be more specifically associated with the PI3K 
pathway. This pathway contains several Ser/Thr-directed kinases of which the most characterised 
are the Akt and mTOR. Previous studies have shown that Smad3 activity can be modulated by 
Akt, a highly pleiotropic kinase downstream of PI3K that has been shown to be responsible for 
mediating cell growth, survival and resistance against apoptosis. More relevant to this study, Akt 
has also been shown to bind to and sequester Smad3 away from receptor-mediated activation and 
hence directly impact Smad3 activity (Conery et al., 2004; Remy et al., 2004). However, there is 
still significant debate as to whether this process requires Akt kinase activity, or indeed whether 
this binding event is even regulated by linker phosphorylation (Song et al., 2006). Furthermore, 
less characterised branches of the PI3K pathway such as the mTOR could also contribute to the 
regulation of Smad2/3 activity, particularly as inhibition of mTOR activity by rapamycin has been 
shown to drive DE differentiation of hESCs (Zhou et al., 2009).  
The mTOR branch of PI3K signalling appeared to be a promising direction of investigation, given 
that in tandem with the PI3K/Akt signalling cascade, PI3K-induced activation of the mTOR 
activity has been shown to antagonise Smad3 activity (Song et al., 2006), whilst another study 
exploring the role mTOR signalling plays in hESCs has also hinted its role in regulating the 
maintenance of pluripotency (Zhou et al., 2009). Furthermore, the physiological roles of mTOR 
in controlling cell growth and survival counters many of the anti-proliferative properties attributed 
TGFβ signalling, which therefore suggest a role for mTOR in modulating TGFβ activities, 
although the molecular underpinnings remain undefined. mTOR also fulfils two distinct properties 
that make it a likely candidate. Firstly, mTOR kinase activity, be it as part of mTORC1 or 
mTORC2, has been shown to be dependent on PI3K activation (Vander Haar et al., 2007; Gan et 
al., 2011; Zinzalla et al., 2011), and secondly, mTOR is inherently a proline-directed Ser/Thr kinase 
which confers upon it the ability to possibly phosphorylate residues such as the Smad2/3-
T220/T179.  
To bring more clarity to these issues, experiments in this chapter attempted to identify the PI3K-
dependent kinase responsible for phosphorylation of the T220 linker residue, which serves as the 
defining link mediating PI3K and TGFβ crosstalk. Since the activity of Akt is primarily controlled 
by three critical residues serving to both activate (phosphorylation of T308 and S473) and confer 
kinase activity (K179) to the enzyme, I decided to mutate Akt by targeting these residues 
individually or in combination to investigate their effects on Smad2/3-T220/T179 
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phosphorylation. In relation to mTOR, given that its kinase activity is dependent upon association 
with either of two different protein complexes, I utilised specific inhibitors to explore their 
involvement in regulating this phosphorylation. As with the previous linker kinase screening 
experiments, inhibition of mTOR should replicate the effects observed when LY or Wort 
treatment is applied to the cells in terms of both prolonged Smad2/3 activity and downregulation 
of the linker T220 phosphorylation should it be involved in this mechanism.  
 
6.2 Results 
6.2.1 PI3K-mediated phosphorylation of the T220 residue is unaffected by Akt 
activity 
Since PI3K-mediated T220/T179 phosphorylation was shown to be independent of both Erk and 
CDK activity, and occurs only in the presence of HI treatment, I concluded that the identity of 
the linker kinase must lie within the PI3K pathway itself. Given that Akt has been shown by other 
studies to affect Smad3 activity (Conery et al., 2004; Remy et al., 2004; Song et al., 2006), I explored 
whether Akt functions to either directly regulate this phosphorylation or indirectly via a 
downstream kinase. To experimentally investigate this idea, I obtained constructs (Section 2.2.1.3) 
encoding for a constitutively active (WT), dominant negative (Tri-mut whereby K179M, T308A 
and S473A), and partially active (S473A) forms of Akt, which were ectopically expressed in Hep3B 
cells that retain a largely normal PI3K and TGFβ signalling response. Control cells that were 
transfected with an expression construct for GFP responded in the same manner in terms of their 
Smad2-T220 phosphorylation status as PC-3 and hESCs when treated with LY or HI after 
overnight starvation as expected. Contrastingly, expression of Akt of various activation states had 
no impact on the phosphorylation of this residue (Figure 6.1A). This implies that Akt activity does 
not affect T220 phosphorylation, which therefore also suggests that Akt does not function as a 
linker kinase. This was proven by an in vitro kinase assay in that no increase in T220 
phosphorylation was detected when de-phosphorylated Smad2-WT substrate was incubated with 
fully active Akt as opposed to with active Erk2 (Figure 6.1B). Hence Akt does not act to regulate 
Smad2 activity via this mechanism.  
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Figure 6.1: Effect of Akt to the PI3K-mediated downregulation of T220 phosphorylation  
(A) Hep3B cells transfected with control GFP or Flag-Myr-Akt constructs encoding for various forms 
of Akt as indicated. Cells were starved overnight 24 hours post-transfection and control cells were 
treated for 1 hour with indicated factors. Expression and mutations were verified via immunoblotting 
with phospho-specific and total Akt antibodies as indicated. (B) In vitro Akt and Erk2 kinase assay. 
Active Akt was obtained via IP from HEK293T cells and assessed for activity via incubation with GST-
GSK3 fusion protein. Reactions were supplemented with 200 µM ATP and dephosphorylated Flag-
Smad2 or recombinant GST-Flag-Smad2 as substrate. Phosphorylation of T220 residue was analysed 
via immunoblotting. All experiments repeated twice with representative image depicted. 
 
6.2.2 Inhibition of mTOR prolongs Smad2/3 activation and downregulation of 
the linker T220 phosphorylation 
In order to explore the impact of mTOR activation upon Smad2/3 activity, I utilised specific 
inhibitors to inhibit its kinase activity. As mTOR is found within two distinct complexes I also 
sought to distinguish the effect of inhibiting either complex. Although specific inhibition of 
mTORC1 is readily accomplished by the use of rapamycin, inhibitors targeting specifically 
mTORC2 have yet to be developed. Therefore, to indirectly distinguish the effects of mTORC2 
from mTORC1, I compared cells treated with rapamycin against Torin-2, an inhibitor that inhibits 
mTOR activity irrespective of which complex they reside in. PC-3 cells treated with rapamycin for 
1 hour in the presence or absence of AA demonstrated no significant difference in terms of Smad2 
activation or T220 phosphorylation (Figure 6.2A). Rapamycin treatment was shown to be specific 
in inhibiting mTORC1 alone as characterised by a reduction in the downstream P70S6K-
pT421/S424 in the absence of any change to Akt-p473 phosphorylation, which is induced by 
mTORC2 activity. However, cells treated with Torin-2 in the presence of AA fully replicated the 
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effects of AA-LY treatment, exhibiting higher levels of Smad2 activation accompanied by a 
downregulation in T220 phosphorylation (Figure 6.2B). Both complexes were be inhibited by 
Torin-2 as demonstrated by the downregulation of both P70S6K-pT421/S424 and Akt-p473 
phosphorylation. Given that rapamycin-mediated inhibition of mTORC1 had no significant 
impact upon Smad2 phosphorylation, I therefore concluded that the effect of Torin-2 upon Smad2 
activity was likely to be as a consequence of interfering with mTORC2 activity.  
Figure 6.2: Effect of rapamycin and Torin-2 treatment on AA-induced Smad2 activation 
(A) PC-3 cells were starved overnight and treated with factors as indicated for 1 hour before lysis and 
analysis by immunoblotting. Schematic illustrates mechanism of rapamycin-mediated inhibition of the 
mTORC1 complex in cooperation with the FKBP-12 immunophilin. (B) PC-3 cells were treated as in A 
with Torin-2 in the place of rapamycin. Schematic illustrates the Torin-2 mode of inhibition as an ATP-
competitive inhibitor upon the mTOR kinase directly irrespective of which complex it is associated with. 
Experiments were repeated twice with representative image depicted. 
 
6.2.3 Genetic manipulation of Rictor recapitulates the effects of Torin-2 
treatment 
In finding that Torin-2-mediated downregulation of mTORC2 activity appears to replicate the 
effects of LY-mediated inhibition of PI3K, I next asked whether this effect truly is specific to 
mTORC2 rather than any potential side effects upon PI3K activity, particularly due to the fact that 
inhibition of mTORC1 is known to induce the upregulation of PI3K due to reduced S6K activity 
(Trembley and Marette, 2001). Given that Rictor is an essential and specific component of the 
mTORC2 complex and is required for its kinase activity, I thought to address this question using 
spontaneously immortalised MEF cell lines derived from knockout mice in which the Rictor gene 
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was ablated, therefore solely inhibiting the mTORC2 complex by genetic means (Shiota et al., 
2006). Analysis of Rictor protein expression confirmed the presence of the knockout, which did 
not affect the expression of mTOR and hence mTORC1 activity (Figure 6.3). Remarkably, Rictor-
null MEFs also displayed a reduction in Smad2/3-T220/T179 phosphorylation much like that of 
Torin-2 treated cells, which therefore implicates the involvement of mTORC2 in regulating 
Smad2/3 activity via T220/T179 phosphorylation that is independent of mTORC1 activity. This 
was further supported in that transfection of a construct encoding for human Rictor rescued this 
phenotype by restoring the T220/T179 phosphorylation (Figure 6.3). Together, this data strongly 
suggests that mTORC2 may serve as the linker kinase responsible for regulating Smad2 activity 
via my proposed mechanism. 
 
 
 
 
 
 
 
 
 
Figure 6.3: Germline knockout of Rictor mimics effect of Torin-2 treatment on Smad2-
T220 
Control and Rictor-null MEFs were cultured in D10 media. First two columns indicate comparison 
between control Rictor+/+ and Rictor-/- MEFs as assessed by immunoblotting. Last two columns 
represent rescue experiment, whereby Rictor expression was restored in null cells via transfection of 
construct encoding for human Rictor. Control MEFs were transfected with PINCO-CMV-EGFP-PURO 
construct as transfection control. Experiment was repeated twice with representative image depicted. 
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6.2.4 mTORC2 does not function as the direct kinase acting upon the Smad2-
T220 residue 
Since both Torin-2 treatment and germline knockout of Rictor implicated mTORC2 in regulating 
the activity and degradation of Smad2, I assessed whether mTORC2 served as the direct kinase 
regulating T220 phosphorylation. To achieve this, I performed an in vitro kinase assay utilising 
Rictor-immunoprecipitated active mTORC2 isolated from HEK293T cells and incubated with 
dephosphorylated Flag-Smad2 substrate as per the Akt/Erk2 kinase assay. However, mTORC2 
was unable to phosphorylate the T220 residue despite being able to phosphorylate the S473 residue 
of Akt (Figure 6.4). Thus, it appears that mTORC2 does not serve to directly phosphorylate Smad2 
at the T220 residue, and may function to regulate another novel linker kinase that performs this 
function.  
Figure 6.4: mTORC2 in vitro kinase assay with Flag-Smad2 substrate 
Active mTORC2 was immunoprecipitated using Rictor antibody and assessed for activity using 
dephosphorylated His-Akt substrate, which was assessed for S473 phosphorylation upon incubation 
with immunoprecipitates. Non-specific rabbit IgG was used as control for both IP and kinase assay. 
400 μM ATP was used to overcome the low affinity of mTOR for ATP. Experiment was repeated twice 
with representative image depicted. 
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6.2.5 shRNA-mediated Rictor knockdown enhances DE induction in hESCs 
Although mTORC2 does not function as the direct kinase responsible for modulating Smad2-
T220 phosphorylation, germline deficiency and Torin-2 treatment nonetheless showed that 
mTORC2 activity is at the very least, required in inducing the PI3K/mTOR-dependent inhibition 
of Smad2/3 activation via T220/T179 phosphorylation. Therefore, I conducted experiments to 
verify whether deficiency of Rictor can directly affect the differentiation of hESCs to DE and 
thereby recapitulate the phenotypic effects of AA-LY treatment. Efficiency of shRNA-mediated 
knockdown of Rictor was verified in PC-3 cells, characterised by the reduction in Rictor protein 
in addition to the downregulation of Akt-pS473 phosphorylation (Figure 6.5A). Notably, 
Smad2/3-T220/T179 was also observed to be downregulated, albeit not to the same extent as 
with LY or Torin treatment. Nevertheless, utilising the same lentivirus to infect and knockdown 
Rictor in hESCs, I was able to obtain transgenic hESC line deficient in mTORC2 activity. 
Morphologically, these cells resemble parental hESCs albeit the rate of proliferation was reduced, 
which is similar to that observed in Rictor-null MEFs. Subsequent differentiation of these 
shRictor-hESCs with AA produced morphological changes that are reminiscent of both AA-LY 
and AA-Torin treatment when compared to control cells (Figure 6.5B). Improved differentiation 
of shRictor-hESCs towards the DE was subsequently confirmed via gene expression analysis, 
which revealed an increased expression of the majority of mesendoderm and endoderm markers, 
not too dissimilar what was observed in the differentiation of shNedd4L-hESCs (Figure 6.5C). 
Overall, these results demonstrate that genetic ablation of mTORC2 activity via Rictor knockdown 
sufficiently recapitulated all the phenotypic changes associated with improved DE specification 
that was observed in previous treatments.  
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Figure 6.5: Effect of shRNA-mediated Rictor knockdown on DE specification 
(A) PC-3 cells were infected with lentivirus harbouring two different shRNA sequences that 
target the Rictor mRNA. After selection and establishment of stable lines, cells were lysed and 
subjected to immunoblotting to verify Rictor knockdown, mTORC2 activity and Smad2/3-
T220/T179 phosphorylation. (B) Phase contrast images of transgenic hESCs infected with the 
same virus as in A, before being subjected to AA-induced DE differentiation for 1 day. Control 
indicates cells which have been transduced with non-targeting shRNA against GFP. Experiment 
was repeated twice with representative image depicted. (C) Gene expression analysis was 
performed on cells from B which have been differentiated for 2 days in order to assess the 
efficacy of DE induction. Graphs illustrate relative expression normalised to transgenic hESCs 
cultured in MEF-CM. Data represents average of two independent experiment in which PCR 
reactions were performed in triplicate (n=6). Error bars indicate SD. * and ** indicates p<0.05 
and p<0.001 by Student’s t test respectively. 
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6.2.6 AA-induced DE and hepatocyte differentiation occurs more effectively in 
the presence of Torin-2 when compared with LY  
Given that Torin-2 treatment was able to recapitulate the effects of LY in promoting Smad2/3 
activation via the downregulation of T220/T179 phosphorylation, and that shRictor-hESCs 
appeared to differentiate towards the DE with greater robustness than control hESCs, I next 
investigated whether Torin-mediated inhibition of mTORC2 activity induces a better overall 
differentiation when compared to LY treatment. As with AA-LY treatment, AA-Torin treatment 
resulted in increased expression of both mesendoderm and endoderm markers when compared 
with AA alone (Figure 6.6A). Additionally, AA-Torin induced DE cells expressed Sox17 and 
FoxA2 to a greater extent when compared to AA-LY cells, which therefore further indicates a 
more robust differentiation as evidence by Rictor knockdown (Figure 6.6B). Notably, the DE 
induction process additionally benefitted from a reduction in cytotoxic-induced cell death, 
increasing the yield of DE cells from the original hESC culture. Furthermore, AA-Torin 
differentiated DE were fully competent in forming both hepatoblast and hepatocyte-like cells upon 
further differentiation and maturation (Figure 6.6C). Overall, this indicates that direct inhibition 
of mTORC2 with Torin-2 mitigates the cytotoxic effects of PI3K inhibition, which consequently 
results in a more robust and effective DE specification. 
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Figure 6.6: Effect of AA-Torin treatment on DE and hepatic induction   
(A) hESCs were subjected to AA or AA-Torin induced DE differentiation for 2 days. Gene expression 
analysis was performed to assess the efficacy of DE induction. Graphs illustrate relative expression 
normalised to transgenic hESCs cultured in MEF-CM. Data represents average of two independent 
experiment in which PCR reactions were performed in triplicate (n=6). Error bars indicate SD. * and 
** indicates p<0.05 and p<0.001 by Student’s t test respectively. (B) Expression of DE markers Sox17 
and FoxA2 in hESCs differentiated with either AA-LY or AA-Torin was assessed by immunoblotting. 
Experiment was repeated twice with representative image depicted. (C) Phase contrast depicting the 
difference in cytotoxic-induced cell death between AA-LY and AA-Torin treated cells (top panels). AA-
Torin treated cells were subsequently able to progress through Stage II and III of hepatocyte 
specification (bottom panels). Scale bar indicates 50 μm.  
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6.3 Discussion and Conclusions 
Given that both CDK and Erk activity was previously discounted to be involved in modulating 
Smad2/3-T220/T179 phosphorylation, and that the PI3K pathway appeared to play a more direct 
role in regulating this phosphorylation, my attention next turned to Akt, the principal kinase 
functioning downstream of PI3K that has been shown to mediate Smad3 activity via a 
sequestration mechanism via its phosphorylated form (Conery et al., 2004; Remy et al., 2004) or 
through its kinase activity (Song et al., 2006). However, my experiments using various forms of 
Akt indicate that neither phosphorylated Akt nor its kinase activity has any impact on Smad2/3-
T220/T179 phosphorylation and hence does not serve as a linker kinase targeting Smad2/3. 
Additionally, as indicated by mutagenesis studies, regulation of Smad2/3 activity via the proposed 
mechanism does not appear to be dependent on Akt activity at any level, which therefore implies 
that PI3K-mediated phosphorylation of Smad2/3-T220/T179 does not occur via Akt, or via any 
downstream kinase whose activity is regulated by Akt. However, it is likely that the Smad2/3 
sequestration by Akt functions as a distinct mechanism which Smad regulates activity although it 
does not appear to play a role in regualting Smad2/3 activity in this instance.  
Whilst previous studies have hinted at the involvement of mTOR activity in regulating TGFβ-
induced functions via the regulation of Smad activity, no study has thus far been able to propose 
a mechanism that fully accounts for this effect (Song et al., 2006; Zhou et al., 2009). In treating 
PC-3 cells with AA in the presence of rapamycin or Torin-2, I have shown that this effect is likely 
to be mediated via an mTORC2 dependent mechanism. Although the study by Zhou et al. showed 
that rapamycin treatment does induce the loss of pluripotency and the induction of DE, prolonged 
exposure to rapamycin has been shown to ultimately inhibit mTORC2 via the sequestration of 
mTOR by rapamycin-inactivated mTORC1 complexes (Lamming et al., 2012). Therefore, the 
phenotypic changes observed upon long term rapamycin treatment is likely due to the inhibition 
of mTORC2 rather than the acute inhibition of mTORC1. Involvement of mTORC2 in my 
proposed mechanism is also supported genetic manipulation in that both germline knockout and 
shRNA-mediated knockdown of Rictor, a critical component of the active mTORC2, reduced the 
phosphorylation of Smad2 at the T220 residue, as previously observed with LY, Wort and Torin-
2 treatment. This effect was fully rescued upon the re-introduction of human Rictor into Rictor-
null MEFs, which additionally suggests that this mechanism is likely to also exist in other 
mammalian models. These experiments also additionally corroborated the indirect evidence from 
Torin-2 treated cells which suggested that mTORC2 was the principle culprit responsible for this 
effect. Although shRNA-mediated knockdown of Rictor did not reduce the Smad2/3-T220/T179 
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phosphorylation to the same degree as germline knockout or Torin treatment, residual mTORC2 
activity may well be sufficient in maintaining the phosphorylation of this residue given its inherent 
sensitivity to PI3K stimulation (Figure 5.4B vs 5.4C). However, in spite of mTORC2 fulfilling 
most of the criteria necessary for a Smad2/3 linker kinase, the subsequent kinase assay showed 
that immunoprecipitated mTORC2 did not phosphorylate Smad2 at the T220 residue. 
Nonetheless, the mechanism by which mTORC2 acts as a kinase has been shown to be quite 
diverse, and may rely on other components or conditions that are not necessarily present in our 
reactions. For example, one study have reported that the ribosome is required for full activation 
of mTORC2 activity (Zinzalla et al., 2011), whilst two other studies demonstrate a mechanism by 
which mTORC2 phosphorylates its target substrate in a co-translational manner as the protein is 
still being synthesised at the ribosome (Oh et al., 2010; Dai et al., 2013).  
Although mTORC2 does not appear to be the linker kinase responsible for T220/T179 
phosphorylation, mTORC2 activity is nonetheless required for this phosphorylation to occur. As 
indicated in my experiments, absence of Rictor results in the downregulation of T220/T179 
phosphorylation even in the presence of serum and high PI3K activity. Therefore, the original 
effect of PI3K-dependent inhibition of Smad2/3 activity is highly likely to be as a result of PI3K-
dependent activation of mTORC2. This is particularly evident when comparing AA-LY treatment 
to that of AA-Torin, in that AA-Torin can fully replicate the DE inducing effects of AA-LY. In 
many respects, the effect of AA-Torin is superior to that of AA-LY in terms of reducing the 
cytotoxic-associated cells death and increasing the expression of bona fide DE markers such as 
Sox17 and FoxA2. The added effect of these enhancements culminates in the increased yield of 
hepatocyte-like cells from the initial DE population, which are likely to be improved on a 
functional level. Thus, I have uncovered a distinct and direct mechanism by which mTORC2 
activity directly acts to inhibit the duration of Smad2 activation via modulating the T220/T179 
linker phosphorylation. This in turn regulates the recruitment of Nedd4L, which serves to 
selectively target activated Smad2 for degradation. Through this proposed model, PI3K/mTOR 
signalling thereby directly impacts the DE specifying activities of AA, and hence offers a 
convincing explanation as to why high levels of PI3K/mTOR stimulation can act to antagonise 
the derivation of DE from hESCs.  
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7.1 Direct impact of PI3K signalling on Smad2/3 activity via regulation of 
Smad2/3 degradation 
Ever since the discovery of the antagonistic action of PI3K signalling upon the induction of DE 
from hESCs, many studies have tried to uncover and propose a molecular overview for this 
relationship. However, this work has proven challenging, confounded by the unique difficulties 
associated with hESC culture including interference from other signalling inputs and reciprocal 
regulative mechanisms between branches within the PI3K pathway. The work presented here 
marks the culmination of these effort, and represents the most complete molecular description of 
the critical interplay occurring between these two signalling pathways in the derivation of DE. In 
exploring the relationship between PI3K and Smad2/3 activation utilising our fully defined 
differentiation protocol, I initially found that PI3K signalling directly impacts the duration of 
Smad2/3 activation, in that the higher the level of PI3K activation, the greater the suppression of 
endogenous Smad2/3 phosphorylation at the SxS motif. This result correlated well with studies 
that previously identified the negative impact of PI3K signalling upon DE differentiation 
(D’Amour et al., 2005; McLean et al., 2007) and offered the first molecular insights into how this 
antagonism occurs. Specifically, the duration of Smad2/3 activation is attenuated in the presence 
of PI3K signalling, which is mitigated during AA-LY or AA-Wort-mediated DE derivation where 
PI3K activity is robustly suppressed. As demonstrated by luciferase assay, this prolonged activation 
of Smad2/3 results in the upregulation of their transcriptional efficacy, ultimately leading to the 
increased expression of known Smad2/3 target genes such as MixL1, Eomes and GSC that drive 
the differentiation of hESCs to DE (Teo et al., 2011).  
In demonstrating the direct involvement of PI3K in regulating TGFβ activities, the next question 
was how this enhanced activation of Smad2/3 occurs on the molecular level. Although other 
studies have also observed that AA-LY induction of DE is accompanied by increased Smad2/3 
activation (Singh et al., 2012), no mechanism was proposed to explain this effect. Given the 
dynamism of phosphorylation and the fact that Smad2/3 activity is stoichiometrically dependent 
on the degree of Smad2/3-SxS phosphorylation (Inman et al., 2002), it was anticipated that the 
LY-mediated inhibition of PI3K served to affect the regulation of Smad2 at this site. However, 
the fact that LY-treated and untreated cells exhibited similar levels of Smad2/3 activation and that 
inhibition of Activin type I receptors did not alter the outcome of LY treatment suggests that the 
effect of PI3K on TGFβ is likely to be attributed to its role in sustaining Smad2/3 activation rather 
than increasing levels of initial stimulation. Further experiments exploring the regulation of 
Smad2/3-SxS phosphorylation served to discount the involvement of PPM1A, CLIC4 and PP5, 
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which have all been previously reported to regulate Smad2 SxS phosphorylation or TGFβ activity 
(Lin et al., 2006; Shukla et al., 2009; Bruce et al., 2012). The case of PPM1A is especially notable, 
given that despite being shown to be a bona fide Smad2/3 phosphatase, its preferentially cytoplasmic 
localisation along with promiscuity in targeting cytoplasmic targets counters this argument 
(Yoshizaki et al., 2004; Strovel et al., 2000; Bruce et al., 2012). Contrastingly, in finding that the 
decay kinetics of Smad2 in LY treated cells strongly mimicked that of MG132 treated cells, this 
suggested that the effect of LY in prolonging Smad2 activation was likely due to the inhibition of 
its ubiquitin-mediated proteasomal degradation. Indeed, Activin-induced activated Smad2/3 
exhibited a considerably reduced ubiquitination in the presence of LY.  
In the last decade, several studies have attempted to explore the mechanisms underpinning the 
negative effects of PI3K signalling on TGFβ induced apoptosis in cancer cells (Conery et al., 2004; 
Remy et al., 2004; Song et al., 2006), although the vast majority of mechanisms proposed rely 
heavily on the direct interaction between Akt and Smad2/3. Despite there being ample evidence 
for this interaction, the regulative mechanisms mediating Smad2/3 to Akt recruitment are still 
currently ill-defined, casting doubt as to the general applicability of this model, particularly in the 
context of normal cell homeostasis and development. Furthermore, this passive mechanism does 
not explain the other facet of TGFβ signalling in promoting tumourigenic responses at the later 
stages of cancer progression, and given the fact that both pathways are often simultaneously 
activated in certain cancers (Hanahan and Weinberg, 2013), lends further weight to the idea of 
active crosstalk mechanisms modulating the tumourigenic effects of both pathways. Thus, in 
finding that PI3K signalling can act to directly modulate the degradation of activated Smad2/3, 
and therefore, is implicitly involved in the regulation of TGFβ activities, this study has opened 
new avenues for exploring whether such a mechanism influences tumourigenesis and cancer 
progression. 
 
7.2 PI3K-mediated regulation of Nedd4L recruitment 
It has been long proposed that the proteasomal degradation of the active Smad complexes serves 
as an important mechanism that facilitates the termination of Smad2/3 activities (Lo and 
Massagué, 1999). However, the identity of these E3 ubiquitin ligases acting upon Smad2/3 has 
only recently come to light. Notably, several different classes of ubiquitin ligases have been shown 
to mark Smad2/3 for degradation, including the HECT class Smurf2 and Nedd4L as well as the 
RING class Arkadia (Lin et al, 2000; Mavrakis et al., 2007; Gao at al 2009). However, given that 
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these ligases are ubiquitously expressed, questions were raised as to how these ligases identify and 
specifically target activated Smad2/3 for turnover. Furthermore, what role does PI3K signalling 
play in mediating this process, especially with regards to the most characterised Smad E3 ligase, 
Nedd4L in this context? 
The HECT class Nedd4L E3 ubiquitin ligase served as an attractive proposition in mediating the 
PI3K-mediated turnover of activated Smad2/3. In comparison to other reported ligases, its mode 
of action is well defined in that Nedd4L recruitment is modulated by the phosphorylation status 
of the linker T220/T179 residue (Gao et al., 2009). Given that the linker region serves as an 
important site for inter-pathway crosstalk, this immediately suggested a mechanism by which PI3K 
activity can directly influence Smad2/3 activity. Remarkably, PI3K/mTOR signalling is capable of 
modulating the phosphorylation of T220/T179 independent of Smad2/3 activation. Given that 
T220/T179 is necessary for the recruitment of Nedd4L to Smad2/3 and that Nedd4L is a 
cytoplasmic localised E3 ubiquitin ligase, this raised a new question as to how Nedd4L selectively 
targets active Smad2/3 for degradation. In addressing these issues, I found that the recruitment of 
Nedd4L to Smad2 is not solely dependent on T220 phosphorylation, but also dependent on its 
activation state. Additionally, even upon the slightest activation of PI3K/mTOR signalling, the 
Smad2-T220 residue is rapidly phosphorylated regardless presence or absence of AA ligand. This, 
coupled with the previous notion, suggests that inactive Smad2/3 is already poised for Nedd4L 
recruitment, which occurs immediately following activation. It is likely that the conformational 
changes associated with activation increases the accessibility of Nedd4L to the Smad2/3 linker 
region, hence promoting its degradation. However, it is difficult to reconcile this notion with a 
certain discrepancy in that if active Smad2 is immediately subject to turnover even before reaching 
the nucleus, how does any Smad2/3 related upregulation of genes occur? It has been previously 
well documented that the conformational changes of Smad2/3 associated with its activation 
enables the formation of trimeric complexes with themselves as well as with Smad4, and that only 
a small proportion of active Smad2/3 actually are degraded by the ubiquitin-proteasomal system 
(Section 1.3.1.3). Therefore, it remains to be further elucidated whether the interactions between 
the Smad2/3 and Smad4 or other factors act to impede the recruitment of Nedd4L to activated 
Smad2/3, which results in the majority of activated Smad2/3 forming trimeric complexes and 
translocating into the nucleus. It is probable that in the presence of abundant ligand and persistent 
receptor activation, the rate of Smad2/3 activation outpaces that of its Nedd4L-mediated 
degradation. Thus, LY treatment does not result any obvious effect on Smad2/3 activation at 1 
hour post 100 ng/ml AA treatment. The biological significance of this mechanism is only evident 
when activation of the receptor complexes becomes reduced due to ligand scarcity. As receptor 
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activation decreases, the proportion of the activated Smad2/3 becomes targeted for Nedd4L-
mediated degradation becomes relatively high, which in turn promotes the rapid downregulation 
of all Smad2/3 related activities. This is also the likely reason why AA-LY mediated preservation 
of Smad2/3 activation is only observed 3-6 hours into the differentiation process, or when 
receptor complexes are inhibited. Experiments demonstrating that mutation of Smad2-T220 to a 
non-phosphorylatable residue abolished the binding of Nedd4L to Smad2 coupled with the fact 
that this mutation and Nedd4L knockdown both served to diminish the effect of LY on Activin-
Smad2/3 signalling and DE differentiation provides further evidence in support of the proposed 
mechanism. Therefore, Nedd4L-mediated turnover of activated Smad2/3 is a self-propelling 
mechanism that promotes the rapid termination of TGFβ activities upon the reduction of ligand 
availability, which in the context of development, is likely to enhance the stringency of 
differentiation.  
 
7.3 mTORC2: A new player in PI3K/mTOR and TGFβ crosstalk 
One important finding in my study is the identification of mTORC2 signalling as a modulator for 
TGFβ signalling, specifically by regulating the phosphorylation of Smad2/3 linker threonine 
residue. In assessing the contribution of the most prominent of the previously identified linker 
kinases, Erk1/2 and CDK, I found that inhibition of either kinase could not replicate the effects 
observed when PI3K was inhibited by LY. Furthermore, LY-mediated inhibition of PI3K under 
certain conditions served to enhance the activation of Erk1/2, although no significant effects were 
observed in terms of Smad2/3-T220/T179 phosphorylation. As such, enhancement of DE 
differentiation via downregulation of the phosphorylation of this residue and degradation of 
activated Smad2/3 does not appear to be through an Erk/Wnt/β-catenin-mediated mechanism as 
outlined in a recent study (Singh et al., 2012), and is therefore a more distinct and direct 
mechanism. 
The finding that none of the prominent linker kinases appeared to play any part in the LY-mediated 
enhancement of DE differentiation suggests that the presence of a linker kinase along the PI3K 
signalling axis itself. Subsequent experimentation revealed that although Akt has been reported to 
bind to and prevent the activation of Smad3 (Conery et al., 2004; Remy et al 2004), ectopic 
expression of constitutively active Akt does not appear to affect T220/T179 phosphorylation. 
Furthermore, Akt activity itself appears to be dispensable in mediating the PI3K-dependent 
downregulation of Smad2/3-T220/T179 phosphorylation via the proposed mechanism, as shown 
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via mutagenesis studies and also by in vitro kinase assay. The inability of Akt to inhibit the activation 
of Smad2/3 via downregulation of T220/T179 phosphorylation alluded to the presence of a kinase 
whose function is independent of Akt, yet dependent on PI3K.  
Of the numerous kinases forming the core of the PI3K pathway, the two mTOR complexes served 
as prime candidates in fulfilling this role. Moreover, since mTORC1 and mTORC2 are regulated 
down and upstream of Akt respectively, mTORC2 served as the more promising candidate given 
that modulation of Akt activity was previously shown to have no effect on T220/T179 
phosphorylation. Although several studies have alluded to the role of mTORC1 in inhibiting 
Smad2 activation (Song et al., 2006; Zhou et al., 2009), these studies were highly dependent on the 
use of rapamycin, an mTORC1 inhibitor that has also been recently shown to inhibit the activity 
of mTORC2 upon chronic exposure (Lamming et al., 2012). Therefore, in comparing the effects 
of rapamycin-mediated inhibition of mTORC1 with the Torin-2-mediated inhibition of both 
complexes, I was able to also assess the effect of mTORC2 inhibition upon Smad2/3 activity albeit 
indirectly. The ability of Torin-2 rather than rapamycin in completely recapitulating the effects of 
LY treatment strongly hinted to the involvement of mTORC2 in my mechanism, which was 
ultimately confirmed via the gain and loss-of-function of Rictor, a key component of the mTORC2 
complex. Taken together, this clearly demonstrates an important role for mTORC2 in the 
modulation of Smad2/3 linker threonine phosphorylation. Although, mTORC2 does not appear 
to function as the direct kinase responsible for modulating the phosphorylation of the T220 
residue as per in vitro kinase assay, the probability of this occurring through novel mechanisms that 
cannot be detected via the standard assay cannot be fully discounted, (Oh et al., 2010; Zinzalla et 
al., 2011; Dai et al., 2013). Nevertheless, my experiments have established a previously unreported 
role for mTORC2 in the regulation of Smad2 activity, and additionally, outlines a detailed 
mechanistic description of the molecular events responsible for the antagonistic effects of 
PI3K/mTOR signalling upon TGFβ activities as summarised in Figure 7.1.  
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Figure 7.1: Molecular mechanisms governing the inhibition of Smad2 activity via 
PI3K/mTORC2 
PI3K induces the activation of mTORC2 kinase that in turn promotes the phosphorylation of Smad2 at 
the T220 residue. This is mitigated in the presence of LY or Torin-2 (Tor). T220 phosphorylation primes 
Smad2 for Nedd4L binding upon activation by Activin, initiating the polyubiquitination and 
degradation of Smad2. Regardless of whether the T220 is phosphorylated, activated Smad2 translocates 
into the nucleus upon Smad4 binding, inducing the expression of mesendoderm and endoderm genes.  
 
7.4 Future work 
Whilst my current work describes a previously unknown mechanism through which mTORC2 
regulates Smad2/3 activity, several questions remain open for further interrogation. Firstly, an 
immediate question is raised as to how activated Smad2/3 successfully evades degradation in spite 
of enhanced Nedd4L mediated degradation. In keeping with the fact that cofactor recruitment can 
drastically alter the protein conformation and thereby accessibility of activated Smad2/3 to 
Nedd4L, I postulate that homo- and heterodimerisation of activated Smad2/3 as well as the 
recruitment of Smad4 may establish a complex that is resistant to Nedd4L binding and hence 
degradation. Equally, Nedd4L itself may also be subject to regulative mechanisms via the PI3K 
pathway that may additionally influence its binding affinity to activated Smad2/3 (Gao et al., 2009). 
Therefore, the degree to which PI3K/mTOR signalling concurrently influences Smad2/3 and 
Nedd4L activity serves as a notable aveneue for further study. Indeed, both of these hypotheses 
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can be addressed through the ectopic expression of Smad2/3 or Nedd4L truncation mutants, 
which will provide the first experimental evidence to establish a definitive answer. 
Another interesting question which arose from this study relates to the importance of the linker 
residues in mediating Smad2/3 activity in a more general sense. Whilst this study has clearly 
demonstrated the impact of mTORC2 activity upon Smad2/3 linker phosphorylation at the 
T220/T179 residue, it remains whether mTOR activity also influences the phosphorylation status 
of the other linker residues. This is particularly important given that phosphorylation of the other 
linker residues plays a critical role in regulating the timing and competency of Smad2/3 activity 
during the Xenopus development (Grimm and Gurdon, 2002), which thusfar has yet to be 
demonstrated in a mammalian model. Equally, owing to the difficulties in performing Smad2/3 
knockout experiments without compromising hESC pluripotency, experiments conducted in this 
study has always utilised the ectopic expression of Smad2 mutants amongst a background of 
endogenous Smad2 to investigate the effects of linker mutation, which may mask more subtle 
phenotypic effects. With the recent emergence of genome editing technologies such as 
transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short 
palindromic repeat (CRISPR)-Cas (CRISPR-associated nucleases), the technology is now in place 
to generate mutations directly on endogenous Smad2/3 genes without the need for ectopic 
expression. Utilising such methods to generate endogenous phospho-deficient or phospho-
mimetic linker mutants of Smad2/3 represent the definitive method by which to establish their 
importance in regulating Smad2/3 activities, allowing interrogation in the absence of endogenous 
wild-type intereference. In addition, such powerful editing methods also provides a relatively easy 
method to generate mice that harbour Smad2/3 linker mutations, hence allowing the interrogation 
of their phenotypic effects throughout the course of development. This can be further utilised to 
investigate tissue-specific effects aside from endoderm derived lineages. 
7.5 Implications on development and disease 
Inter-pathway crosstalk represents an important mechanism by which the downstream activities 
of each pathway are regulated. In considering these two pathways, the differentiation promoting 
and apoptotic inducing properties of TGFβ/Smad signalling are directly countered by the 
pluripotency promoting and pro-survival activities of PI3K. As outlined above, I propose a 
mechanism by which PI3K/mTOR acts to directly modulate the activity of Smad2/3 via regulation 
of the linker T220/T179 phosphorylation, which in turn regulates the resistance of activated 
Smad2/3 to Nedd4L-mediated degradation. Utilising genetic manipulation, I have verified several 
aspects of the mechanism that lends weight to its existence in an in vivo setting. Specifically, Nedd4L 
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knockdown, ectopic Smad2-T220V expression and Rictor knockdown serve to enhance the 
formation of DE from hESCs, whilst the rescue of Rictor-null MEFs with ectopic expression of 
human Rictor was sufficient in restoring the phosphorylation of the T220 residue and by extension, 
the antagonistic properties of PI3K/mTOR upon Smad2 activation. Equally, these experiments 
can be cross-referenced with inhibitor and growth factor supplementation studies. Treatment of 
hESCs with AA in the presence of PI3K (LY/Wort) and mTORC2 (Torin-2) inhibitors markedly 
increased the efficiency of DE formation, whilst treatment with activators of PI3K 
(serum/Her/IGF-1) increased T220 phosphorylation, which in turn promoted Smad2 degradation 
and decreased the effectiveness of AA-induced DE specification. In fact, AA-Torin appears to be 
far superior in promoting the formation of DE over AA-LY treatment, further testament to the 
improved understanding of the mechanisms behind PI3K-mediated inhibition of AA-induced DE 
differentiation gained during this study.  
The fact that these findings appear to be applicable to PC-3, Hep3B, MEFs and hESCs lends 
further weight to the general applicability of this mechanism, functioning to regulate TGFβ 
activities in tumour, mouse and human cell lines. In relation to tumourigenesis, since stimulation 
of mTORC2 activity intrinsically acts to antagonise the activities of Smad2/3, drugs that 
specifically target to inhibit mTORC2 activity could effectively enhance the pro-apoptotic 
properties of TGFβ signalling without drastically affecting the pro-survival properties of the rest 
of the PI3K cascade. However, it is important to note that any drug developed must not illicit any 
inhibition upon the mTORC1 complex, which has been shown to induce hyperactivation of the 
PI3K/Akt signalling cascade via a S6K-mediated feedback loop (Section 1.3.3.3). This becomes 
evidently more important when considering the biphasic action of TGFβ in initially suppressing 
tumour growth at early stage, yet enhancing tumour metastasis at the latter stages. Whilst 
downregulation of mTORC2 activity at an early stage could serve to mitigate tumour progression 
by reinforcing the pro-apoptotic activities of TGFβ signalling, induction of mTORC2 activity 
could equally serve to inhibit the pro-tumourigenic properties of TGFβ induction. For example, 
in the case of bulk tumours, poor vascularisation and hypoxic nature of the tumour core is thought 
to enhance the emergence of metastatic tumour cells via EMT, which is a TGFβ-induced process. 
Therefore, the delivery of drugs or factors which enhance mTORC2 activity in this situation may 
serve to be beneficial by stimulating the downregulation of Smad2/3 activation, and the hence 
inhibition of EMT. However, given that both mTOR complexes share the same kinase 
component, development of mTORC2-specific inhibitors is currently a rather daunting yet 
challenging prospect. Nonetheless, this work outlines and proposes an elegant crosstalk 
mechanism that occurs between PI3K/mTOR and TGFβ/Activin pathways, which has a direct 
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impact on Activin-induced DE differentiation and possibly other TGFβ functions such as TGFβ-
induced tumourigenesis. The identification of mTORC2 as a key player in the regulation of this 
differentiation provides new avenues through which hESC differentiation protocols can be 
improved for both regenerative and biomedical applications, adding yet another novel function to 
the growing mTORC2 repertoire. Furthermore, in clarifying the involvement of mTORC2 in 
mediating PI3K and TGFβ crosstalk, this work will hopefully spur the development of mTORC2 
specific drug and treatment regimes that will serve to mitigate the disease inducing aspects of 
TGFβ signalling.  
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Appendix 
Figure A-I: Lentivectors and shRNA design 
Cloning strategies and respective shRNA design templates for pLVTHM and pLKO.1 vectors used in 
this study. pLVTHM-Puro-2A-EGFP is a modified lentivector in which the Puro-2A-EGFP sequence 
from pHyg-Puro-2A-EGFP was subcloned to replace original EGFP sequence. MluI/ClaI double 
digestion was used to clone shRNA oligos into pLVTHM vectors whilst AgeI/EcoRI was used to clone 
into pLKO.1. Insertion was verified by sequencing and in the case of pLKO.1 vectors, assessed via 
digestion and loss of the stuffer fragment.    
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Figure A-II: Subcloning of pLVTHM-Puro-2A-Smad2-WT/T220V 
Cloning strategy used to subclone Smad2-WT or Smad2-T220V coding DNA from the pCS2 expression 
vector into the lentiviral pLVTHM vector. Modification of the Bluescript II SK holding vector was first 
performed to prepare it for the insertion of the Smad2 fragment. Oligos (as indicated above) were 
annealed and ligated into the holding vector via BamHI/KpnI digestion. Oligos were designed contain 
a 2 bp GG insertion after the BamHI site to ensure the final Smad2 sequence will be in-frame after 
insertion into pLVTHM. After verification of oligo insertion via digestion, Smad2-WT/T220V fragment 
was ligated into the new holding vector following NcoI/XhoI digestion. Finally, the Smad2-WT/T220V 
fragment was further ligated into the pLVTHM-Puro-2A backbone via triple ligation following 
NdeI/BamHI digestion. Clones obtained from last step were screened for inversion using NdeI/FseI and 
NdeI/NotI digestion, and sequenced to ensure correct orientation of the fragments. 
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Figure A-III: Subcloning of pGEX-6p-GST-Smad2-WT/T220V 
Cloning strategy used to subclone Smad2-WT or Smad2-T220V coding DNA from the pCS2 expression 
vector into the bacterial pGEX expression vector. Modification of the pGEX-6p-GST vector was first 
performed to prepare it for the insertion of the Smad2 fragment. Oligos (as indicated above) were 
annealed and ligated into the vector via BamHI/SalI digestion. Oligos were designed to contain an NcoI 
site to facilitate insertion of Smad2 fragment from pCS2 expression vector. After verification of oligo 
insertion via digestion, Smad2-WT/T220V fragment was ligated into the new holding vector following 
NcoI/XhoI digestion. Clones were screened by digestion, and sequenced to ensure correct insertion. 
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Figure A-IV: Subcloning of pcDNA3-T7-Myr-HA-AktI-S473A 
Cloning strategy used to generate pcDNA-T7-Myr-HA-Akt-S473A from triple mutant and wild-type 
containing vector. Mutated S473 fragment was isolated from the triple mutant vector via Blp1/EcoRI 
digestion and switched with the opposing wild-type fragment for ligation to generate the final vector. 
Presence of mutated sequence was confirmed via sequencing.
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PI3K/mTORC2 regulates TGF-b/Activin signalling
by modulating Smad2/3 activity via linker
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Crosstalk between the phosphatidylinositol 3-kinase (PI3K) and the transforming growth
factor-b signalling pathways play an important role in regulating many cellular functions.
However, the molecular mechanisms underpinning this crosstalk remain unclear. Here,
we report that PI3K signalling antagonizes the Activin-induced deﬁnitive endoderm (DE)
differentiation of human embryonic stem cells by attenuating the duration of Smad2/3
activation via the mechanistic target of rapamycin complex 2 (mTORC2). Activation
of mTORC2 regulates the phosphorylation of the Smad2/3-T220/T179 linker residue
independent of Akt, CDK and Erk activity. This phosphorylation primes receptor-activated
Smad2/3 for recruitment of the E3 ubiquitin ligase Nedd4L, which in turn leads to their
degradation. Inhibition of PI3K/mTORC2 reduces this phosphorylation and increases the
duration of Smad2/3 activity, promoting a more robust mesendoderm and endoderm
differentiation. These ﬁndings present a new and direct crosstalk mechanism between these
two pathways in which mTORC2 functions as a novel and critical mediator.
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C
ytokines of the transforming growth factor-b (TGF-b)
superfamily including Nodal and Activin, control many
cellular functions, such as cell growth, apoptosis and cell
fate determination. These functions are not only controlled by the
TGF-b pathway itself but are also extensively regulated by
crosstalk between TGF-b and other signalling pathways1–3.
TGF-b/Activin signalling is initiated upon ligand binding and
activation of receptor complexes, which leads to the phos-
phorylation of the Smad2 and Smad3 (henceforth Smad2/3)
C-terminal SxS motif, promoting their interaction with Smad4
and facilitating the translocation of the Smad2/3–Smad4
complexes to and accumulation within the nucleus where they
regulate targeted gene expression in cooperation with other
cofactors4–6. The efﬁcacy of this pathway is not solely determined
by the abundance of ligands and receptors but is also inﬂuenced
by other signalling pathways3. Notably, the phosphatidylinositol
3-kinase (PI3K) pathway has been shown to alleviate
TGF-b-induced apoptosis and cell cycle arrest in several
tumour cell lines7–10, as well as inhibiting the Activin-induced
DE differentiation of human embryonic stem cells (hESCs)11–13.
However, the molecular mechanisms behind these effects remain
contentious8–10. Although it has recently been proposed that the
negative effects of PI3K upon DE differentiation are an indirect
effect attributed to the inhibition of the Wnt-b-catenin
pathway14, it is unclear how this mechanism results in
enhanced Smad2/3 activity, thereby positing the existence of a
more direct relationship between these two pathways15.
In this study, we demonstrate that PI3K signalling has a direct
inhibitory effect on Activin-induced Smad2/3 activity in hESCs
via the activation of mechanistic target of rapamycin complex 2
(mTORC2), leading to a reduction of Smad2/3 transcriptional
activity and DE differentiation efﬁcacy. PI3K/mTORC2 nega-
tively regulates Smad2/3 activity by modulating their degradation
via phosphorylation of a particular threonine residue within the
Smad2/3 linker region. Our results therefore demonstrate a new
and novel mechanism underpinning the crosstalk between the
PI3K/mTOR and TGF-b/Activin signalling axes and in particular,
ﬁrmly establishes mTORC2 as a critical mediator in modulating
Smad2/3 activity.
Results
PI3K inhibits Activin-induced DE differentiation of hESCs. To
decipher the mechanisms underlying the antagonistic impact of
the PI3K pathway upon TGF-b/Activin activities and the DE
differentiation of hESCs, we developed a serum-free and chemi-
cally deﬁned culture condition to convert hESCs to DE, in which
high-dosage Activin A (henceforth AA) was shown to enhance
the activation of Smad2/3 signalling and DE differentiation as
previously reported (Supplementary Fig. 1a; Fig. 1a)11,12,16.
Under this culture condition, treatment of hESCs with
LY294002 (LY), a PI3K inhibitor, diminished Akt activation
even in the presence of AA (Fig. 1b). In comparison with the
differentiation using AA alone, co-treatment of hESCs with AA
and LY evidently enhanced the Activin-induced DE differen-
tiation as shown by a higher expression of mesendoderm and
DE markers (Fig. 1c–f). This LY-dependent enhancement of
DE differentiation was further corroborated by an increase in the
generation of functional hepatocyte-like cells and in multiple
hESC lines (Fig. 1g; Supplementary Fig. 1b,c). Therefore, this
chemically deﬁned culture system provides a useful platform
from which to further interrogate the underlying molecular
mechanisms driving the improvement of DE speciﬁcation.
Inhibiting PI3K prolongs Activin-induced Smad2/3 activation.
To interrogate the mechanisms through which PI3K signalling
interferes with TGF-b activities, we ﬁrst evaluated the activation
status of Smad2/3 under AA±LY conditions. Time-course ana-
lysis revealed that although LY treatment had no effect on the
initial activation of Smad2/3 (Smad2/3-pTail), the decline of
active Smad2/3 was clearly attenuated in AA–LY-treated cells
compared with cells treated with AA alone (Fig. 2a), resulting in a
marked increase of active Smad2/3 six hours post treatment
(Fig. 2b). AA–LY-treated cells also exhibited a signiﬁcant increase
in Smad2/3 transcriptional activity evidenced by higher luciferase
reporter activity (Fig. 2c) and a considerable upregulation of
mesendoderm markers MixL1, Eomes and goosecoid and DE
marker Sox17, which are known Smad2/3 targets (Fig. 2d)1,17,18.
This ﬁnding implies preferential speciﬁcation of the cells towards
the mesendoderm and DE even at this early stage of
differentiation. Furthermore, to rule out the possibility that
these enhancements were due to any off-target effects of LY, we
treated hESCs with two other PI3K inhibitors in the place of LY,
the more commonly used wortmannin and the more selective
Pictilisib (also known as GDC-0941). Both experiments largely
replicated the changes observed using AA–LY treatment
(Supplementary Fig. 2) Therefore, inhibition of PI3K directly
enhances Activin-induced DE formation by extending the
duration of Smad2/3 activity.
PI3K modulates ubiquitination and degradation of Smad2/3.
Since inhibition of PI3K extended the duration of Smad2/3
activation rather than altering their initial response to AA, we
reasoned that PI3K signalling might affect Smad2/3 activity
by regulating its turnover, either via phosphatase-mediated
dephosphorylation of the SxS motif or by ubiquitin-mediated
proteasomal degradation of the active Smad2/3 protein2. Until
recently, nuclear PPM1A was the only phosphatase identiﬁed to
dephosphorylate Smad2/3 at the SxS motif19, which is inhibited
by CLIC4 (chloride intracellular channel 4) protein20. However,
not only did LY treatment not affect the expression of either
protein, PPM1A was also detected primarily in the cytoplasm
(Supplementary Fig. 3a,b). It is therefore unlikely that Smad2/3
dephosphorylation by PPM1A is the mechanism accounting for
the phenotypic changes associated with AA–LY treatment.
Although one recent study has shown that PP5, a member of
the PPP phosphatase family, is able to dephosphorylate active
Smad2/3 upon overexpression21, treatment of hESCs with
okadaic acid, a potent inhibitor of PPP phosphatases, had no
effect on the decay kinetics of active Smad2 (Supplementary
Fig. 3c). Furthermore, enhanced TGF-b-induced transcriptional
responses that were observed in PP5-null mice has been shown to
result from increased levels of Smad3 protein rather than through
any direct effect upon the duration of their activation21.
These ﬁndings therefore further discount the involvement of
phosphatases in our underlying mechanism.
Given that ubiquitin-mediated proteasomal degradation is
another mechanism by which Smad2/3 activity is terminated22,
we next investigated whether LY acts to protect active Smad2
from proteasomal degradation. Similar decay kinetics for active
Smad2 was observed between LY- and MG132-treated cells, albeit
not with the same efﬁcacy (Fig. 3a–c). In addition, inhibition
of the Activin receptor by SB431542 did not abolish the effect of
LY, but rather made it observable much earlier at 1 h post
treatment (Fig. 3b). Together, this suggests that PI3K affects the
TGF-b/Activin pathway independent of receptor activity and acts
to promote the ubiquitin-mediated proteasomal degradation of
active Smad2/3. Although Nedd4L has been previously identiﬁed
as the ubiquitin ligase responsible for Smad2/3 ubiquitination23,
we observed no LY-dependent changes in its expression
(Supplementary Fig. 3d). However, LY treatment substantially
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reduced its interaction with Smad2 (Fig. 3d), which was
corroborated by decreased ubiquitination of Smad2 (Fig. 3e).
These results therefore highlight the critical role PI3K signalling
plays in regulating the association of Nedd4L with Smad2/3,
which in turn, dictates the duration and efﬁcacy of Smad2/3
activity.
PI3K primes Smad2/3 interaction with Nedd4L via pT220/T179.
Although activation of TGF-b/Activin signalling is primarily
determined by the receptor-mediated phosphorylation of
Smad2/3 C-terminal SxS motif that induces their accumulation
within the nucleus, it is increasingly apparent that the linker
region of Smad2/3 serves a critical site through which their
activity is regulated. This region contains multiple S/T residues,
which are targeted by various S/T kinases stemming from other
signalling pathways24–28. Phosphorylation of these residues
alters the interaction of Smad2/3 with other proteins, which
subsequently affects Smad2/3 stability, translocation and
transcriptional activity3,23,29,30. Recruitment of Nedd4L to
Smad2/3 was shown to be dependent on the phosphorylation
status of their linker T220/T179 residue, which lies directly
upstream of the PPXY-binding motif (Fig. 4a)23. Therefore,
we anticipated that PI3K signalling might affect Smad2/3
degradation through altering the phosphorylation of this
residue. Indeed, LY treatment signiﬁcantly reduced the
phosphorylation of T220/T179, irrespective of Smad2/3
activation, but had negligible effects on the other linker serine
residues in both hESC and tumour cell lines (Fig. 4b–d;
Supplementary Fig. 4a–e). This suggests that Smad2/3 linker
threonine and serine residues are differentially regulated,
with PI3K speciﬁcally modulating the phosphorylation of the
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T220/T179 linker residue. Our results also demonstrate that
PI3K-mediated phosphorylation of this residue can occur in the
absence of Smad2/3 activation (Fig. 5a,d), which raised the
question as to whether Nedd4L binds to both active and inactive
Smad2/3 or solely to the active form. To address this, PC3 cells,
which retain high levels of PI3K signalling even after overnight
starvation due to the presence of a PTEN mutation, were used for
Nedd4L co-immunoprecipitation experiments upon treatment
with AA±LY post starvation. This showed that Nedd4L
recruitment and ubiquitination of Smad2/3 occurred most
effectively only when both T220/T179 and SxS residues were
phosphorylated (Fig. 4e), offering an explanatory mechanism
by which Nedd4L selectively targets active Smad2/3 for
ubiquitination and turnover.
We hence postulated that PI3K promotes phosphorylation of
Smad2/3-T220/T179 and primes Smad2/3 for the binding of
Nedd4L upon activation, resulting in increased ubiquitin-
mediated Smad2/3 degradation, which acts to reduce the
transcriptional activation of endoderm genes. If this is correct,
mutagenesis of T220/T179 to a non-phosphorylatable residue
should enhance the resistance of Smad2/3 to degradation
independent of LY. To test this, we ectopically expressed
wild-type (WT) or T220V mutant Smad2 in hESCs and PC3
cells. PC3 cells expressing Smad2-T220V showed higher Smad2/3
activation upon AA stimulation irrespective of whether LY
was present (Fig. 4f) and correspondingly, hESCs expressing
Smad2-T220V exhibited improved mesendoderm differentiation
in response to AA alone (Fig. 4g). In further support of the view
that Nedd4L-mediated degradation of active Smad2/3 accounts
for the inhibitory effect of PI3K during Activin-induced DE
differentiation, Nedd4L knockdown in PC3 cells resulted in
increased Smad2/3 activation in the absence of LY (Fig. 4h;
Supplementary Fig. 4f), while Nedd4L-deﬁcient hESCs expressed
endoderm genes at much higher levels upon AA stimulation
(Fig. 4i). Taken together, PI3K signalling therefore inhibits
Activin-induced DE differentiation by phosphorylating the
T220/T179 of Smad2/3, enabling the recruitment of Nedd4L
upon their activation, which leads to the degradation and
termination of active Smad2/3.
Smad2/3-pT220/pT179 is a direct effect of PI3K activity.
Although many kinases including Erk (extracellular-signal-
regulated kinases), p38 and CDK (cyclin-dependent kinase) have
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been shown to phosphorylate Smad2/3 linker residues24,26,27,30,
inhibitors that speciﬁcally target these kinases were less effective
in suppressing T220/T179 phosphorylation when compared
with LY (Fig. 5a,b; Supplementary Fig. 5a). Notably,
ﬂavopiridol-mediated inhibition of CDKs only diminished the
phosphorylation of the linker serine residues, whereas the
T220/T179 residue was unaffected. Furthermore, PI3K-mediated
phosphorylation of T220/T179 requires neither Smad2/3
activation nor nuclear localization, which thereby eliminates the
direct involvement of CDK in causing this effect. Although active
Erk can phosphorylate the T220/T179 residue, inhibition of PI3K
elicited a greater reduction in T220/T179 phosphorylation than
that of MAPK/Erk inhibition. In addition, LY treatment did not
inhibit, but rather increased Erk activation under certain
conditions (Fig. 5c; Supplementary Fig. 5a–c)14, which therefore
excludes the possibility of LY-induced downregulation of
T220/T179 phosphorylation being an Erk-related event.
Furthermore, treatment of hESCs in RPMI base media along
with heregulin and IGF-1 (HI), two potent stimulators of the
PI3K pathway, increased T220/T179 phosphorylation (Fig. 5d),
suggesting that this phosphorylation is regulated by the PI3K
pathway itself independent of Erk and CDK activity.
Since Akt is one of the principal kinases acting downstream
of PI3K, we next investigated whether Akt was responsible for
T220/T179 phosphorylation by ectopically expressing constitu-
tively active (Myr-Akt-WT), partially active (S473A) and inactive
(K179M/T308A/S473A) Akt in Hep3B cells, using green
ﬂuorescent protein (GFP)-expressing Hep3B as controls. In
comparison with the marked upregulation and reduction of
T220/T179 phosphorylation observed in control cells upon
heregulin and IGF-1 and LY treatment, respectively, expression
of Akt possessing varying states of activation had negligible
impact on T220/T179 phosphorylation (Fig. 5e), suggesting that
Akt is not directly responsible for this phosphorylation. This was
further conﬁrmed by an in vitro kinase assay that demonstrated
the inability of fully active Akt to phosphorylate this residue
(Fig. 5f), which is consistent with previous ﬁndings8–10.
mTORC2 induces the phosphorylation of Smad2/3-T220/T179.
The mTOR branches of the PI3K signalling pathway acts to
regulate cell growth, differentiation and metabolism. mTOR is the
kinase component of two distinct multi-protein complexes,
mTORC1 and mTORC2, which differ not only in their con-
stituent components, but also in their response to rapamycin31.
mTORC1 contains an adaptor protein, raptor, as a key subunit,
while mTORC2 comprises rictor as its novel component; while
mTORC1 activity is rapidly inhibited by rapamycin, mTORC2 is
more resistant to acute rapamycin exposure32. To investigate
whether mTOR complexes are involved in Smad2/3 regulation,
PC3 cells were treated with AA in the presence of rapamycin or
Torin-2 (henceforth Torin), an mTOR inhibitor that inhibits both
complexes. While rapamycin showed no obvious effects on both
Smad2 activation and T220/T179 phosphorylation (Fig. 6a),
Torin treatment mimicked that of LY in prolonging Smad2
activation and inhibiting T220/T179 phosphorylation (Fig. 6b),
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thereby suggesting that mTORC2, rather than mTORC1, is
involved in the regulation of Smad2/3 activity. In support of this
notion, phosphorylation of T220/T179 was shown to be
downregulated in rictor knockdown PC3 cells (Fig. 6c) and this
reduction of pT220/pT179 appeared more evident in MEFs
(mouse embryonic ﬁbroblasts) that were derived from rictor null
mice (Fig. 6d)33. The difference between rictor knockdown and
rictor null cells could be due to the incomplete removal of rictor
in the former as we have shown that PI3K/mTORC2-dependent
phosphorylation of T220/179 is highly sensitive to any trace
amount of PI3K/mTORC2 activity (Fig. 5d vs Supplementary
Fig. 5b). Furthermore, this downregulation of T220/T179
phosphorylation in rictor null cells was fully rescued by the
ectopic expression of human rictor (Fig. 6d), highlighting the
important role mTORC2 plays in regulating Smad2/3-T220/T179
phosphorylation. Moreover, hESCs expressing rictor short
hairpin RNA (shRNA) exhibited improved DE differentiation
in response to AA treatment evidenced by rapid morphological
changes and increased expression of DE markers, effects that are
reminiscent of those observed upon AA–LY treatment (Fig. 6e,f).
Therefore, these results suggest that mTORC2 plays an important
role in modulating Activin-induced Smad2/3 activity by
modifying the phosphorylation of the Smad2/3 linker
T220/T179 residue. Intriguingly, immunoprecipitated mTORC2
was unable to phosphorylate Smad2-T220 in an in vitro kinase
reaction (Fig. 6g), while inhibition of SGK1, one of the limited
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substrates identiﬁed to be regulated by mTORC2 (refs 34,35),
exhibited considerable reduction of both active and total Smad2/3
(Supplementary Fig. 6), effects that are completely different to
that of either LY treatment or mTORC2 inhibition. Thus,
the exact mechanisms by which mTORC2 regulates the
phosphorylation of Smad2/3 linker residue await further
elucidation.
Suppression of mTORC2 leads to more efﬁcient DE formation.
Consistent with the posited role for mTORC2 in regulating
T220/T179 phosphorylation and inhibiting Smad2/3 activity,
treatment of hESCs using a combination of AA and Torin yielded
a substantial increase in the expression of endoderm genes
(Fig. 7a,b), recapitulating the effects of AA–LY treatment, but
with noticeably less cell death. Consequently, this led to both a
more efﬁcient DE differentiation and hepatocyte generation
(Fig. 7c,d). Thus, the greater yield of DE cells in combination with
the reduction in cytotoxicity makes AA–Torin a superior alter-
native to AA–LY treatment and provides compelling evidence to
suggest that the mTORC2-mediated regulation of Smad2/3 linker
phosphorylation is a critical mechanism accounting for the
inhibitory effect of PI3K on Activin-induced DE differentiation.
Discussion
In the present study, we have identiﬁed a novel and direct role for
PI3K/mTORC2 signalling in regulating the phosphorylation
status of the Smad2/3 linker T220/T179 residue. This phos-
phorylation permits the recruitment of the E3 ubiquitin ligase
Nedd4L to Smad2/3 upon their activation, which subsequently
promotes the ubiquitin-mediated proteasomal degradation of
active Smad2/3. PI3K/mTORC2-mediated degradation of
active Smad2/3 curtails the duration and intensity of the
Activin-Smad2/3 signal, which ultimately leads to the attrition
of Activin-induced DE differentiation in hESCs.
Our results are in line with previous ﬁndings, in that ubiquitin-
mediated proteasomal degradation of active Smad2/3 plays an
important role in the regulation of TGF-b/Smad2/3 activity22,23
and that the phosphorylation of Smad2/3 linker T220/T179 is
critical for the recruitment of the E3 ubiquitin ligase Nedd4L23.
However, we have found that the T220/T179 residue can be
readily phosphorylated by PI3K/mTORC2 signalling in the
absence of Smad2/3 activation and is thus independent of
AA-induced CDK or Erk activation. Furthermore, this
phosphorylation can only recruit Nedd4L efﬁciently upon
Smad2/3 activation, thereby offering a mechanism by which
preferential selectivity for active Smad2/3 degradation is
established. In addition, TGF-b ligands are able to activate
PI3K signalling through non-canonical means concurrently with
the canonical activation of Smad2/3 (ref. 36), which may act as an
internal regulative mechanism that prevents overactivation of
Smad2/3. However, given that the majority of active Smad2/3 is
still able to translocate into the nucleus despite the presence of
Inhibitors
SB431542
Inhibitors
SB43152
Smad2-pTail
Smad2-pTail
Smad2-pT220
Smad3-pT179
Smad2-pT220
Smad3-pT179
Smad2-pT220
Smad2-pT220
Kinase Erk2 Akt
Akt
ATP
Akt-pS473
–
– – –
––
–
– +
+
+
+
+
+
+
Flag-Smad2 (T220V)
Flag-Smad2 (WT)
Smad3-p179
Smad2-pT220
Smad3-pT179
Smad2-pLS
Smad2-pLS Smad2-pLS
Smad2-pLS
Smad2 (short-exp)
Smad2 (long-exp)
Smad2
β-Actin
β-Actin β-Actin
β-Actin
β-Actin
+ + + + + +
+ + + + + +
55 kDa
Time (h)
LY
LY
Media RPMI
–
–
–
–
+
+
Activin A
Erk1-pT202/Y204
Erk2-pT185/Y187
Erk1/2
Smad2/3
Smad2
Akt
Flag
Akt
Akt-pS473
Akt-pS473
Akt-pT308
35 kDa
Treatment
Exp. vector
– – – –LY HI
HI
GFP W
T
Tr
i-m
ut
S4
73
A
Myr-Akt1
35 kDa
55 kDa
55 kDa
55 kDa
70 kDa
70 kDa
70 kDa
70 kDa
55 kDa
55 kDa
55 kDa
70 kDa
55 kDa
55 kDa
35 kDaGSK3α-pS21
GSK3β-pS9
GST-GSK3α/β
35 kDa
55 kDa
25 kDa
25 kDa
70 kDa
–
–
– – – +
++
+
++
+
++
0 1 3 6
55 kDa
55 kDa
55 kDa
55 kDa
70 kDa
70 kDa
70 kDa
70 kDa 55 kDa
70 kDa
55 kDa
70 kDa
55 kDa
70 kDa
55 kDa
70 kDa
70 kDa
55 kDa
70 kDa
55 kDa
70 kDa
55 kDa
70 kDa
–
–
–
0.82
0.55 0.76 0.65 0.66 0.89 0.76 0.35
0.94 0.41 0.61 0.67 0.19 0.89
– U0
12
6
U0
12
6
SB
20
35
80
SB
20
35
80
SP
60
01
25
SP
60
01
25
LY
29
00
42
LY
29
00
42
Fl
av
op
iri
do
l
Fl
av
op
iri
do
l
70 kDa
Figure 5 | Phosphorylation of Smad2/3 linker residues are differentially regulated by various signalling pathways. (a,b) Immunoblot of Smad2/3
phosphorylation in hESCs that were pre-treated with Activin A, then incubated with indicated inhibitors for 1 h (a) or 6 h (b). (c) Immunoblot with Erk1/2
antibodies on cell extracts from hESCs with indicated treatments. (d) hESCs were starved for1 h in RPMI medium followed by treatment with either LYor HI
for 1 h before being analysed by immunoblotting. (e) Hep3B cells transiently expressing either green ﬂuorescent protein (GFP) or the various forms of Akt
as indicated were starved overnight while GFP-expressing cells were treated with either LY or HI for 1 h before harvest for immunoblot. (f) In vitro kinase
assay. Active Akt was isolated from PC3 cells by immunoprecipitation and incubated with recombinant GST-Flag-tagged wild-type (WT) or T220Vmutant
Smad2 in the presence of ATP. The protein mixtures were then resolved by SDS–polyacrylamide gel electrophoresis and analysed by immunoblotting with
indicated antibodies. Commercially bought Erk2 and GST-GSK3 were used as positive controls. HI represents co-treatment with heregulin and IGF-1.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8212 ARTICLE
NATURE COMMUNICATIONS | 6:7212 | DOI: 10.1038/ncomms8212 | www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
Rap Torin
HI
Activin A
D
ay
 0
D
ay
 1
Smad2-pTail55 kDa
55 kDa 55 kDa
55 kDa
55 kDa
55 kDa
55 kDa
55 kDa
70 kDa
70 kDa
70 kDa
70 kDa
70 kDa
70 kDa
70 kDa70 kDa
70 kDa
70 kDa
– – – – ++
– – – –++
– – – +++ – – – +
– – – – ++
+
– – – –++
+
HI
Activin A
Smad2-pTail
Smad2-pT220
Smad3-pT179
Smad2/3
Akt-pS473
p85S6K-pT444/S447
p70S6K-pT421/S424
p85-S6K
p70S6k
shRNA
Transfection
R
el
at
ive
 e
xp
re
ss
io
n
(no
rm
a
liz
e
d 
to
 d
ay
 0
 o
f c
on
tro
l)Co
nt
ro
l
R
ic
to
r
245 kDa
245 kDa
70 kDa
70 kDa
55 kDa
70 kDa
55 kDa
70 kDa
55 kDa
55 kDa
Rictor
Rictor
mTOR
mTOR
Smad2-pT220
Smad2-pT220
Smad3-pT179
Smad3-pT179
Smad2/3
Smad2/3
Akt-pS473
Akt
β-Actin β-Actin
β-Actin
Akt
Smad2-pT220
Smad3-pT179
Smad2/3
Akt-pS473
p85S6K-pT444/S447
p70S6K-pT421/S424
p85S6K
p70S6K
β-Actin
Akt
Rictor-shControl
R
ic
to
r
G
FP
– –
245 kDa
245 kDa
245 kDa
70 kDa
70 kDa
70 kDa
70 kDa Smad2-pT220
FlagSmad2
Akt-pS473
Rictor
IB
In
 v
itr
o 
ki
na
se
 a
ss
ay
mTOR
Akt
245 kDa
55 kDa
55 kDa
70 kDa
70 kDa
Rictor +/+ +/+–/– –/–
MixL1Brachyury
IP antibody
R
ic
to
r
Ig
G40
30
20
10
0
0
1
2
0
1
2
3
0
1
2
3
40
30
20
10
0
0
5
10
15
20
25
40
30
20
10
0
40
30
20
10
0
40
60
20
0
Eomes
Oct4GSCFoXA2
Nanog Sox2
Control shRictor
Pax6
Figure 6 | mTORC2 regulates Smad2/3 activity by modulating the phosphorylation of T220/T179 residue. (a) Effect of rapamycin on Smad2/3
signalling. PC3 cells were treated with rapamycin in the presence of Activin A or HI for 6 h and then harvested for immunoblot with indicated antibodies.
(b) Effect of Torin treatments on Activin-Smad2/3 signalling. Immunoblot of PC3 cells treated similar as in a but replacing rapamycin with Torin-2 (Torin).
(c,d) Reduction of Smad2/3-pT220/T179 in rictor-shRNA knockdown PC3 cells (c) and in rictor null MEF (d). Ectopic expression of human rictor in rictor
null MEF reverted the levels of Smad2/3-pT220/T179. (e,f) Knockdown of rictor in hESCs accelerated morphological changes associated with DE
speciﬁcation (e) and increased expression of DE markers (f) in response to Activin A. Scale bar, 100mm. hESCs in f were treated with Activin A for 2
days before the analysis and data represent mean±s.d. from at least six measurements of two independent experiments. (g) In vitro kinase assay of
mTORC2 on Smad2-T220 phosphorylation. mTORC2 complexes were isolated by immunoprecipitation with rictor antibody and incubated with
recombinant GST-Flag-Smad2 or inactive Akt in the presence of ATP. The protein mixtures were then resolved by SDS–polyacrylamide gel electrophoresis
and analysed by immunoblot.
Activin Activin+Torin
Torin-2
LY
70 kDa
55 kDa
– –
– – +
– ++
+
Media CM RPMI/B27
Activin A
Activin+LY Activin+Torin Stage 2—day 6 Stage 3—day 9
Sox17
FoxA2
β-Actin
1.0
0.8
0.6
0.4
0.2
0.0
R
el
at
ive
 e
xp
re
ss
io
n
(no
rm
a
liz
e
d 
to
 d
ay
 0
) 250
200
150
100
50
0
So
x2
N
an
og
O
ct
4
Eo
m
es
Br
a
ch
y
M
ix
L1
Fo
xA
2
G
SC
Pa
x6
Figure 7 | Inhibition of mTOR enhances DE differentiation of hESCs. (a) qRT–PCR showing gene expression in hESCs treated with Activin A±Torin for
2 days. Data represent mean±s.d. of six measurements from two independent experiments. (b) Immunoblot showing protein expression in hESCs treated
as in a. (c) Phase-contrast images of hESCs treated for 3 days with Activin A together with either LY or Torin. Scale bar, 100 mm. (d) Phase-contrast
images of the cells from c that were further differentiated by a hepatic differentiation protocol as shown in Fig. 1. Days of differentiation are indicated.
Scale bar, 50mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8212
8 NATURE COMMUNICATIONS | 6:7212 | DOI: 10.1038/ncomms8212 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
T220/T179 phosphorylation (Supplementary Fig. 4e), this
suggests that additional factors that interact with active
Smad2/3 may hinder the recruitment of Nedd4L and prevent
their degradation. Receptor-mediated activation of Smad2/3 has
been well characterized for inducing conformational changes that
enable the homo- and heterodimerization of R-Smads, as well as
interaction with Smad4. However, whether or not such
interactions between the Smad2/3 and other factors can act to
impede the recruitment of Nedd4L awaits further investigation.
In any case, despite only a small proportion of the activated
R-Smads being targeted for degradation, this appears to be
sufﬁcient in impeding the proper formation of DE from hESCs.
To deﬁnitively establish that Smad2/3 linker phosphorylation
mediates the mTORC2-dependent inhibition of DE differ-
entiation of hESCs, one would need to generate hESCs with
knock-ins of linker phospho-deﬁcient or phospho-mimetic
mutants of Smad2/3.
As shown in our experiments, AA–LY-induced enhancement
of Smad2/3 activation in hESCs is only apparent at 3 h post
treatment, despite the effectiveness of LY in reducing T220/T179
phosphorylation by 1 h of treatment. In explaining this
discrepancy, it is probable that initially in the presence of
abundant ligand (100 ngml 1 AA) and persistent receptor
activation37, the rate of Smad2/3 activation outpaces that of its
Nedd4L-mediated degradation, which consequently obscures
the effect of LY-induced downregulation of T220/T179
phosphorylation in prolonging Smad2/3 activation. However, as
the ligand availability diminishes with increasing time, the
proportion of the active Smad2/3 that is targeted for Nedd4L-
mediated degradation becomes increasingly higher relative to the
total active Smad2/3 pool, which ultimately promotes the rapid
downregulation of Smad2/3 activity (Fig. 8). In support of this,
the LY-dependent effect on active Smad2/3 was shown to be
evident at 1 h post treatment when a lower dose of ligand
(10 ngml 1 AA) is applied or when receptor activation is
blocked by SB431542. Putting this in a biological context, during
embryonic development where TGF-b/Nodal/Activin are
at physiological levels, this PI3K/mTOR/Nedd4L-mediated
degradation mechanism may act as an internal thermostat
that regulates the amplitude of Smad2/3 induction and
thereby allowing proper readout of the morphogenic gradient
in vivo.
One important ﬁnding of this study is the identiﬁcation of
mTORC2 as a modulator of TGF-b signalling, speciﬁcally by
regulating the phosphorylation of the Smad2/3 linker T220/T179
residue. In assessing the contribution of the previously identiﬁed
linker kinases, Erk1/2 and CDK24,26,27, we showed that when
inhibited, neither could replicate the effects of PI3K inhibition.
Furthermore, under certain conditions, LY-mediated inhibition
of PI3K did not reduce, but rather enhanced the activation of
Erk1/2. As such, enhancement of DE differentiation via
downregulation T220/T179 phosphorylation and enhancement
of Smad2/3 activity does not appear to be solely through an
Erk/Wnt/b-catenin-mediated mechanism as outlined in a recent
study14, but is rather through a more distinct and direct
mechanism. The PI3K pathway bifurcates at many points and
constitutes a large family of serine/threonine kinases of which the
best characterized are the Akt and mTOR branches. Our data
have shown that Akt does not affect phosphorylation of Smad2/3-
T220/T179, which is consistent with previous ﬁndings8–10. In
manipulating mTORC2 activity using both inhibitor-based and
genetic means, we have identiﬁed mTORC2 as a key player in the
regulation of the linker T220/T179 phosphorylation opposed to
mTORC1. Although it has been reported that inhibition of
mTORC1 by rapamycin can enhance the DE speciﬁcation of
hESCs38, chronic exposure of hESCs to rapamycin over several
days will also inhibit mTORC2 activity32, which may ultimately
be the reason for the reported improvement in DE speciﬁcation.
Furthermore, since mTORC2 activation is mediated by PI3K39, it
is not surprising that the inhibition of PI3K signalling could lead
to a cessation of mTORC2 kinase activity. Although mTORC2
immunoprecipitates could not phosphorylate the T220/T179
residue in an in vitro kinase reaction, this cannot completely
exclude the possibility of mTORC2 being the direct kinase
responsible for this phosphorylation, as the substrate recognition
mechanisms of mTORC2 are still poorly deﬁned39,40.
Alternatively, mTORC2 may indeed act via indirect means
through activation of downstream kinases that in turn regulate
Smad2/3 linker phosphorylation; however, such kinases remain to
be identiﬁed.
As a whole and to the best of our knowledge, we have for
the ﬁrst time identiﬁed a role for mTORC2 in mediating
TGF-b/Activin signalling activities, and established a plausible
mechanism through which mTORC2 activity directly impacts the
Activin-induced DE differentiation of hESCs. Identiﬁcation of
mTORC2 as a key component of this mechanism not only
provides new avenues through which hESC differentiation
protocols can be improved, but also warrants the initiation of
further studies into the impact of this mechanism on other
TGF-b activities, adding to the growing repertoire of novel
mTORC2 functions.
Methods
Cell culture and differentiation. H1 and H9 hESCs from WiCell were routinely
cultured on Matrigel-coated plates in MEF conditioned medium (MEF-CM)
supplemented with 10 ngml 1 of bFGF41. DE differentiation was carried out as
summarized in Fig. 1a12. When hESCs were grown to 70–80% conﬂuency,
MEF-CM was replaced with RPMI-1,640 supplemented with 1 B27 (RPMI/B27
medium) containing Activin (100 ngml 1, PeproTech) and LY294002 (20 mM
day 1 and 10mM day 2 and 3, Sigma) or Torin-2 (15 nM, Tocris) or wortmannin
(300 nM, Sigma) for 2–3 days with daily medium change (Supplementary Fig. 1b).
For hepatocyte differentiation, cells were further cultured in knockout-DMEM
(KO-DMEM) containing 20% KO serum replacement, 1mM glutamine,
1% non-essential amino acids, 0.1mM b-mercaptoethanol (all from Life
Technologies) with either DMSO (1%, Sigma) or BMP2 (20 ngml 1, PeproTech)
and bFGF (10 ngml 1, R&D systems) for another 4 days, followed by 3–5 days
culture in L15 medium supplemented with 8.3% foetal bovine serum (FBS),
8.3% tryptose phosphate broth, 10 mM hydrocortisone 21-hemisuccinate, 1 mM
insulin (all from Sigma), 50mgml 1 ascorbic acid and 2mM glutamine containing
10 ngml 1 hepatocyte growth factor (PeproTech) and 20 ngml 1 oncostatin M
(R&D systems). In the experiments using various inhibitors, hESCs were cultured
in RPMI/B27 medium containing Activin (100 ngml 1) for 20min following
MEF-CM removal and 2 PBS wash (Fig. 3a). The Activin-containing medium
was then replaced with fresh RPMI/B27 containing the indicated inhibitors, and
cells were harvested 1–6 h later as indicated. The following inhibitors were used:
MG132 (10 mM) and okadaic acid (5 nM) from Merck/Millipore; SB431542
(10 mM) from Sigma; U0126 (10 mM) and SP600125 (500 nM) from Reagents
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Direct; SB203580 (20 mM) from R&D systems, ﬂavopiridol (1mM) and GDC-0941
(200 nM), both from Selleck Bio.
PC3 cells were kindly provided by Dr Kypta of Imperial College London.
Hep3B and HEK293T tumour cell lines were obtained from ATCC (HB8064 and
CRL-3216, respectively). Rictor null and corresponding control MEF were a gift
from Professor Magnuson, VUMC, Tennessee33. PC3 cells were cultured in RPMI-
1,640 medium containing 10% FBS. Hep3B, HEK293T and transgenic MEF cells
were cultured in DMEM containing 10% FBS. All reagents for tumour cell cultures
are from Sigma. Treatment of PC3 cells were performed by starving the cells
overnight in RPMI-1,640 medium and then treating them for 1 h with Activin
(10 ngml 1)±LY (20 mM) or indicated factors, including rapamycin (100 nM),
LongR3 IGF-1 (I, 200 ngml 1, both from Sigma), Heregulin (H, 10 ngml 1,
PeproTech) and SGK inhibitor, GSK650394 (100 mM, Sigma).
All cell lines have been regularly checked for the absence of mycoplasma.
Plasmids. Expression vectors for WT Smad2 (pCS2-Flag-Smad2, #14042), active
Akt (pcDNA3 Myr-HA-Akt1, #9008) Akt triple mutant (pcDNA3-T7-Akt-
K179M/T308A/S473A, #9031) and Rictor (pRK-myc-Rictor #11367) were obtained
from Professor J. Massague42, Professor W. Sellers43 and Professor D. Sabatini44
through Addgene. Smad2 mutant T220V was generated by site-directed
mutagenesis of pCS2-Flag-Smad2 using the Q5 Site-Directed Mutagenesis Kit
(NEB) following the manufacturer’s protocol, with the following oligonucleotides:
forward primer 50-GAGTAATTATATTCCAGAAGTGCCACCTCCTGGA
TATATC-30 and reverse primer 50-TGTGGCTCAATTCCTGCTGG-30 . The
resulting sequences were validated by bidirectional sequencing. Partially active Akt
(S473A) plasmid was generated by subcloning to replace the BlpI/EcoRI fragment
of pcDNA3-Myr-HA-Akt1 containing S473 with A473 from pcDNA3-T7-Akt1-
K179M/T308A/S473A. Lentivector containing shNedd4L was generated by cloning
shNedd4L oligonucleotides into modiﬁed pLVTHM expressing puro-2A-GFP
complementary DNA (cDNA)45. The sequence of shNedd4L was as previously
published23:
50-GCTAGACTGTGGATTGAGTttcaagagaACTCAATCCACAGTCTAGCtttttgg
aaa-30 . Lentivectors that contained two different shRNAs targeting Rictor within a
pLKO.1 backbone were obtained from Addgene and used in combination to
generate Rictor deﬁcient lines. The sequences are as previously published46:
50-ccggtCAGCCTTGAACTGTTTAActcgagTTAAACAGTTCAAGGCTGtttttg-30
and 50-ccggtACTTGTGAAGAATCGTATCTTctcgagAAGATACGATTCTTCACA
AGTtttttg-30 . Lentivectors containing non-targeting shGFP was used to generate
control cells. GST-Flag-Smad2/Smad2-T220V plasmids were generated by
inserting NcoI/XhoI fragment containing Flag-Smad2 or Flag-Smad2-T220V from
their respective expression vectors into the pGEX-6p2 vector (GE Healthcare).
Transfection and lentiviral transduction. Hep3B cells and transgenic MEFs were
grown to 70–90% conﬂuency on the day of transfection. Akt or GFP expression
plasmids were transfected using Lipofectamine LTX with PLUS reagent (Life
Technologies) with modiﬁcations. In brief, for 1 106 tumour cells, 1.6 mg of kit-
puriﬁed plasmid DNA was suspended in 50 ml of OptiMEM supplemented with
1.6 ml of PLUS reagent. In another tube, 4 ml of Lipofectamine LTX reagent was
resuspended in another 50 ml of OptiMEM. Both tubes were incubated at room
temperature for 5min before being mixed together and incubated for a further
25min. During this time, target cells were trypsinized, counted and pelleted before
being directly resuspended in the transfection mix and incubated for 15min. The
transfection process was stopped upon the addition of growth media and cells were
allowed to plate down overnight in the appropriate culture vessel. Cells were
typically split 1:2–1:3 following transfection. Reagents were scaled up accordingly
depending on the number of cells to be transfected. For hESCs and MEFs,
lipofection was conducted following the accompanying manufacturer’s instructions
with a DNA to Lipofectamine LTX ratio of 1:3 and 1:10, respectively. Transfected
Hep3B cells were starved overnight the following day and then treated with the
appropriate reagents for 1 h before being harvested for analysis. Transfected MEFs
were allowed to recover and proliferate for 48 h before being harvested for
immunoblot.
Lentiviruses were produced by transient transfection of HEK293T cells with a
lentivector containing the desired transgenic cDNA or shRNA, as well as
pCMVD8.91 helper and pVSV-G envelope plasmids using standard protocols47.
hESCs were split 1:3 the day of transduction by being dissociated with accutase
(Sigma) into single cells and resuspended in MEF-CM supplemented with 10 mM
ROCKi (Y-27632 or ROCK inhibitor, Reagents Direct) to prevent apoptosis
induced by the loss of cell–cell contact48. The cells were incubated overnight with
concentrated viral particles and consequently became infected as they were plating
down. Forty-eight hours post infection, cells were selected with puromycin
(2mgml 1) and upon stable passaging, assessed for transgene expression or
knockdown via immunoblot and quantitative reverse transcription (qRT–PCR),
which was phenotypically assessed via DE differentiation.
Quantitative reverse transcription–PCR (qRT–PCR). Total RNAs were isolated
from cells with TRI reagent (Sigma) and cDNA samples were synthesized with
Protoscript II Reverse Transcriptase (NEB). qRT–PCR was performed in a DNA
Engine Opticon (Bio-Rad) or Step One thermocycler (Applied BioSystems) using
SYBR Green Jumpstart Taq Ready Mix (Sigma). Two housekeeping genes were
used as normalizer. Two independent biological samples were used and multiple
measurements were carried out for each treatment. Data were presented as
mean±s.d. for six measurements. A list of primers used in this study are provided
in Supplementary Table 1.
Cytoplasmic/nuclear fractionation. Cells were harvested in cytoplasmic buffer
(10mM HEPES pH 7.9, 0.1mM EDTA, 0.1mM EGTA, 10mM KCl and 0.5mM
dithiothreitol (DTT)) supplemented with phosphatase and protease inhibitors and
allowed to swell on ice for 20min after which Nonidet-P40 was added to a ﬁnal
concentration of 0.5%. Samples were quickly vortexed and centrifuged to pellet the
cell nuclei. The supernatant was extracted and retained as the cytoplasmic fraction.
The nuclear pellet was washed three times with cytoplasmic buffer to remove
residual cytoplasmic contamination and resuspended in nuclear buffer (20mM
HEPES pH 7.9, 1mM EDTA, 1mM EGTA, 1mM DTT and 0.4M NaCl) before a
ﬁnal centrifugation at 15,000g to extract the nuclear fraction. Samples were
quantiﬁed using bicinchoninic acid assay kit (Thermo Fisher Scientiﬁc) before
being analysed by immunoblot.
Antibodies. The following are the primary antibodies used in this study; indicated
dilutions refer to use in immunoblotting, unless otherwise stated: anti-Akt (#9727,
1:2,000), pAkt-S473 (#4060, 1:2,000), pAkt-T308 (#9275, 1:1,000), Erk1/2 (#9102,
1:1,000), pErk1/2-T202/Y204 (#9106, 1:1,000), mTOR (#2972, 1:1,000), pNedd4L-
S448 (#8063, 1:1,000), P70S6K (#9202, 1:1,000), pP70S6K-T421/S424 (#9204,
1:1,000), pGSK3a/b-S21/9 (#9331, 1:1,000), pRb-S780 (#9307, 1:1,000), pSAPK/
JNK-T183/Y185 (#4668, 1:1,000), Smad2 (#3122, 1:1,000), Smad2/3 (#3102,
1:1,000), pSmad2-S245/250/255 (#3104, 1:1,000), pSmad2-S465/467 (#3122,
1:1,000), Smad4 (#9515, 1:1,000) and Ubiquitin (#3936, 1:1,000) were from Cell
Signalling/New England Biolabs; anti-Brachyury (AF2085, 1:500, IF:1:50), CXCR4-
PE (FAB170P, 1:25) and Sox17 (MAB1924, 1:500, IF:1:100) were from R&D sys-
tems; anti-CLIC4 (sc-130723, 1:500), Lamin B (sc-365962, 1:500) and PPM1A (sc-
56956, 1:500) were from Santa Cruz; anti-AFP (A8452, 1:500), b-actin (A5316,
1:5,000), Flag (F1804, 1:1,000) and GST (G7781, 1:1,000) were from Sigma; anti-
pSmad2/3-T220/179 (AP3675a, 1:500) and pSmad3-S423/425 (EP823Y, #04-1042,
1:1,000) were from Abgent and Millipore, respectively; anti-b-tubulin (ab6046,
1:1,000), FoxA2 (ab60721, 1:200) and Nedd4L (ab131167, 1:5,000) were from
Abcam; anti-albumin (A0001, 1:500) was from DAKO and anti-Rictor (A300-
459A, 1:5,000) was from Bethyl Labs.
Secondary antibodies for immunostaining used were as follows: Alexa Fluor
goat anti-mouse IgG 488, 1:400, Alexa Fluor goat anti-mouse IgG 568, 1:400, Alexa
Fluor goat anti-rabbit IgG 488, 1:400 and Alexa Fluor donkey anti-goat IgG 488,
1:400 were from Life Technologies. For immunoblotting: goat anti-rabbit
IgG-HRP, 1:2,000, goat anti-mouse IgG-HRP, 1:5,000, donkey anti-goat IgG-HRP,
1:5,000 were from Santa Cruz and goat anti-rabbit or mouse IgG-HRP (light-chain
speciﬁc), 1:10,000 were from Jackson ImmunoResearch Laboratories. Isotope
controls: normal mouse IgG2a and normal rabbit IgG were from Santa Cruz.
Immunostaining of hESCs. hESCs were split and cultured on Matrigel-coated
Thermanox coverslips (Thermo Fisher Scientiﬁc) until the desired conﬂuency was
reached. Cells were then washed with Dulbecco’s PBS (DPBS) and ﬁxed for
10–20min with 4% fresh paraformaldehyde solution. Excess paraformaldehyde was
removed by washing three times with DPBS and the coverslips were then incubated
with blocking/permeabilization buffer for 1 h followed by an overnight incubation
with primary antibody at the appropriate dilution at 4 C with tilting. The
following day, coverslips were subjected to 10-min washes three times with DPBS,
followed by a 40-min incubation with the appropriate ﬂuorophore-conjugated
secondary antibody in the dark. Coverslips were then subjected to two further 10
min washes with DPBS followed by a 10-min DPBS/40 ,6 diamidino-2-phenylindole
(DAPI) wash, with DAPI at a ﬁnal concentration of 1 mgml 1 to counterstain the
nuclei. All washes were carried out in dark. Slides were mounted onto microscope
slides using Mowiol 4–88 solution and allowed to dry overnight. Slides were
visualized using a Leica SP5 II confocal ﬂuorescent microscope typically at  64
magniﬁcation.
Immunoblotting. Cells were harvested using RIPA (radio immunoprecipitation
assay) buffer (50mM Tris-HCl, pH 8.0, 150mM NaCl, 1% Nonidet-P40, 0.5%
sodium deoxycholate and 0.5% SDS) supplemented with phosphatase (Na3VO4,
1:100, NaF, 1:200 or phosphatase inhibitor cocktail 2, Sigma, 10 ml ml 1) and
protease inhibitors (phenylmethylsulphonyl ﬂuoride in ethanol or protease
inhibitor cocktail, Sigma). Proteins were puriﬁed by centrifugation at 15,000g at
4 C for 20min and then quantiﬁed using bicinchoninic acid assay kit (Thermo
Fisher Scientiﬁc) and resolved on 7.5% Bis-Tris polyacrylamide gels, before being
transferred onto polyvinylidene ﬂuoride membranes via electroblotting. Blots were
probed with primary antibody overnight followed by horseradish peroxidise
(HRP)-conjugated secondary antibodies before being developed via enhanced
chemiluminescent substrate and exposure onto CL-XPosure ﬁlm (Thermo Fisher
Scientiﬁc). Molecular weight markers (Thermo Fisher Scientiﬁc 11832124 or New
England BioLab #7712) were run alongside all samples and values are as indicated
in both the main and uncropped scans (Supplementary Fig. 7).
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Co-immunoprecipitation of Nedd4L with Smad2. Cells were harvested in HEPES
lysis buffer (40mM HEPES pH 7.4, 10mM EDTA and 10% glycerol) supplemented
with phosphatase and protease inhibitors as per immunoblotting. Cell lysis was
induced mechanically by repeatedly passing lysate through a 23-G needle on ice.
Protein within lysates were puriﬁed by centrifugation at 13,000g at 4 C for 10min
and quantiﬁed, with 1mg used in the subsequent immunoprecipitation with Smad2
antibody for 90min at 4 C with rotation. Immunocomplexes were isolated with
the lysates using Protein-G conjugated Dynabeads (Life Technologies) through a
further 1 h incubation under the same conditions. Beads were then washed 3 times
with cold HEPES lysis buffer to remove nonspeciﬁc binding prior to protein elution
with 2 Laemmli buffer. Elutes were subjected to immunoblotting and the
co-immunoprecipitation assessed using relevant primary antibodies.
Smad2 ubiquitination assay. Cells were harvested in non-denaturing lysis buffer
(20mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA, pH 8.0, 1mM EGTA,
pH 8.0 and 0.5% Nonidet-P40) supplemented with phosphatase and protease
inhibitors as per immunoblotting. Lysates were additionally supplemented with
2 mM ubiquitin aldehyde (Boston Biochem) to prevent the action of deubiquiti-
nating enzymes. Protein within lysates were puriﬁed and quantiﬁed, with 1mg used
in the subsequent immunoprecipitation with Smad2 antibody for 90min at 4 C
with rotation. Immunocomplexes were isolated from the lysates using Protein-G
conjugated Dynabeads through a further 1 h incubation under the same conditions.
Beads were then washed 3 times with cold non-denaturing lysis buffer to remove
nonspeciﬁc binding prior to protein elution with 2 Laemmli buffer. Elutes were
subjected to immunoblotting and the degree of ubiquitination was assessed using
an anti-ubiquitin antibody.
Generation of recombinant GST-Flag-Smad2/Smad2-T220V. pGEX-6p2
vectors containing Flag-Smad2/Smad2-T220V cDNAs were transformed into
BL-21 E. coli strain. Upon ampicillin selection, single colonies were used to
inoculate overnight cultures, which were then subsequently used to inoculate new
cultures the following day. Expression of GST-Flag-Smad2/Smad2-T220V was
induced in these cultures using 0.1M isopropyl b-D-1-thiogalactopyranoside
(Sigma) once they reached mid-log phase growth (OD550–600B0.6–1.0). Proteins
were harvested via centrifugation and sonication, followed by immunoprecipitation
with glutathione-conjugated magnetic beads (Thermo Fisher Scientiﬁc).
Recombinant proteins were eluted from the beads in 50mM Tris-HCl containing
10mM reduced glutathione. Proteins were then taken for immunoblotting with the
relevant antibodies to check for successful expression and then used as substrate for
subsequent kinase assays.
Akt/Erk2 kinase assay. HEK293T or PC3 cells were harvested using non-
denaturing lysis buffer (as per the Smad2 ubiquitination assay) to retain kinase
activity and supplemented with phosphatase and protease inhibitors as per
immunoblotting. Active Akt was immunoprecipitated using anti-pAkt (S473)
antibody and was tested for kinase activity via incubation with recombinant
GST-GSK3a/b fusion protein (NEB) as a substrate in kinase assay buffer
(25mM Tris-HCl, pH 7.5, 5mM b-glycerophosphate, 2mM DTT, 10mM MgCl2
and 200mM ATP) for 40min at 30 C. Kinase assay was repeated using GST-Flag-
Smad2/Smad2-T220V as substrate and phosphorylation of the linker region was
analysed via immunoblotting with the appropriate primary antibody. As a positive
control, GST-Flag-Smad2/Smad2-T220V proteins were incubated with Erk2 kinase
(NEB) in the supplied buffer supplemented with 200mM ATP and assessed for
phosphorylation via immunoblotting.
mTORC2 kinase assay. The assay was carried out using previously described
methods46 with the following modiﬁcations. HEK293T or PC3 cells were harvested
in mTORC lysis buffer (40mM HEPES pH 7.5, 120mM NaCl, 1mM EDTA,
10mM Na4P2O7, 50mM NaF and 0.5% Nonidet-P40) supplemented with
phosphatase and protease inhibitors as per immunoblotting. Cells were gently lysed
with rotation for 20min at 4 C after which 1mg of total protein was used in the
subsequent immunoprecipitation with Rictor antibody to selectively isolate
mTORC2 over mTORC1. Immunoprecipitated complexes were washed 3 times
with mTORC lysis buffer followed by washing with mTOR kinase assay buffer
(25mM HEPES, 100mM potassium acetate, 1mM MgCl2 and 500mM ATP)
twice to remove residual detergent. mTORC2 complexes were incubated with
l-phosphatase-treated His6-tagged-Akt1 (Millipore) protein or GST-Flag-Smad2/
Smad2-T220V recombinant proteins in mTORC kinase assay buffer for 40min at
37 C. Reactions were stopped upon the addition of 2 Laemmli buffer, and the
phosphorylation on Akt-S473 or SmadT220 residues was assessed by
immunoblotting with the appropriate primary antibodies.
Luciferase assay. hESCs were split 1:6 into 12-well plates using the accutase/
ROCKi method as above and allowed to reach 70–80% conﬂuence prior to
transfection. Both ﬁreﬂy pGL3-CAGA12-luc and renilla pRL-T7-renilla (Promega)
plasmids were transfected at a ratio of 10:1 using Lipofectamine 2000 following the
manufacturer’s protocol. Forty-two hours post transfection, hESCs were differ-
entiated for 6 h, harvested using accutase and dispensed into a 96-well luminometer
plate. Luciferase assay was performed using the Dual-Glo luciferase assay
kit (Promega) following the accompanying protocol. Both ﬁreﬂy and renilla
luminescence was recorded using a Victor II luminometer (Perkin Elmer). Fireﬂy
luminescence readings were normalized with corresponding renilla luminescence
readings to give representative luciferase expression values that are independent of
transfection efﬁciency and cell number. Data presented are mean±s.d. from three
independent transfection experiments.
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